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Part I
Introduction

 1 General introduction
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1Worldwide hundreds of millions of people suffer from chronic respiratory diseases which have major personal, social and economic impact 1. In the Netherlands about 1 million 
patients are diagnosed with a chronic respiratory disease. Most chronic respiratory dis-
eases in adult life originate in early childhood 2. Importantly, lung function is known to 
track over time: a low lung function during childhood will result in a lower lung function 
in later life 3. Patients with a lower maximal lung function level, as a result of respiratory 
diseases during childhood, will reach lung function values associated with respiratory 
symptoms and disability much earlier than patients who achieved normal lung function 
at the start of adulthood (Figure 1) 4.
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Figure 1. Theoretical model of changes in forced expiratory volume in 1 second in healthy subjects and 
in survivors of bronchopulmonary dysplasia according to age. Adapted from Baraldi et al. N Eng J Med 
2007;357:1946-55.
Early intervention and improved management of pediatric respiratory diseases today 
will positively influence adult lung health tomorrow 5. Therefore, early diagnosis and 
better monitoring of respiratory diseases in childhood may potentially alter lung growth 
and prevent lung function decline, thereby improving quality of life and reducing the 
risk of chronic lung disease in adulthood.
RolE oF BioMARkERs in thE DiAgnosis AnD MonitoRing oF PEDiAtRic 
REsPiRAtoRy DisEAsEs
The World Health organization defines a biomarker as “any substance, structure, or 
process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease”  6. Biomarkers can be used as an early marker of disease 
and may play a role in the diagnostic process. Furthermore, they can give insight in the 
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pathogenesis of lung disease and may help in monitoring therapeutic effects with the 
ultimate goal to prevent or attenuate disease progression. Biomarkers in respiratory 
diseases can be measured systemically (e.g. in blood) or locally in the lung and airways 
(e.g. in endobronchial biopsies, bronchoalveolar lavage fluid (BALF), sputum, exhaled 
breath and exhaled breath condensate). Particularly in pediatrics, noninvasive ways 
to obtain biomarkers are preferred over invasive tests. Thousands of biomarkers have 
been identified in respiratory diseases, reflecting the complexity of processes in lung 
and airways. Obviously, single biomarkers are probably not able to reflect the biological 
complexity in health and disease. An 'omics approach' (e.g. proteomics, metabolomics) 
enables the identification and quantification of all biological compounds, without a 
priori hypothesis. Such a profile of biomarkers is the ultimate expression of (epi)genetic 
information and interaction with environmental agents, micro-organisms, nutritional 
factors, medication and toxic substances. Hence, this approach allows individual pheno-
typing and opens the door to personal individualized medicine.
This thesis investigates the role of several biomarkers which may play a role in either 
inflammation, injury or growth and repair processes of the lungs and airways, which are 
the hallmarks of many respiratory diseases. The biomarkers studied in this thesis have 
been obtained from exhaled breath and tracheal aspirates of children and infants with 
respiratory diseases. The first part of this thesis focuses on diagnosing and monitoring of 
children with asthma and cystic fibrosis by a new laser-based spectroscopy technique for 
the detection of volatile organic compounds in exhaled breath. The second part focuses 
on the pathogenesis and prediction of bronchopulmonary dysplasia and investigates 
biomarkers involved in alveolar development and pulmonary angiogenesis in tracheal 
aspirates of preterm infants. In addition, infants who developed severe BPD are included 
in a clinical follow-up program at the Pediatric Chest Center of Sophia Children’s Hospi-
tal. Data of this follow-up program are analyzed to investigate both lung structure and 
ventilator function in these children at 6 months corrected age.
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1AsthMA AnD cystic FiBRosis: ExhAlED BREAth AnAlysis with lAsER-
BAsED sPEctRoscoPy
Asthma and cystic fibrosis
Asthma
Asthma is the most common chronic disease in children in the western world, affect-
ing 5-10% of all school children worldwide and in most countries the prevalence is still 
increasing 7. Asthma is defined by clinical symptoms like episodic wheezing, dyspnea 
and/or cough, and is characterized by variable airways obstruction, airways hyper 
-responsiveness and airways inflammation 8. Today, treatment of childhood asthma 
mainly consists of anti-inflammatory drugs, with inhaled corticosteroids (ICS) as first 
choice, in combination with bronchodilators.
Asthma is a complex heterogeneous disease and despite effective medication many 
children with asthma suffer poor asthma control with frequent symptoms, nocturnal 
awakenings, exercise intolerance and impaired lung function. Future risks of asthma are 
impaired lung function development, exacerbations, emergency care visits, hospital 
admissions, and even fatal or near-fatal asthma attacks 9.
Cystic fibrosis
Cystic fibrosis (CF) is the most common life shortening genetic disease in the Cau-
casian population, with a prevalence of 70,000 patients worldwide. The disease is 
caused by impairment or absence of the CF transmembrane conductance regulator 
(CFTR) protein, which results in reduced or absent chloride secretion and increased 
sodium absorption, leading to an increase in mucus viscosity and impaired mucocili-
ary clearance 10. The main cause of both morbidity and mortality in CF is lung disease, 
characterized by chronic airway inflammation, recurrent airways infections, oxidative 
stress and fibrosis 11,12.
Like asthma, CF is a very heterogeneous disease. The most prevalent mutation in the 
CFTR gene in the Netherlands is the dF508 deletion, but nowadays over 2000 different 
mutations have been described 13. However, there is poor correlation between geno-
type and phenotype 14. The variability in clinical phenotypes and treatment response 
amongst children with chronic respiratory diseases like asthma and CF stresses the need 
for more individualized phenotyping and treatment.
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Asthma and cF: role of inflammation
In both asthma and CF chronic airways inflammation, infections and oxidative stress 
may result in structural changes of the large and small airways.
In asthma, chronic airway inflammation is characterized by the presence of various 
inflammatory cells (e.g. mast cells, macrophages, eosinophils, neutrophils and T cells) 
and the release of many inflammatory mediators in the airways 8,15. Allergic asthma is 
characterized by infiltration of airway mucosal tissue with eosinophils 16. The airway 
pathology in asthma may consist of accumulation of mucus, epithelial shedding, 
goblet cell hyperplasia, thickening of the epithelial reticular basement membrane and 
increase in airway smooth muscle mass 17. Persistent airways inflammation in children 
with asthma may result in structural, irreversible changes in the airway wall, a complex 
process called remodeling which eventually may lead to irreversible airway obstruction 
in adulthood 17,18.
In CF airways inflammation is mainly characterized by persistent and excessive infiltra-
tion of airway mucosal tissue with neutrophils. Neutrophils release large quantities of 
reactive oxygen species (ROS), leading to increased oxidative stress. In addition, the 
production of proteases like neutrophil elastase causes direct damage to the airway wall 
by digesting elastin and other structural proteins 19. Neutrophils and macrophages also 
generate and stimulate the production of pro-inflammatory cytokines and chemokines, 
while the airways of CF patients are relatively deficient in anti-inflammatory cytokines 
and anti-proteases 20,21. The disruption of this balance causes structural damage, ulti-
mately leading to structural changes of the bronchi, so called bronchiectasis. These 
structural changes in combination with the increased mucus viscosity creates an ideal 
environment for overgrowth of several pathogens. In summary, lungs of CF patients are 
subject to continuous inflammation and recurrent infections, creating a vicious cycle 
leading to damage of the airways and the lung parenchyma, which is the primary cause 
of morbidity and mortality.
Current monitoring of asthma is based on clinical history, physical examination, lung 
function tests, and in CF additionally microbiological studies and imaging of the lungs 
are used for monitoring. However, neither of these monitoring tools have shown a close 
association with airways inflammation, the hallmark of these diseases. Bronchoalveolar 
lavage, endobronchial biopsies and sputum induction are invasive techniques to obtain 
material from the airways and are not suitable for routine use. Hence, there is a need 
for noninvasive methods to assess airways inflammation in monitoring asthma and CF.
Exhaled breath analysis
The sense of smell has been used as a medical diagnostic tool for thousands of years. 
Already in ancient times Hippocrates suggested that a specific breath odor could reflect 
a certain disease. Since the fraction of exhaled nitric oxide (FeNO) was recognized as a 
General introduction, aims and outline 15
1noninvasive marker of eosinophilic airway inflammation 
22, research into volatile organic 
compounds (VOCs) in exhaled breath has progressed rapidly. Exhaled breath is a mix-
ture of water vapor, carbon dioxide, oxygen, nitrogen, and small amounts of inert gasses 
such as nitric oxide and carbon monoxide. In the 1970’s Pauling et al. were the first to 
discover that exhaled breath also contains multiple VOCs in very low concentrations 23. 
Currently more than 4500 different VOCs have been identified originating from the hu-
man body 24. It is most likely that these VOCs result from metabolic fractioning of larger 
molecules, however the exact biological source of most VOCs is still unknown. Exhaled 
VOCs originate from both local (upper and lower airways) and systemic endogenous 
processes (diffusion from pulmonary capillary bed into the alveolar compartment). 
In addition, exhaled VOCs can also originate from exogenous sources (environmental 
contamination) that have been inhaled, which is one of the biggest disturbing factors 
in breath collection. VOCs in exhaled breath consist of different groups of molecules, 
e.g. acids, alcohols, aldehydes, esters, furans and ethers, hydrocarbons, halogen con-
taining compounds, ketones, nitrogen, sulfer containing compounds and others 24. 
An important group of VOCs in relation to airways inflammation are hydrocarbons. 
During inflammatory processes, ROS are produced, which react with lipid components 
in cell membranes resulting in lipid peroxidation and degradation of cell membranes. 
Hydrocarbons are the stable breakdown products of this lipid peroxidation. The detec-
tion of VOC profiles in exhaled breath has the potential to assess the degree of airways 
inflammation and therefore may have the potential for early detection of exacerbations, 
to detect the presence of specific micro-organisms and to evaluate treatment effects. 
Thus, exhaled breath profiling may provide a step towards personalized management of 
chronic inflammatory respiratory diseases like asthma and CF.
Several methods are available for exhaled breath analysis. Gas chromatography coupled 
to mass spectrometry (GC-MS) is most commonly used for the identification of VOCs in 
exhaled breath. This technique is applicable for broad-spectrum detection and quanti-
fication of specific VOCs at relatively low concentrations based on their mass-to-charge 
ratio. Disadvantages include the need for preconcentration of the samples, the fragmen-
tation of molecules and the need for qualified technicians and expensive equipment. 
Another sensor-based technology is the 'electronic nose' (eNose) 25. Combined sensor 
responses provide a real-time analysis of the complete spectrum of VOCs and can be 
analyzed by pattern recognition algorithms. This technique allows real-time measure-
ment and is rapid, easy to use and relatively inexpensive, however it is not possible to 
identify separate molecules. We cooperated with the Technical University Delft (Delft, 
the Netherlands) to develop a broadband quantum cascade laser-based spectroscopy 
technique, with the aim to combine the advantages of both previously mentioned 
techniques, to identify and quantify VOCs with the future potential to be miniaturized.
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BRonchoPulMonARy DysPlAsiA: EARly MARkERs in tRAchEAl 
AsPiRAtEs AnD clinicAl Follow uP
Bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) was first described in 1967 by Northway et al. The 
classic form of BPD, now referred to as ‘old’ BPD, was typically seen in preterm born infants 
exceeding 1200 gram and 30 weeks gestational age (GA) who received high concentra-
tion oxygen therapy and pressure regulated mechanical ventilation for the treatment 
of respiratory distress syndrome 26. In these infants pathology was mostly characterized 
by emphysema, atelectasis, parenchymal fibrosis and airway inflammation  27. Due to 
advances in perinatal and neonatal care including antenatal glucocorticoid therapy, 
surfactant replacement therapy and advanced ventilation strategies, this form of BPD 
is now rare in infants exceeding 1200 gram and 30 weeks GA 28. However, the incidence 
of BPD did not decrease during the last decade due to increased survival of extremely 
preterm born infants.
Bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is a chronic lung disease and is clinically defined 
in infants born before 32 weeks of gestational age (GA) as need for oxygen supple-
mentation for ≥ 28 days at 36 weeks postmenstrual age 29. In Europe the incidence 
of BPD ranges from 4% at a GA of 31 weeks to 56% at a GA of <26 weeks 30. BPD is 
characterized by impaired lung development with fewer and larger alveoli as a result 
of interrupted alveolar septation and abnormal pulmonary vascular organization 31. 
Treatment of infants with BPD is limited and symptomatic with diuretics, (inhaled) 
corticosteroids, vaccinations and supplemental oxygen as the most frequently 
prescribed treatments. Survivors of preterm birth and BPD experience long term 
cardio-respiratory complications, but also neurological and cognitive impairment 
are common 32.
The risk for BPD increases substantially with lower GA 33 and lower birth weight 34,35. 
Extremely preterm infants (< 28 weeks GA) are born when lung development is still in 
the saccular stage, resulting in alveolar simplification. This ‘new’ form of BPD is charac-
terized by an impaired lung development with fewer and larger alveoli as a result of 
interrupted alveolar septation and abnormal vascular organization, while inflammation 
and fibrosis are less prominent 31. This suggests that poor lung development at the time 
of birth and during exposure to mechanical ventilation and supplemental oxygen is 
crucial for the development of ‘new’ BPD. The etiology is multifactorial and besides GA 
at birth, includes (epi)genetic predisposition and exposure to antenatal and postnatal 
environmental factors, such as chorio-amnionitis or preeclampsia, intrauterine growth 
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1retardation, mechanical ventilation, oxygen exposure, postnatal infections, persistent ductus arteriosus and malnutrition. Even though progress has been made over the last 
decades in the management of extremely preterm infants with BPD, to date treatment 
modalities are still limited. Survivors of preterm birth and BPD have more respiratory 
symptoms, such as wheeze, cough and dyspnea than term and preterm controls without 
BPD 36-41. Both preterm infants with and without BPD have obstructive lung function, 
although the level of obstruction is more pronounced in the children with BPD 42. Lung 
CT imaging studies reveal structural abnormalities in almost all patients with BPD, 
both in the neonatal period 43-45 and in later life 46-51. Severe BPD is also associated with 
pulmonary hypertension 52-54. Besides cardio-respiratory sequelae also neurological and 
cognitive impairment are common in preterm born infants with BPD 32,39,55.
Many of the above mentioned follow-up studies describe populations born before 1990 
and reflect the 'old' BPD population. The increasing rates of preterm birth and the im-
proved survival of especially extremely preterm born infants (< 28 weeks GA) result in an 
increasing incidence of 'new' BPD. Therefore, it is important to gain more insight in the 
pathophysiology of this chronic lung disease as well as into the structural and functional 
respiratory changes across their life course.
impaired lung development in BPD
Prenatal lung development consists of an embryonal and a fetal phase. The fetal phase 
is subdivided in 3 separate stadia: canalicular, saccular and alveolar phase (Figure 2). In 
preterm born infants, lung development is still in the saccular phase (24-36 weeks GA), 
during which lengthening and widening of the saccules distal to the terminal bronchi-
oles take place. In the saccular phase the lungs are immature, which is characterized 
by insufficient gas exchange, insufficient surfactant production, poor airway supportive 
structures, reduced antioxidant mechanisms, reduced compliance and insufficient fluid 
clearance compared to lungs in the alveolar phase. The primary septa in this saccular 
phase form the basis for a process called secondary alveolar septation, which is crucial 
for the formation of alveoli. The alveolar phase follows the saccular phase and lasts until 
2-3 years of age 56,57,58.
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Figure 2. Diff erent phases of lung development. Adapted from de Kleer et al. Kinderarts en Wetenschap 
2014. Oct;11:13-19.
During alveolarisation secondary septa subdivide the immature saccules into smaller al-
veolar units to increase the surface area for gas exchange. Also, the capillary monolayer is 
formed reducing the septal thickness and thereby improving gas exchange properties 59. 
The most prominent pathological fi nding in 'new' BPD is an impairment in this alveolar 
development, resulting in large and simplifi ed airspaces with varying degrees of inter-
stitial fi brosis. Since angiogenesis is a driving force of alveolarisation during normal lung 
development, disruption of microvascular development in premature lungs has recently 
been postulated as a critical factor in the alveolar development in BPD 60,61.
Pathophysiological aspects of bronchopulmonary dysplasia: role of 
infl ammation and angiogenesis
Infl ammation is a hallmark of BPD development. Indeed, numerous reports have shown 
associations between increased cytokine concentrations in blood and BAL fl uid and 
development of BPD, as reviewed elsewhere 62. This infl ammation is often already pre-
natally induced by maternal factors like chorio-amnionitis 63, and postnatally aggravated 
by exposure to mechanical ventilation and both hypoxemia and hyperoxia causing 
acute pulmonary injury followed by an infl ammatory response. Both neutrophils and 
macrophages are immune cells involved in this infl ammatory process 64-66. Activated 
neutrophils and macrophages produce cytokines, proteases, elastase, collagenase, 
metallomatrix proteases (MMPs) and oxygen radicals (reactive oxygen species, ROS). 
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1Proteases cause direct damage to the extracellular matrix, in which interstitial capillar-ies need to grow, hampering secondary alveolar septation. ROS cause direct damage 
inducing microvascular permeability and edema and inhibit protective anti-proteases. 
Additionally, the imbalance of oxidative and anti-oxidant properties increases the sus-
ceptibility of preterm infants for damage by ROS 67.
Besides the presence of inflammation, BPD is also characterized by abnormal pulmonary 
vascular development and interrupted septation 60,61,68. Several pro-angiogenic and 
anti-angiogenic factors have shown to play a role in these processes: such as vascular 
endothelial growth factor (VEGF) 69,70, soluble fms-like tyrosine kinase-1 (sFlt-1) 63, 64, 
placenta growth factor (PlGF) 64, 65, insulin-like growth factor 1 (IGF-1) 71, angiopoietin 
1 and 2 72, platelet derived growth factor (PDGF)-AA 73,74 and transforming growth 
factor beta (TGF-β) 75,76. Placental mediated pregnancy complications (e.g. gestational 
hypertension, preeclampsia and HELLP syndrome) with fetal consequences (e.g. fetal 
growth restriction) are associated with moderate to severe BPD development 77. In these 
disorders increased blood levels of anti-angiogenic factors arising from the placenta 
have been found 78. This suggests that an imbalance in circulating pro-angiogenic and 
anti-angiogenic factors can disrupt vasculogenesis in fetal lungs, which may lead to 
impaired lung development 79.
Pathophysiological aspects of bronchopulmonary dysplasia: role of 
sphingolipids
Sphingolipids are important structure-bearing constituents of cell membranes and 
function as regulatory molecules in cell proliferation and cell death, endothelial barrier 
function, angiogenesis, and immune response (Figure 3) 80,81,82.
Figure 3. Pathway of sphingolipid metabolism. The regulation of sphingolipid metabolism is complicated 
and involves many enzymes, marked in italics. Adapted from Tibboel et al. Chest 2014 Jan;145(1):120-8.
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Altered sphingolipid levels have been found in a variety of diseases such as atheroscle-
rosis, chronic heart failure, diabetes mellitus, sepsis, but also in respiratory disorders 
like asthma, cystic fibrosis and chronic obstructive pulmonary diseases 82. Sphingolipids 
are involved in lung development and damage and repair processes after lung injury 81. 
Recently, we investigated the role of sphingolipids in a hyperoxia-induced mouse 
model of BPD 83. In short, we observed a transient increase in long chain and very long 
chain ceramides in the first 2-4 weeks of hyperoxia 84. Additionally, supplementation 
of D-sphingosine, a synthetic precursor of sphingosine-1-phosphate, during normoxia 
recovery of hyperoxia-induced lung damage accelerated normalization of ceramides 
and improved the hyperoxia-induced alveolar arrest in this neonatal mouse model 
of BPD 84. We hypothesize that ceramides may be involved in the early stages of BPD 
development, can be used as an early biomarker for BPD, and might be a promising 
target for new therapies.
tracheal aspirate analysis
In the second part of this thesis we used tracheal aspirates to analyze inflammatory 
factors, angiogenic growth factors and ceramides in preterm infants who did or did not 
develop BPD. Tracheal aspirates are suitable substitutes for BALF samples in studies of 
newborn lung fluid 85,86. Tracheal aspirates can be collected relatively noninvasively dur-
ing routine suctioning procedures in children who are mechanically ventilated through 
an endotracheal tube. Numerous reports have shown the possibility to measure 
cytokines, chemokines and growth factors in the supernatant of lung-derived fluid 
including tracheal aspirates  62,87-89. Over recent years, newer molecular techniques al-
low simultaneous detection of an increasing number of biomarkers in small samples of 
body fluid using multiplex assays. Both proteome analysis and multiplex immunoassays 
(Luminex) are examples of such techniques to identify and quantify multiple biomarkers 
simultaneously in a systematic matter.
AiMs AnD outlinE oF this thEsis
The aims of this thesis are:
– To review the use of biomarkers in exhaled breath and exhaled breath condensate in 
diagnosing and monitoring respiratory diseases in children.
– To study the potential of exhaled breath profiling using broadband quantum cas-
cade laser-based spectroscopy in healthy children and children with asthma and 
cystic fibrosis.
– To identify early biomarkers for BPD development and possible new targets for 
therapeutic intervention in BPD.
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1– To review structural lung abnormalities that have been described on chest CT scans of children and adults with BPD and to propose a new quantitative CT scoring 
method.
– To investigate the structural and functional pulmonary outcomes of preterm born 
infants with severe BPD at 6 months corrected age.
Part i focuses on exhaled breath analysis in healthy children and children with asthma 
or CF. In chapter 2 the current knowledge on the methodological issues and clinical 
applications of exhaled breath and exhaled breath condensate analysis in children with 
respiratory disorders is reviewed. In chapter 3 we present our new broadband quantum 
cascade laser-based spectroscopy method to detect VOC profiles in exhaled breath. In 
chapter 4 we describe the results of a pilot study investigating the clinical applicability 
of this new exhaled breath analyzing technique in healthy children and in children with 
asthma or CF.
Part ii focuses on children with BPD. In chapter 5 we study the role of inflammation and 
angiogenesis in BPD development in a prospective study performed in preterm born 
infants (≤ 32 weeks of GA). We assess whether profiles of monocytes/macrophages and 
their products in tracheal aspirates correlate with BPD development. In chapter 6 we 
aim to evaluate our earlier findings in a mouse model of hyperoxia induced lung injury 
and investigate the presence of sphingolipids in tracheal aspirates of preterm born 
infants, and their role as possible early new biomarker for BPD development. At Sophia 
Children’s Hospital Pediatric Chest Center, we follow preterm born children with severe 
BPD until adulthood in a multidisciplinary team of specialists. In chapter 7 we review 
the current literature regarding chest CT scoring in BPD patients and propose a new 
quantitative scoring system, the 'Perth-Rotterdam Annotated Grid Morphometric Analy-
sis', PRAGMA-BPD scoring system. In chapter 8 we present follow-up data of severe BPD 
patients, combining information on lung structure, function and postnatal growth.
In chapter 9 we discuss our main findings and conclusions and give recommendations 
for future research. In chapter 10 our findings, as described in this thesis, are summa-
rized in English and in Dutch.
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ABstRAct
Current monitoring strategies for respiratory diseases are mainly based on clinical 
features, lung function and imaging. As airway inflammation is the hallmark of many 
respiratory diseases in childhood, noninvasive methods to assess the presence and 
severity of airway inflammation might be helpful in both diagnosing and monitoring 
pediatric respiratory diseases. At present, the measurement of fractional exhaled nitric 
oxide is the only noninvasive method available to assess eosinophilic airway inflamma-
tion in clinical practice.
We aimed to evaluate whether the analysis of volatile organic compounds (VOCs) in 
exhaled breath (EB) and biomarkers in exhaled breath condensate (EBC) is helpful in 
diagnosing and monitoring respiratory diseases in children.
An extensive literature search was conducted in Medline, Embase and PubMed on the 
analysis and applications of VOCs in EB and EBC in children.
We retrieved 1165 papers, of which 9 contained original data on VOCs in EB and 84 on 
biomarkers in EBC. These were included in this review. We give an overview of the clini-
cal applications in childhood and summarize the methodological issues.
Several VOCs in EB and biomarkers in EBC have the potential to distinguish patients from 
healthy controls and to monitor treatment responses. Lack of standardization of collec-
tion methods and analysis techniques hampers the introduction in clinical practise. The 
measurement of metabolomic profiles may have important advantages over detecting 
single markers. There is a lack of longitudinal studies and external validation in order 
to reveal whether EB and EBC analysis have added value in the diagnostic process and 
follow-up of children with respiratory diseases. In conclusion, the use of VOCs in EB 
and biomarkers in EBC as markers of inflammatory airway diseases in children is still a 
research tool and not validated for clinical use.
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intRoDuction
The analysis of volatile and non-volatile substances in exhaled breath (EB) and exhaled 
breath condensate (EBC) for diagnosis and management of respiratory and nonrespira-
tory diseases has raised great interest. Current monitoring strategies of chronic inflam-
matory lung diseases such as asthma and cystic fibrosis (CF) are mainly based on clinical 
features, lung function and imaging techniques. However, neither of these have shown 
a close association with airway inflammation, a hallmark of these diseases. Available 
techniques to quantify airway inflammation, including assessment of biomarkers in 
bronchoalveolar lavage fluid, induced sputum and endobronchial biopsies are invasive 
and not suitable for routine use. In pediatric pulmonary medicine, noninvasive methods 
to assess airway inflammation might be helpful in diagnosing and monitoring airway 
diseases. The analysis of EB and EBC has the potential to meet these expectations. Re-
search into noninvasive assessment of airway inflammation has progressed rapidly since 
it was recognized that exhaled nitric oxide (eNO) is elevated in exhaled air of asthmatic 
patients as compared to healthy persons 1,2. However, the use of only a single biomarker 
cannot be expected to reflect complex pathological processes, nor to monitor hetero-
geneous diseases such as asthma. A profile of several biomarkers has the potential to 
reflect disease phenotypes and may provide a key step towards personalized medicine. 
In this review we will give an overview of methodological issues and clinical applications 
of EB and EBC analysis in children with respiratory diseases.
MAtERiAls AnD MEthoDs
We conducted a literature search on the clinical applications of volatile organic com-
pounds (VOCs) in EB and EBC analysis in children, in Medline, Embase and PubMed. 
The last search was run on July 15, 2013. Key words/Mesh terms included: Breath Tests 
(Mesh), Volatile Organic Compounds (Mesh), Biological Markers (Mesh), breath analysis, 
Infant (Mesh), Pediatric (Mesh), Adolescent (Mesh). The search was limited to articles 
published in English. We retrieved 1165 articles. Reference lists were reviewed for ad-
ditional references. To be included in this review, studies had to address original data, 
either VOC profiles in EB or at least one EBC marker, in children up to 18 years of age 
with a respiratory disease. Finally, we included 151 articles, of which 9 clinical studies 
regarding VOC profiles in exhaled breath and 84 clinical studies regarding biomarkers 
in EBC. This could be randomized controlled trials, case-control studies, observational 
studies and case reports. Fifty-eight additional papers, arguing methodological issues 
on EB and EBC analysis, were retrieved. The great majority of the reviewed articles did 
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not meet criteria for formal grading of quality, so we decided not to grade, but to focus 
on clinical applicability.
ExhAlED BREAth
Volatile organic compounds in exhaled breath most likely result from metabolic frac-
tioning of larger molecules. However, the exact biological source of most VOCs is still 
unknown 3. VOCs can originate not only from the lungs or upper airways but also from 
the circulation and diffuse from the lung capillary bed into the alveoli 4. Therefore, the 
measurement of VOCs is a potential diagnostic tool not only for diseases of the respira-
tory tract, but also for nonrespiratory diseases. In this review we will focus on VOCs in 
respiratory disorders (Table 1).
Methodology of exhaled breath collection and processing
The collection of VOCs is influenced by environmental, physiological and methodologi-
cal factors. In general, these can be divided in precollection, collection and postcollec-
tion conditions.
Precollection conditions
Volatile organic compounds are abundant in ambient air, and significant linear relation-
ships between ambient and exhaled concentrations of VOCs, such as ethane, propane, 
pentane and methanol, were demonstrated 5. To minimize the influence of ambient 
VOCs, various techniques have been proposed. These include prior inhalation of purified 
air 6, tidal breathing through a charcoal filter 7,8 and correction for the calculated alveolar 
gradient 5,9-11. None of these techniques has proven superior, but for every substance 
in EB contamination from ambient air should be considered. Also, intake of food and 
beverages, smoking habits and medication have been shown to influence exhaled VOC 
profiles. Not surprisingly, several studies have shown that both active and passive smok-
ing influence components in EB 4,12. Similarly, medication like inhaled corticosteroids 
(ICS) influences VOC patterns due to either exogenous contamination or indirectly by 
their effect on the disease process 6. Patient characteristics, such as age and gender, also 
influence VOC patterns in EB as lung volume, pulmonary circulation and metabolism 
may contribute to variation in VOC patterns 6,13,14.
Collection conditions
Both breathing manoeuvres and sampling materials can potentially influence the 
composition of EB. EB is a mixture of alveolar air and environmental air from the dead 
space of the conducting airways. Alveolar air has undergone gaseous exchange with 
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the blood, and its composition may therefore specifically reflect systemic diseases. In 
contrast, components derived from the conducting airways provide information that 
is relevant to airway diseases. To determine the anatomical origin of exhaled breath, 
simultaneous measurement of CO2 in exhaled air has been proposed 9,10,15. In contrast to 
eNO which is highly flow dependent 16, only limited influence has been reported of both 
breathing pattern and expiratory flow on exhaled VOC profiles and current data do not 
suggest that breathing manoeuvres need to be standardized 6,17-19.
Several techniques to collect EB samples have been described. Breath samples can be 
collected for offline analysis via canisters, bags, syringes or sorbent tubes, or can be di-
rectly exhaled via inert tubing into an analyser for online measurement. Reservoirs carry 
the risk of being permeable for certain VOCs, absorb VOCs, or release VOCs themselves. 
A suitable material is Tedlar, which is chemically inert to most compounds, impermeable 
for gases and does not absorb molecules. However, Tedlar bags release (N,N-dimethyl) 
acetamide and phenol in relatively high concentrations 4. Siliconized metal canisters 
and thermal desorption tubes have reliable storage properties for many VOCs, but are 
expensive 20. Furthermore, one should be aware of contamination by disposable plastic 
components in mouth pieces, tubes and valves.
Postcollection conditions
Several techniques have been used for the detection and analysis of VOCs in exhaled 
breath samples. Gas chromatography coupled with mass spectrometry (GC-MS) or flame 
ionization detection (GC-FID) is most commonly used. These techniques can detect and 
quantify specific VOCs at relatively low concentrations. Disadvantages include the need 
for preconcentration of the samples, mainly by solid-phase micro-extraction, and the 
need for highly qualified technicians and expensive equipment 11. Other techniques also 
make use of mass spectrometry as detection technique, such as selected ion flow tube 
(SIFT-MS) and proton transfer reaction (PTR-MS), and have the advantage to enable real 
time measurement. Ion mobility spectroscopy and laser spectroscopy also allow for real-
time measurement, although detection is restricted to those substances which can be 
ionized or can absorb the laser within the specific wavelength spectrum. Breath samples 
can also be analysed using different sensor-based techniques, such as colorimetric sen-
sor array, gold nanoparticle sensors and the electronic nose. These techniques make 
use of an array of specific sensors of which the optical, chemical or electrical properties 
change when they interact with the molecules present in EB samples 21. Advantages of 
these techniques include that pretreatment of samples is not required, online real-time 
measurement is possible and that they are rapid, easy to use and relatively inexpensive. 
The combined sensor responses provide a spectrum of VOCs, but determination of indi-
vidual molecular components is not possible. This is a major disadvantage, which limits 
the opportunity to understand the pathophysiology of diseases. Moreover, the results of 
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individual analysers are not comparable 22. Presently, sensor-based techniques are being 
studied for their possible clinical applications.
clinical applications in pediatric respiratory diseases
Asthma and allergy
Overall, VOCs in EB samples can discriminate asthmatic from healthy children, and atop-
ics from nonatopics (Table 1) with a relatively high sensitivity and specificity 23-25 and 
limited intra-individual variability 17,23,24. A combination of six VOCs was able to predict 
exacerbations in asthmatic children 26. Collection of VOCs is also feasible in preschool 
children, and it has been shown that VOC profiles differ between children with and with-
out recurrent wheeze 27. Overall, the best discriminating VOCs for asthma seem to be 
hydrocarbons 23-25,27. However, each individual study demonstrates a different superior 
set of VOCs, and there clearly is a need for external validation. Also, further research 
is needed on the effects of disease severity and ICS on VOCs in children with asthma. 
Hence, VOCs in EB may be helpful for asthma diagnosis, but their role in asthma monitor-
ing is still unclear.
Cystic fibrosis
Only one study investigated VOC profiles in 48 children with CF compared to 57 healthy 
controls. About 6000 different VOCs were identified and by using 22 VOCs, 100% correct 
identification of CF patients and controls was possible with good short-term reproduc-
ibility 17. In addition, VOC profiles could discriminate CF patients with positive cultures 
for Pseudomonas aeruginosa (Pa) from patients with negative cultures and predict CF 
exacerbations 17. As Pa colonization is associated with a less favourable prognosis in CF, 
early detection is important to facilitate early eradication; especially in young children 
who are not able to produce adequate sputum samples, the analysis of EB may prove 
useful.
The electronic nose was able to distinguish children with CF or primary ciliary dyskinesia 
(PCD) from healthy controls, and children with and without a pulmonary exacerbation; 
however data on longitudinal patterns are lacking 28.
ExhAlED BREAth conDEnsAtE
Contrary to EB, EBC is thought to reflect the epithelial lining fluid and therefore, studies 
of EBC have been limited to respiratory disorders. EBC is collected by cooling the exhaled 
air of a tidally breathing subject 29. Multiple biomarkers have been detected in EBC, such 
as acidity, nitrogen oxide-related compounds, oxidative stress markers, eicosanoids, 
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cytokines and others. Airway acidity is the simplest and best validated marker in EBC. 
EBC pH is reproducible 30,31 and normative data have been published 32.
With eNO as an established biomarker of eosinophilic airway inflammation, the 
measurement of metabolites of nitrogen oxides (NOx) in EBC, such as nitrate, nitrite, 
nitrosothiols, peroxynitrite and nitrotyrosine, may also be informative. In the presence 
of airway inflammation, increased amounts of reactive oxygen species (ROS), such as 
hydrogen peroxide (H2O2), are released and can be measured in EBC. ROS induce lipid 
peroxidation that results in the formation of isoprostanes. Other eicosanoids, such as 
prostaglandins, leukotrienes, hydroxyeicosatetraenoic acids (HETE), eoxins and lipoxins 
can also be measured in EBC 33. Cytokine levels have been measured with varying suc-
cess. In general, cytokine concentrations in EBC are at or below the detection limit in 
most samples.
Collection of EBC is simple, safe, noninvasive and highly repeatable. In an attempt to 
standardize EBC measurements and compare results between centres and between 
studies, the American Thoracic Society (ATS) and European Respiratory Society (ERS) 
published methodological recommendations for collection and analysis of EBC samples 
in 2005 and 2010, and the recommendations will be updated soon 34,35. Today, several 
methodological issues, such as variability in collection devices, the issue of dilution and 
the sensitivity of available assay techniques, remain a challenge 36. We will briefly discuss 
the methodology of EBC collection and processing, and focus on the clinical application 
of EBC markers in pediatric respiratory disorders (Table 2).
Methodology of EBc collection and processing
Exhaled breath condensate can be easily collected during tidal breathing, even in 
very young children. Again several methodological factors are critical for the study of 
biomarkers in EBC, separated in precollection, collection and postcollection conditions.
Precollection conditions
Most physiological and environmental factors, which can potentially influence the 
composition of EBC, have not been studied systematically. Overall, biomarkers in EBC 
show no relation with gender and age 32,37-40 except for cysteinyl leukotrienes and 8-iso-
prostane, which both increase with age, and pH, which decreases with age 41,42.
Active smoking influences biomarker composition of EBC 43. The effect of passive smok-
ing seems less clear. A study in healthy children showed no influence of passive smoking 
on H2O2 concentrations in EBC 44. It was recommended to document smoking exposure 
and refrain from smoking at least 3 h before EBC sampling 34. Also beverages significantly 
influence, for example, EBC acidity 45. Similarly, the ATS/ERS taskforce advised to refrain 
from eating and drinking for a period of a few hours before collecting EBC 34.
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The effect of exercise on EBC has been considered in a number of studies, as exercise 
may increase oxidative stress. No differences have been found in 8-isoprostane, pH and 
cysLT before and after exercise, however these studies all lacked power 46,47. While better 
studies are awaited, it seems prudent to avoid exercise immediately before EBC collec-
tion 48.
Collection conditions
Exhaled breath condensate collecting devices have in common that subjects breathe 
tidally via a mouthpiece through a two-way nonrebreathing valve. The exhaled air is 
cooled into a condenser and EBC is collected in a container attached to the free end of 
the tube. Commercially available devices include the Ecoscreen® (Jaeger, Hoechberg/
Wurzburg, Germany), the RTube® (Respiratory Research Inc., Charlottesville, VA, USA) and 
the ’Transportable Unit for Research on Biomarkers Obtained from Disposable Exhaled 
Condensate Collection Systems’ (TURBO DECCS®). An important difference between 
these three collection devices is the cooling temperature. The Ecoscreen and TURBO 
DECCS both collect EBC at a stable cooling temperature of respectively -10 to -15⁰C, and 
-5⁰C. In contrast, the R-tube uses a precooled -20⁰C aluminium sleeve, which is placed 
over the collection tube; therefore, the collection temperature gradually increases dur-
ing the procedure, which affects the amount of EBC volume collected 49.
Other collection conditions can influence EBC volume and biomarkers, such as sampling 
material, expiratory flow and contamination by saliva or ambient air. Current condenser 
chambers are made of glass, silicone, Teflon, aluminium, polystyrene or polypropylene. 
Loss of EBC biomarkers due to adhesive properties of these materials can influence re-
sults 50. Coating of all surfaces with bovine albumin to avoid adherence of proteins (such 
as cytokines) and with Tween 20 (polysorbate 20) to prevent adherence of fatty acid 
derivatives (such as leukotrienes and prostaglandins) has been suggested to overcome 
this problem 51.
Expiratory flow may be an important factor influencing the size and number of respira-
tory droplets formed, which might increase variability of biomarker concentrations 52. 
Indeed, both minute ventilation and tidal volumes significantly affect EBC volume 53,54. 
However, to date, no studies have shown that minute ventilation or tidal volumes influ-
ence specific EBC biomarkers 53,55.
Most biomarkers in EBC are also present in much higher concentrations in saliva. There-
fore, it is important to avoid contamination with saliva, which can be achieved with 
either a saliva trap, rinsing of the mouth prior to collection, or regular swallowing during 
the collection procedure. In addition, samples can be tested for the presence of salivary 
amylase. Exposition of EBC samples to room air should be avoided, as ambient air may 
influence the composition of EBC through direct contribution or indirect via chemical 
reaction with molecules in EBC.
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Postcollection conditions
The dilution of respiratory droplets by water affects biomarker concentrations in EBC, 
and several ways to correct for dilution have been suggested, including conductivity, 
total cations or urea concentration 56-59. All of these have disadvantages and may intro-
duce more variability. Presently, there is no generally accepted method to correct for 
dilution, and it is not recommended to apply any correction. Furthermore, storage time 
and conditions may influence biomarker concentrations in EBC. The ATS/ERS task force 
recommended to freeze EBC samples immediately after collection and to store samples 
at -70°C until analysis 34. Data are available regarding the stability of EBC pH 60, H2O237,44 
and nitrite 61, but there is a lack of data on the long-term stability of other biomarkers.
clinicAl APPlicAtions oF EBc AnAlysis in PEDiAtRic REsPiRAtoRy 
DisEAsEs
Asthma and allergy
Acidity
Airway acidity is one of the best validated markers in EBC, at least in adults, and norma-
tive data for healthy children aged 0-20 years have been published, with a median (IQR) 
pH of 8.0 (7.8-8.1) 32.
In children with stable asthma, lower pH in EBC was demonstrated compared to healthy 
controls, and children with severe asthma had lower pH compared to mild asthmat-
ics 30,55,62-67. In addition, asthmatic children treated with ICS had higher pH values than 
steroid naïve patients 65,67, and patients with an acute exacerbation had significantly 
higher pH values after 1 week of treatment with inhaled budesonide 66. No associa-
tion between EBC pH and other measures of asthma control such as symptoms, lung 
function, airway hyperresponsiveness or FeNO has been shown 30,68-71. However, when 
interpreting results, one should take into account that gas standardization by means 
of removing CO2 does have a significant effect on EBC pH 72. Indeed, studies measur-
ing pH directly after collection without de-aeration found no difference in pH between 
asthmatic children and healthy controls 68-70,73,74, and pH did not reflect asthma severity 
nor changed after treatment 68,69,75.
Ammonium, thought to be a buffer of airway epithelial lining fluid, was found to be 
significantly lower in stable asthmatic children compared to healthy controls. However, 
there was a considerable overlap, and ammonium levels did not decrease further during 
an acute exacerbation or show any change during treatment 69.
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Nitrogen oxide related-compounds
Conflicting results on EBC NOx have been found in asthmatic children 40,61,70,73,76-82. Over-
all, EBC NOx were not related to asthma severity 40,61,77,81, did not differentiate between 
stable disease and exacerbations 79 and were not influenced by ICS 77,81. In addition, most 
studies did not show a correlation between EBC NOx and either symptoms 70,83, lung 
function 39,70,76,78,83 or FeNO 61,76-78. These conflicting results may be due to the high inter- 
and intra-individual variability, and perhaps to contamination 52,61.
Oxidative stress
Exhaled breath condensate H2O2 is increased in asthmatic children, especially during 
exacerbations 84-86 and decreases after treatment with ICS, supporting the hypothesis 
that H2O2 reflects airway inflammation 84,86. On the contrary, others found no differences 
in H2O2 between stable asthmatic children and controls, and H2O2 did not predict exac-
erbations in childhood asthma 73,87,88. Normal values differ between studies, most likely 
due to different methodologies 89.
Another potential biomarker of oxidative stress in asthma is asymmetric dimethylargi-
nine (ADMA). ADMA is a L-arginine analogue, which inhibits NOS, resulting in a decreased 
synthesis of NO and increased synthesis of superoxide. Higher levels of ADMA have been 
found in asthmatic children compared to healthy controls, with no difference between 
asthmatic children with or without ICS treatment 90. In addition to increased oxidative 
stress, several authors also found a reduction of the antioxidant defence system, as 
reflected by lower glutathione in EBC of children with asthma 91-93.
Eicosanoids
Children with asthma have increased EBC 8-isoprostane compared with healthy con-
trols 64,94-97. Particularly high levels have been found in patients with severe asthma or 
with an asthma exacerbation 98-100. Moreover, 8-isoprostane predicted asthma control 
and severity 73. Contrastingly, no difference could be found between preschool children 
with and without recurrent wheeze symptoms 82. Overall, there was no correlation 
between 8-isoprostane and lung function or eNO 46,94,95. Interestingly, 8-isoprostane was 
hardly affected by ICS 94,96,97,101,102, but did decrease after oral corticosteroids in children 
with asthma exacerbations 95.
In children with asthma also, increased cysteinyl leukotrienes (CysLT) have been found 
compared with healthy controls with higher levels during exacerbations 41,97,102-111. 
Also, in wheezing preschool children, increased levels of LTB4 and LTE4 were found 82. 
Although some authors reported a significant reduction in cysLTs following 5 days of 
oral corticosteroids or 6 months of ICS 95,109 others reported no response of CysLT levels 
following ICS treatment 102,106,107,111. A significant reduction in cysLTs after treatment with 
the cys-LT1 receptor inhibitor montelukast was reported 104,108,112. In general, only weak 
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correlations have been found between lung function, FeNO and cysLTs and LTB4 in 
EBC 41,95,98,102,104,105,107,113.
Cytokines
Overall, children with asthma have increased levels of T helper 2 (Th2) cytokines and 
decreased T helper 1 (Th1) cytokines compared with healthy controls 67,73,114-116. Also 
in preschool wheezing children, several Th2-derived cytokines were increased in EBC 
(IL-1α, IL-2, IL-4, IL-5, IL-8, IL-10 and IL-13) 117,118. IL-4 was a significant predictor for an 
asthma diagnosis and IL-5 predicted asthma exacerbations 88. Also increased levels of 
Th1 (IL-2 and IFN-γ) and proinflammatory cytokines (IL-6) have been reported in children 
with asthma 119. In multivariate models, both IL-4 and IFN-γ were able to assess asthma 
control. Contradictory results have been reported on the effect of ICS treatment on 
EBC cytokine levels 67,75,120. Higher levels of several chemokines and soluble adhesion 
molecules have been reported in asthmatic children 115,119.
Other markers
Extracellular adenyl purines, such as adenosine triphosphate (ATP) and metabolites, are 
important signalling molecules on airway surfaces and are thought to be released in 
reponse to inflammation. One study reported elevated levels of adenosine-urea ratio in 
children with asthma 59.
During chronic airway inflammation, activated neutrophils release proteolytic enzymes, 
such as matric metalloproteases (MMPs), which probably contribute to airway damage. 
Increased MMP-9 levels in EBC have been found in children with persistent asthma 
compared to children with intermittent asthma and healthy controls 114.
cystic fibrosis
Acidity
In children with CF, lower pH compared to healthy subjects was found, although the 
lowest pH values were observed in CF children without bacterial infection 64,121. This is in 
contrast with what one would expect and it has been suggested that certain bacterial 
products may buffer airway pH. However, others found an increase in pH after 2 weeks 
of antibiotic treatment in children with a CF exacerbation 122, or observed lower pH dur-
ing CF exacerbations, while pH did not change after antibiotic treatment 123. Hence, the 
interpretation of EBC acidity in children with CF is not straightforward, and based on the 
available data, EBC pH cannot be used as a marker of airway inflammation in CF.
Nitrogen oxide-related compounds
In children with CF, a discrepancy exists between low eNO in EB and high NOx in 
EBC 39,40,76,124,125. One possible explanation could be an increased metabolism of NO to 
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reactive nitrogen metabolites or interaction with ROS resulting in an increased forma-
tion of nitrotyrosine. The presence of abundant airway secretions in CF may impair dif-
fusion of NO to the airway lumen and stimulate chemical conversion to nonvolatile NO 
metabolites. Another explanation could be that high EBC nitrite levels in patients with 
CF originate from the oropharynx as antibacterial mouthwash reduced the difference 
between patients with CF and controls substantially 126, and nitrite was almost exclu-
sively found in orally collected EBC compared with EBC obtained via a tracheostomy 127. 
Contradictory results have been found regarding the predictive value of nitrite levels for 
CF exacerbations 83,125.
Oxidative stress
Children with CF have increased EBC H2O2, especially during exacerbations, which de-
crease after antibiotic treatment 128. Rosias et al. detected free radicals in EBC as another 
potential biomarker for oxidative stress and reported a trend to more free radicals in 
children with CF compared to healthy controls 129.
Eicosanoids
Children with CF have high EBC 8-isoprostane compared with healthy controls 125,130. 
These levels further increase in unstable patients with CF and seem to be predictive for 
CF exacerbations 130.
Cytokines
In patients with CF high levels of IL-8 are reported compared with healthy controls and 
IL-8 decreased significantly after antibiotic treatment 119. IL-8 is known to play a role in 
both chemotaxis and activation of neutrophils 64,121, 122.
Other markers
In children with CF, elevated ATP levels were found during exacerbations, with a three-
fold decrease after treatment 131. In addition, the AMP-to-urea ratio was elevated in 
patients with CF, with a negative relationship between changes in lung function and 
AMP-to-urea ratio after treatment for an exacerbation 59. Also, in a longitudinal study by 
the same authors, adenosine-to-urea ratio correlated negatively with lung function in 
patients with CF 131.
MMP-9 levels are higher in children with CF- and non-CF-bronchiectasis and are related 
to pulmonary infections, lung function and abnormalities on computed tomography 132.
other respiratory diseases
In pediatrics, the search for biomarkers in EBC has mainly focused on asthma and CF. 
Some individual biomarkers have been studied in relation to other respiratory disorders 
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(Table 2). In children with PCD and in prematurely born adolescents 8-isoprostane was 
found to be increased compared with controls 133,134. However, no difference was found 
between prematurely born adolescents with and without bronchopulmonary dysplasia 
(BPD) 134. LTB4, associated with neutrophilic inflammation, was increased in children 
with a community acquired pneumonia and levels returned to levels of healthy controls 
after antibiotic treatment 135. On the contrary, in children with PCD, LTB4 concentrations 
were not different compared with healthy controls, despite the presence of sputum 
neutrophilia 133.
MEtABoloMic PRoFiling
Single biomarkers may not be able to reflect complex pathological processes, nor 
monitor complex and heterogeneous diseases such as asthma. Metabolomic profiling 
is a nonselective approach, without a priori hypothesis, enabling the identification 
and quantification of all metabolites in a biological system. The metabolomic profile 
is the ultimate expression of genetic information, and interaction with environmental 
agents, micro-organisms, nutritional factors, medication and toxic substances. Hence, 
with metabolomic profiles, disease phenotypes might be discerned and this might 
open the door to personalized medicine. Although identification of all molecules in 
metabolomic profiles may be essential to unravel disease pathways, this may be difficult, 
time-consuming and costly. Expert statistical analysis is needed to account for multiple 
observations, for example by applying discriminant analysis with cross-validation. Also, 
data from single studies need external validation in independent datasets.
Currently, metabolomic profiling is mainly used for the detection of VOC profiles. In 
chapter 1, the results of metabolomics in pediatric respiratory medicine have been sum-
marized. Only in the last years, metabolomic profiling instead of measuring individual 
biomarkers has been applied to EBC in childhood respiratory disorders. Several research 
groups were able to distinguish asthmatic children from healthy controls 33,74,136,137, dif-
ferentiate between asthma severities 136,137 and between patients with unstable or stable 
CF and healthy controls based on a metabolomic approach 138.
conclusion
Exhaled breath and EBC analysis are noninvasive methods to assess potential biomark-
ers of airway inflammation that may be useful in the assessment of respiratory diseases 
in childhood. Standardization of biomarker analysis in EB and EBC remains problematic. 
High variability and low reproducibility in exhaled biomarkers may be explained by dif-
Volatile organic compounds in exhaled breath and biomarkers in exhaled breath condensate 53
2
ferences in a large number of precollection, collection and postcollection conditions. 
Hence, the interpretation of results is seriously hampered by the lack of standardization. 
Furthermore, biomarker detection in EB and EBC remains a challenge as concentrations 
are close to the detection limits of currently available analysis techniques. New tech-
niques, such as the multiplex immunoassay in which multiple inflammatory markers 
can be measured simultaneously in low volume samples with increased sensitivity and 
reliability, might improve analysis of, for example, cytokines in EBC.
Despite these limitations, several biomarkers have shown the potential to distinguish 
patients with various diseases from healthy controls. In EBC, especially the measurement 
of acidity, H2O2 and 8-isoprostane seems promising. However, in the cross-sectional 
studies that have appeared until now, patient groups and controls have been clearly 
defined, which will give a flattered impression of their diagnostic performance. In real 
life, populations will be more heterogeneous, which will induce variability in exhaled 
biomarker profiles and concentrations. Recently, metabolomic approaches were applied 
to both EB and EBC, with the potential to restrain this problem by detecting complete 
profiles instead of single markers. These studies are still in an early phase. Besides rigor-
ous standardization of procedures and more longitudinal studies, particularly external 
validation of specific breath metabolomic profiles for certain diseases or disease phe-
notypes is needed. In the future, the analysis of EB and EBC might prove of additional 
value to clinical features, lung function and imaging techniques. Whether or not these 
technically demanding methods pay off in terms of feasibility, discriminatory power and 
reproducibility, and in future will be used in clinical practice remains to be shown.
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ABstRAct
We present a broadband quantum cascade laser-based spectroscopic system covering 
the region between 850 and 1250 cm−1. Its robust multipass cavity ensures a constant 
interaction length over the entire spectral region. The device enables the detection and 
identification of numerous molecules present in a complex gas mixture without any pre-
treatment in two minutes. We demonstrate that we can detect sub-ppmv concentration 
of acetone in presence of 2% of water at the same wavenumber region.
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intRoDuction
Detection of trace levels of gases is an integral part of life in modern societies. The ability 
to detect trace gases in real time or offline plays a major role in industrial processes, en-
vironmental monitoring, medical diagnostics 1, security, air quality monitoring besides 
other applications. For this reason and to be able to identify specific molecules, many 
optical techniques have been developed based on spectroscopy like long path absorp-
tion spectroscopy, cavity enhanced spectroscopy, cavity ring down spectroscopy, pho-
toacoustic spectroscopy to name a few. The main advantage offered by spectroscopy 
is that specific molecules can be identified using their distinctive fingerprints. This can 
be beneficial when several molecular species are present simultaneously in the gas be-
ing analyzed. The devices which have been developed for this purpose can be based 
on high sensitivity, looking for parts per million by volume (ppmv), parts per billion by 
volume (ppbv) and even parts per trillion by volume (pptv) concentrations of a specific 
gas, or on a broad band technique which looks for many species simultaneously. These 
optical techniques are noninvasive and very little preprocessing is needed in most cases.
Most devices for spectroscopic gas detection are based on absorption by the molecular 
species as described by the Beer-Lambert law. Therefore to optimize the sensitivity of 
the device, the illumination source wavelength and the interaction length have to be 
carefully chosen. Many systems are based in the near to mid-infrared region of the elec-
tromagnetic spectrum. This is mainly because the fundamental rovibrational absorption 
modes of the molecules produce strong spectroscopic fingerprints in this region 2. In 
the near infrared region of the spectrum a host of sources of varying complexity, size 
and price exist because of the needs of the telecommunication industry for which this 
is the favored wavelength. However the spectroscopic fingerprints of molecules found 
in this region are 1000 times weaker than the fundamental absorption modes located in 
the mid-infrared. Sources in the mid-infrared are scattered over the entire wavelength 
range (3-24 μm) and are of varying types such as gas lasers, color center lasers, difference 
frequency generation, optical parametric oscillators, lead salt diodes and the recently 
developed quantum cascade lasers (QCLs), among others. The quantum cascade lasers 
which have been developing very fast in recent years are rapidly filling the holes in the 
wavelength axis, making them an attractive light source for gas analysis 3, 4. Most QCLs 
have a well-defined central wavenumber and a narrow linewidth that allow an accurate 
molecular identification.
The next important element is the optimization of the interaction length between the 
light and the gas volume. In this case considering that sometimes the gas volume is 
limited, the choice is generally made to concentrate the light in the volume confining 
the gas using specifically designed optical cavities. The cavities are designed with two 
different methodologies namely, they can be resonant cavities or multipass cavities. 
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The resonant cavities offer the possibility to obtain interaction distances in the order of 
kilometers inside volumes lower than a liter. However the resonators have strong con-
straints that make their implementation difficult. They require mirrors with reflectivity’s 
higher than 99.9% to achieve the needed finesse 5, 6. Although such mirrors are available 
with the right reflectivity, their bandwidth is still limited to a few nanometers in the mid-
infrared. Another restriction resonators have is the need of a feedback system to correct 
the position of the mirrors because they are susceptible to small mechanical and ther-
mal changes. Furthermore it is necessary to couple the transversal mode of the laser to 
the cavity mode. Multipass cavities, on the other hand, only allow interaction distances 
of tens of meters but their requirements are less demanding. The mirrors’ reflectivity is 
lower, but their working bandwidth is much broader. Multipass cavities are more robust 
to mechanical and thermal changes eliminating the need of a feedback system.
The combination of QCLs’ relatively high power and adequate optical cavities has been 
successfully used to implement highly sensitive spectroscopic techniques such as cav-
ity ring down, photoacoustic spectroscopy, wavelength modulation spectroscopy and 
integrated cavity output spectroscopy 6, 7. Some of these techniques have demonstrated 
sensitivities in the orders of ppmv, ppbv and pptv levels. However, these techniques 
only focus on the detection of one or two selected molecules mainly because they only 
use a small range of the QCLs’ tunability bandwidth. By using the full QCLs’ tunability 
it is possible to detect and differentiate the components present in a more complex 
molecular mixture 8.
In this work we report a broad band spectroscopic trace gas analysis device that cov-
ers the atmospheric window between 850 and 1250 cm−1 (8-11.76 μm) 9. Our approach 
targets the simultaneous detection and identification of several molecules present in 
the gas volume, exploiting the fact that the molecular spectra in this region have a 
broad profile. We compare the detected spectral profile of the gas mixture with well-
established molecular databases, like HITRAN 10 and the Pacific Northwest National 
Laboratory (PNNL) database 11 and identify the specific molecules. Furthermore, the 
multipass cavity employed in our system allows us to detect concentrations in the ppmv 
and sub-ppmv levels.
ExPERiMEntAl sEtuP
A schematic overview of the experimental setup is shown in Figure 1. Its main com-
ponents are: a laser source, a multipass cavity to enhanced the absorption and two 
detectors to monitor the laser intensity and to measure the absorption signal after the 
multipass cavity. A visible laser distance-meter (Leica DISTO D2) co-aligned with the la-
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ser is used as guiding beam and to measure the interaction distance inside the multipass 
cavity.
 QCLs  
Multipass cavity
 
 
Normalization
Detector
Main
Detector
Distance-meter
DetectorLaserZnSe lens
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window
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stage
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mirror
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mirror
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Figure 1. Schematic overview of the experimental setup. The translation stage allows to switch between 
the cavity length determination and the measurement configurations.
The laser source is part of a Laser Scope unit from Block Engineering. It consists of two 
co-aligned tunable QCLs. One QCL covers the region between 850 cm−1 and 1010 cm−1 
and the second QCL emits in the region between 1010 cm−1 and 1250 cm−1. The QCLs 
use diffraction gratings in a Littrow configuration with back extraction to tune the 
wavenumber 12. The angular position of the grating is controlled using a piezoelectric 
component. Therefore, the emitted wavenumber is calibrated with the voltage applied 
to the piezo. The QCLs wavenumber accuracy is 0.1 cm−1. The QCLs’ average power varies 
between 0.5 and 12 mW depending on the emitted wavenumber. Both QCLs are pulsed, 
with a pulse repetition rate of 200 kHz and the pulses have a temporal width of 208 ns. 
These parameters are optimum for the emission of the QCLs in terms of intensity and 
stability. We use pulsed QCLs because they have stable operation at room temperature.
The multipass cavity is based on the modified Herriot configuration described by Mc-
Manus et al.13. It consists of two 2.5 in. (1 in. = 2.54 cm) astigmatic mirrors (Aerodyne 
Research, Inc.) with a reflectivity r > 0.983 over the full spectral range of the QCLs. The 
distance between the mirrors measured along the optical axis is 32.4 cm. The mirrors 
are placed on custom made mounts inside a stainless steel vacuum cell. The cell has an 
input ZnSe window (Thorlabs WG71050-F) with a transmission t > 0.95 in the working 
spectral range. The number of reflections n inside the cavity determines the interaction 
path-length achievable but it also defines the amount of light coming out of the cavity 
through the intensity reduction coefficient k,
k = t2rn (1)
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Even though this type of cavities allow interaction lengths of up to 100 meters 13 we 
prefer a configuration with an interaction length of 54.36 meters, which is long enough 
to detect molecules in concentrations levels of few ppmv and at the same time provides 
a strong output signal. The power coming out of the multipass cell is 5.5% of the laser 
power sent into the cell. The total volume of the cell is 0.6 liters. The multiple reflections 
and the compact configuration allows the laser to travel through most of the volume of 
the cell, which allows a homogeneous interaction with the entire gas sample. We use 
a pressure controller (Bronkhorst, P-702CV-1K1A-RAD-22-V) and a diaphragm vacuum 
pump (Vacuubrand MD 1) to control the pressure inside the cavity. The pressure mea-
surements are particularly important for molecules whose spectra contain sharp ab-
sorption lines. Such lines can suffer broadening because of different effects, for example 
collisional or Doppler broadening. To control the injection of samples inside the cell we 
use a set of mass flow controllers (Bronkhorst, F-201CV-1K0-RAD-22-V), which allows us 
to prepare samples with the desired concentrations using single and double dilution 
techniques 14. For the detection we use two thermo-electric cooled (TEC) Mercury Cad-
mium Telluride (MCT) detectors and a fast acquisition card (NI-PCI 5922). As depicted 
in Figure 1 the main detector collects the signal emerging from the multipass cavity. 
The 100 MHz cut-off frequency of this detector (VIGO System, PVI-4TE-10.6-0.3x0.3-TO8-
BaF2) and the 10 mega samples per second (MS/s) sampling rate of the acquisition card 
allows to detect the peak power of each pulse, increasing the signal to noise ratio (SNR) 
of the measurement 9. A second detector (Laser Scope unit, Block Engineering) is neces-
sary to monitor the laser intensity directly outside the QCLs and normalize the intensity 
of each pulse. This normalization minimizes the pulse to pulse intensity variation of the 
QCLs and increases the sensitivity of the system 15, 16.
MultiPAss chARActERizAtion
Robustness
In most multipass cavities the allowed input angle of the incoming laser beam has a 
small tolerance. Our configuration increases the tolerance using a 500 mm ZnSe lens 
in front of the multipass cavity. As explained before, the broadband tunability of our 
QCLs is obtained using a Littrow configuration with back extraction, which reduces the 
wavenumber-dependent angular displacement of the laser beam to less than 3 mrad. To 
demonstrate the robustness of our device we produced pulses with a temporal width of 
112 ns and measured the normalization signal and the signal from the cavity using one 
detector. For this experiment the configuration of Figure 1 was modified to place both 
signals on the main detector. We only used one detector to have the same detection re-
sponse and avoid any electronic delay. The signal was analyzed using a RIGOL DS1102E 
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oscilloscope. We repeated this measurement for three different central wavenumbers 
as shown in Figure 2. In all cases the delay between signals is 185 ns when the cavity is 
empty, confirming that all pulses travel the same distance inside the cavity. In particular 
the angular displacement between the pulses of Figure 2(b) and (c) is maximum, which 
confirms the tolerance of the multipass cell.
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Figure 2. Delay time between the nor-
malization and the main signals for three 
different wavenumbers. (a) 950 cm−1, (b) 
1000 cm−1 and (c) 1150 cm−1.
internal path-length determination
To measure the path-length inside the multipass cavity we used two methods. First we 
used the laser distance meter, averaged 50 measurements and subtracted the path the 
laser travels outside the cavity, getting a path-length of 54.36 meters. Then we used the 
185 ns pulse delay between the normalization and the main signal shown in Figure 2. 
Subtracting the distance traveled by the laser outside the cavity we got a measured 
distance of 54.33 meters. These two independent measurements are consistent. The 
3 cm difference between them represents a delay of 100 ps which we cannot resolve 
using our oscilloscope.
Measurements
For the absorption measurements we first build a reference spectra I0(ν), where ν is the 
wavenumber. For that we record the transmission of a laser scan through the multipass 
cavity with vacuum or filled with a neutral gas which has no absorption lines in the 
spectral region of our device. Then we average the result of ten laser scans. Immediately 
after, we introduce the gas sample inside the cavity to minimize the effects on our mea-
surements induced by atmospheric variations outside the cavity. Then we scan the laser 
ten times and average the signal to construct a measurement spectrum Im(ν). Using the 
Beer-Lambert law 17 we obtain the absorbance A(ν) of the sample,
A(ν) = - log10 
⎛
⎝
lm(ν) ⎞
⎠ (2)l0(ν)
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The absorbance can also be written in terms of the molecular concentration C in ppmv, 
the interaction path-length between the light and the molecules (l = 54.36 meters in the 
case of the present device) and the molecular absorption coefficient ε(ν) in ppmv−1m−1, 
which is an intrinsic property of the material,
A(ν) = ε(ν)CI (3)
Using this last relation we can determine the molecular concentration from the strength 
of the absorbance.
noise determination and sensitivity analysis
The noise level of our system is determined comparing two reference spectra. As they 
are taken with an empty cavity the variations are only induced by the laser and detector 
fluctuations. The ratio between two reference spectra is a good comparison and as we 
are interested in the absorbance we can use directly Equation (2). From this result the 
noise level is established by taking the absorbance root mean square (rms) value. For 
our system it has a value of 0.02.
To determine the performance of our system we used the formalism developed by 
Moyer et al.18. The minimum detectable absorption per scan (MDAps) is given by
MDAps = 
⎛
⎝
ΔP ⎞
⎠  (4)P n
Where ΔP/P correspond to the rms level calculated above, the number of scans integrated, 
n, is equal to 10 and the time a single scan takes, Tscan, is equal to 5.3 s. The MDAps for our 
system has a value of 0.14 Hz−1/2. To compare with systems that scan over a narrower or 
broader spectral region is important to define the minimum detectable absorption per 
point (MDApp). As we have a well-defined number of data points, #pts = 8000, we use the 
data acquisition rate, rdata = #pts/Tscan as our relevant bandwidth. In this case the MDApp 
= MDAps/(#pts)−1/2 and has a value of 1.6 ×10−3Hz−1/2. The comparison with systems with 
different interaction path lengths is better done using the noise equivalent absorption 
sensitivity (NEAS) 18,19. Since the interaction distance inside the cavity, l, was determined 
to be 54.36 meters the NEAS = MDApp/l and gives a value of 2.99 ×10−7cm−1Hz−1/2.
specific gas measurements
In this section we present a series of measurements to show the performance of our setup. 
In these measurements the reference spectrum was taken with vacuum of 0.10 mbar 
inside the cavity. In all cases we use an atmosphere of N2 as buffer for the sample gas 
mixture because N2 does not have absorption lines in the spectral range of the present 
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device. The first two measurements correspond to controlled mixtures of acetone and 
ethanol. The mixtures were obtained using a double dilution process 14. This way we could 
cross-check the concentration of the samples. We choose these molecules because they 
have strong and smooth absorption profiles in our spectral region. Then we prepared a 
single dilution mixture of CO2 to study the wavenumber resolution and the sensitivity 
of our system, because CO2 has a lower absorption in our region. Finally we present the 
measurement of two complex mixtures to show the applications of our method.
Acetone, ethanol and co2 spectra
In Figure 3(a) the measured spectrum of acetone with a concentration of 22 ppmv at 900 
mbar in an atmosphere of N2 is shown in red. The black line corresponds to the acetone 
spectrum in the same wavelength region from the PNNL database. In this case there are 
broad features that can be easily identified, they are centered at 900 cm−1 and 1218 cm−1.
In Figure 3(b) we present the measured spectrum of ethanol with a concentration of 
60 ppmv at 900 mbar in an atmosphere of N2, in red. The black line corresponds to 
the ethanol spectrum in the same wavelength region from the PNNL database. In this 
spectrum the experimental setup captures the finer spectral details, such as the peaks at 
1028, 1038, 1058 and 1066 cm−1. In this case there is a mismatch in the region between 
980 cm−1 and 1020 cm−1 corresponding to the transition between the two QCLs. But this 
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Figure 3. (a) Absorption spectrum of 22 ppmv of acetone and (b) 60 ppmv of ethanol. Both at 900 mbar 
in an atmosphere of N2.
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is not a limitation to detect the desired molecules since the main spectroscopic features 
are clearly identifiable.
Furthermore, from a measurement of a 15% concentration of CO2 at 500 mbar in an 
atmosphere of N2 we could resolve the rovibrational spectrum as shown in Figure 4(a). 
The observed CO2 absorption lines are four orders of magnitude weaker than the 
strongest absorption lines of CO2. However, when we compare the spectrum with the 
theoretical information contained in the HITRAN database we notice that the strength 
of the absorbance does not match with the information contained in the database, 
Figure 4(b). This effect is due to the wavenumber accuracy of our device, which is too 
large to correctly retrieve the profile of each absorption line. Therefore, it is not possible 
to directly measure the strength of each absorption line and the sample concentration. 
To determine the sample concentration we first fit a Voigt profile to each individual 
absorption line, then we compare the maxima of the peaks with the HITRAN database 
using Equation (3) to obtain a concentration value for each peak. We thus have several 
concentration values calculated for different lines of the same molecule. The mean value 
of these concentrations give us the sample concentration. From this analysis we ob-
tained a 15% concentration of CO2 with a standard deviation of 5%.
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Figure 4. Spectrum of 15% of CO2 in an atmosphere of N2 at 500 mbar. (a) Experimental measurement. (b) 
HITRAN database.
These measurements show some of the system’s advantages and limitations. The 
broadband coverage of the system allows the molecular identification of molecules with 
a smooth spectral profile because all the available absorption features are used, this 
permits to determine the sample concentration in a couple of minutes. For molecules 
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with sharp spectral features the identification is possible but the concentration determi-
nation strongly depends on the absorption strength.
Lab air spectrum
An easy test for our setup is the measurement of the environment from our lab. For 
this purpose we filled the multipass cavity with lab air and obtained the absorbance 
depicted in Figure 5. In this spectrum we can clearly observe five absorption lines of 
water at 1136 cm−1, 1175 cm−1, 1187 cm−1, 1212 cm−1 and 1225 cm−1. As in the case of 
CO2 there is a mismatch between the strength from some measured spectral lines and 
the HITRAN database. Again the main reasons for this mismatch is the fact that we are 
observing absorption lines three orders of magnitude weaker than the strongest water 
absorption lines and the wavenumber accuracy mentioned previously. However, using 
the method described above we determined a concentration of 1% with a standard 
deviation of 0.7%, which reflects how the magnitude of the absorption strength of the 
molecule improves the concentration determination.
To obtain an independent measurement of the water concentration in the lab air we 
used a Vaisala transmitter (PTU300). It allowed us to measure the atmospheric pressure 
P = 1001.0 mbar, the relative humidity RH = 31.0% and the temperature T = 23.0°C in the 
lab. With this information we calculated the saturated pressure of water vapor p*w using 
the relation 20,
P*w = ⎡⎣1.0007 + (3.46 × 10
-6P)⎤⎦ × (6.1121) exp
⎡
⎣
17.502T ⎤
⎦ (5)240.97 + T
and then we calculated the concentration in percentage,
Cw = 
P*wRH (6)
P
From this independent measurement we obtained a concentration of 0.9%. This value 
is consistent with the spectroscopic measurement obtained using our device. The main 
source of error is the uncertainty in the strength of the absorption signal due to the 
wavenumber spacing.
Breath sample
Finally we measured a breath sample from a healthy volunteer from our research group. 
The pressure inside the multipass cavity was 900 mbar and there was a continuous flow 
of the sample at 500 milliliter normal per minute (mln/min) 22. As seen in Figure 6, we 
could resolve the absorption lines of CO2 with a concentration of 3% and water at 2%. 
An interesting feature is the shift upwards of the base line in the region between 1170 
and 1250 cm−1 as shown by the red curve in the inset of Figure 6. In this region there 
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Figure 5. Lab air sample at 1001.0 mbar, at a temperature of 23.0 °C and a relative humidity of 31.0%. In 
black is depicted the spectrum of water from HITRAN database with a concentration of 1 %.
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Figure 6. Breath sample at 900 mbar and flowing at 500 mln/min. In black is depicted the theoretical spec-
trum with 3% of CO2 and 2% of water from HITRAN database and 500 ppbv of acetone from the PNNL 
database. In blue is the spectrum of acetone with a concentration of 500 ppbv taken from PNNL database.
Broadband quantum cascade laser spectroscopy 77
3
is absorption from water and acetone. The black line in the inset of Figure 6 shows the 
water absorption and the 500 ppbv of acetone, giving a better match to the red curve 
corresponding to the measured spectrum. This concentration of acetone is in the normal 
range for a healthy person 23.
This measurement demonstrates the capability of the system to detect the presence 
of several molecules in a single sample. Using the overall profile allows to make an ac-
curate and fast initial molecular identification of molecules with high concentrations. By 
examining closely the baseline of the spectrum we can identify and observe molecules 
with broad and smooth absorption profile. Their presence shifts the spectrum baseline 
and allows us to detect sub-ppmv concentrations.
conclusion
In this work we present a broadband spectroscopic gas analysis device which covers 
the molecular fingerprint region between 850 and 1250 cm−1. It complements the direct 
absorption spectroscopic systems available in the 1250 - 3000 cm−1 region. At the same 
time broadens the spectral bandwidth covered by one single setup. This device enables 
the study of complex gas mixtures because the robustness of the multipass cavity guar-
antees a stable interaction length over the full spectral scan. For applications requiring 
sensitivities in the ppmv and hundreds of ppbv levels this system is ideal to quickly 
estimate the composition of a gas sample without any pre-treatment. The sensitivity 
characterization gave us a NEAS of 2.99 ×10−7cm−1Hz−1/2. Furthermore, the sensitivity can 
be increased by a factor of 10 by incrementing the delay introduced by the multipass 
cavity and measuring the absorption and the normalizing signal in one single detector 21.
The most important feature of the system is the fast identification of molecules with a 
broad and smooth spectral profile as shown with the acetone signature in the breath 
sample measurement. This shows that our system is reliable for applications such as the 
detection of molecular markers in complex gas mixtures like breath. Especially for cases 
where the concentration levels are in the order of hundreds of ppbv or higher.
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ABstRAct
Background
Exhaled breath analysis is a potential noninvasive tool for diagnosing and monitoring 
airway diseases. Gas chromatography-mass spectrometry and electrochemical sensor 
arrays are the main techniques to detect volatile organic compounds (VOCs) in exhaled 
breath. We developed a broadband quantum cascade laser spectroscopy technique for 
VOC detection and -identification.
objectives
To assess the repeatability of exhaled breath profiling with broadband quantum cascade 
laser-based spectroscopy and to explore the clinical applicability by comparing exhaled 
breath samples from healthy children with those from children with asthma or cystic 
fibrosis (CF).
Methods
Healthy children and children with stable asthma or stable CF, aged 6-18 years, were in-
cluded. Two to four exhaled breath samples were collected in Tedlar bags and analyzed 
by quantum cascade laser spectroscopy to detect VOCs with an absorption profile in the 
wavenumber region between 832 and 1262.55 cm-1.
Results
We included 35 healthy children, 39 children with asthma and 15 with CF. Exhaled breath 
VOC profiles showed poor repeatability (Spearman’s rho = 0.36 to 0.46) and agreement 
of the complete profiles. However, we were able to discriminate healthy children from 
children with stable asthma or stable CF and identified VOCs that were responsible for 
this discrimination.
conclusion
Broadband quantum cascade laser-based spectroscopy detected differences in VOC pro-
files in exhaled breath samples between healthy children and children with asthma or 
CF. The combination of a relatively easy and fast method and the possibility of molecule 
identification makes broadband quantum cascade laser-based spectroscopy attractive 
to investigate the diagnostic and prognostic potential of volatiles in exhaled breath.
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intRoDuction
Over the last decades, the measurement of volatile organic compounds (VOCs) in 
exhaled breath has raised great interest as a potential tool for diagnosis and manage-
ment of respiratory diseases. Especially in pediatric respiratory medicine exhaled breath 
profiling is attractive to assess the presence and degree of airway inflammation, to 
distinguish disease phenotype and enable targeted and individualized treatment. Hy-
drocarbons are potential biomarkers for airway inflammation, as they derive from lipid 
peroxidation induced by e.g. reactive oxygen species during inflammatory reactions in 
the airways. Previous studies on VOC profiling in children with asthma and cystic fibrosis 
(CF) have identified hydrocarbons as the most discriminating VOCs between patients 
with and without asthma or CF. Hydrocarbons were helpful in the diagnosis of asthma 
and CF, and predicted clinical deterioration 1-5.
Currently, gas chromatography coupled to mass spectrometry (GC-MS) is the gold 
standard for the identification of VOCs. Disadvantages of this technique include the 
need for sample preconcentration, the fragmentation of molecules and the necessity 
for expensive equipment and highly trained personnel. An alternative is the electronic 
nose (eNose), an easy and fast sensor-based technique which allows online real-time 
analysis of the complete spectrum of VOCs, but cannot identify separate molecular 
components 6. We developed a new broadband quantum cascade laser-based spectros-
copy setup to detect VOC profiles in exhaled breath 7. This technique enables the fast 
detection and identification of whole molecules with the potential for miniaturization, 
thereby combining the advantages of both previously mentioned techniques. In the 
present study, we explored the clinical applicability of this technique by determining 
the repeatability and comparing exhaled breath samples from healthy children with 
samples from children with either stable asthma or stable CF lung disease, two condi-
tions that have different types of chronic airway inflammation as a prominent feature.
MAtERiAls AnD MEthoDs
study subjects
We included children aged 6-18 years. Healthy controls were recruited at a primary 
school in Rotterdam. Healthy controls had a negative ISAAC questionnaire for asthma 
and allergy and a normal forced expiratory volume in 1 s (FEV1) 8. Children with stable 
asthma or stable CF were recruited at the outpatient clinic KinderHaven (Harbor Hos-
pital, Rotterdam) and Sophia Children’s Hospital (Erasmus Medical Center, Rotterdam), 
between September 2013 and February 2014. Inclusion criteria for stable asthma were 
a doctor’s diagnosis of asthma, and well controlled asthma at the time of the study de-
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fined as a stable dose of inhaled corticosteroids, need for short acting ß2 agonists less 
than 3 times per week, minimal daytime symptoms (<3 times per week), no limitations 
of activity, a normal lung function (FEV1 >80% predicted or >80% of personal best), and 
no exacerbations in the previous 3 months. Atopy was defined as a positive radioal-
lergosorbent test (RAST) or a positive skin-prick test ever, for at least one aeroallergen 9. 
Children with stable CF had a positive sweat test or 2 CF-specific DNA mutations, and 
were not treated for exacerbations with oral or intravenous antibiotics in the 6 weeks 
before the study visit. Written informed consent was obtained from parents or caretak-
ers, and from children themselves if 12 years or older. The study was approved by the 
Medical Ethical Committees of Erasmus MC-Sophia Children’s Hospital and of the Harbor 
Hospital, Rotterdam.
study design
In healthy children, exhaled breath samples were collected twice with 30 min intervals 
and again 24 hours and 1 week later in order to assess short- and long-term repeatability 
of exhaled breath profiling. In asthmatic children and children with CF we collected 
2 exhaled breath samples 30 min apart during a routine clinical visit. Spirometry (Mas-
terscreen, CareFusion, Würzburg, Germany) and measurements of fractional exhaled 
nitric oxide (FeNO, NIOX MINO NO analyzer, Aerocrine, Solna, Sweden) were performed 
according to ATS/ERS guidelines during the first visit only in the healthy children and the 
children with asthma 10,11.
Exhaled breath samples were collected during a single, slow exhalation from total lung 
capacity following 5 s of breath holding. Children exhaled via a disposable mouthpiece 
and one-way valve into a 3 L re-usable Tedlar bag (Tedlar bag 231-03, SKC Inc., Pennsyl-
vania, USA) (Figure 1). Eating and exercise were not allowed within 1 h before sampling. 
The bags were transported the same day towards the laboratory at Delft University of 
Technology, where samples were analyzed immediately. Tedlar bags were cleaned by 
flushing 3 times with synthetic air (Purity grade 5.5, Linde, The Netherlands) and nitro-
gen (Purity grade 6, Linde, The Netherlands) after which they were heated overnight at 
60oC, and again flushed with both synthetic air and nitrogen, according to the recom-
mendations of the Environmental Protection Agency of USA (EPA 1991 Method 422) 12.
sample analysis
Exhaled breath samples were analyzed using broadband quantum cascade laser-based 
spectroscopy 7. For this purpose, we developed a quantum cascade laser spectroscopy 
setup, to detect volatile molecules with an absorption profile in the wavenumber region 
between 832 and 1262.55 cm-1. The detection limit of this system is given by the noise 
equivalent absorption sensitivity (NEAS), 2.99 x 10-7cm-1Hz-1/27. The setup consisted of a 
Laser Scope unit (Block Engineering Inc., Massachusetts, USA), a home-built multipass 
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cell of 0.6 liters and an infrared mercury cadmium telluride detector (PVI-4TE-10.6-
0.3x0.3-TO8-BaF2, VIGO System S. A., Poland) (Figure 2). The Laser Scope unit contained a 
quantum cascade laser which scans wavenumber region between 832 and 1262.55 cm-1 
with a wavenumber resolution of 0.05 cm−1. The laser was directed to the multipass cell, 
in which two astigmatic mirrors (Aerodyne Research Inc., Massachusetts, USA) ensured 
multiple reflections confining the laser to travel for 54.36 meters inside the volume 
of the multipass cell. When the laser exited the multipass cell its intensity profile was 
measured using an infrared Mercury Cadmium Telluride (MCT) detector. To measure the 
absorption profile of the breath samples we first recorded the laser signal with the mul-
tipass cell emptied, by reducing the pressure inside the cell to less than 0.1 mbar using 
both a pressure controller (P-702CV-1K1A-RAD-22-V, Bronkhorst High-Tech BV, Ruurlo, 
The Netherlands) and a diaphragm vacuum pump (MD 1, Vacuumbrand GMBH + CO KG, 
Wertheim, Germany). Subsequently, a breath sample was injected in the multipass cell 
using a set of mass flow controllers (F-201CV-1K0-RAD-22-V, Bronkhorst High-Tech BV, 
Ruurlo, The Netherlands) ensuring a continuous flow of 500 mL.min-1 until the internal 
pressure reached 900 mbar, this uses around 600 mL of the breath sample. At this point 
the flow was reduced to 50 mL.min-1 and the internal pressure stabilized during 6 min, 
the time needed for the quantum cascade laser scan. In total, we used at least 900 mL of 
each breath sample. Before injection, the breath sample passed through a Nafion dryer 
(MD-070-24S-4, Perma Pure LLC, New Jersey, USA) to improve the signal-to-background 
ratio. The absorption profile of the breath sample was calculated as the ratio of the signal 
of the breath sample over that of the empty cavity. This way, we removed the influence 
of any residues that may have been in the multipass cell before introducing the breath 
sample. Furthermore, after each measurement the multipass cell and the tubing were 
cleaned by flushing once with synthetic air and twice with nitrogen. This was done to 
Figure 1. Collection of an exhaled breath sample in 
a healthy child.
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remove all gases from the cell. The empty cell was measured after this procedure to 
verify that no trace of detectable molecules were present in the cell. The total procedure 
for measuring one exhaled breath sample, including scanning, obtaining the complete 
absorption spectrum and cleaning the setup for the next sample, takes less than 15 min.
Figure 2. The spectroscopic setup consist of the quantum cascade laser, a multipass cell and a Mercury 
Cadmium Telluride (MCT) detector. The multipass cell has a volume of 0.6 L with a total length of 50 cm and 
a diameter of 4 cm in the middle of the tube. The housing for the astigmatic mirrors has a conical shape 
with a maximum diameter of 12 cm.
Data analysis
Subject characteristics of the study groups were presented as median (interquartile 
range, IQR). The distribution of wavenumbers in all samples was approximately Gaussian 
with a similar median and variance. To increase the sensitivity of subsequent analyses 
for each spectroscopic wavenumber we subtracted the median of all wavenumbers, 
divided by the median absolute deviation and added the global median of all sample 
spectra. For all analyses, we separated the complete spectral data into 0.05 cm-1 bins, 
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yielding 8612 bins in total from 832 cm-1 through 1262.55 cm-1. Each bin, referred to as a 
wavenumber point, was treated as a discrete measurement in all subsequent analyses. 
Spearman’s correlation coefficient was used to compare the 1st and 2nd exhaled breath 
samples in each patient group and the 1st with the 2nd, 3rd and 4th exhaled breath sample 
in the healthy children. Agreement between the first 2 exhaled breath samples was 
assessed for each group with a Bland and Altman plot to assess the mean and 95% 
limits of agreement. Principal component analysis was performed on the mean of the 
first two exhaled breath profiles of each individual, in order to reduce the influence of 
intra-individual variability on the discriminative ability of laser spectroscopy to separate 
exhaled breath profiles of healthy children from exhaled breath profiles of children with 
stable asthma or CF. We employed the BioConductor package limma (version 3.22.1) 
to identify differences in spectroscopic wavenumbers between the 3 study groups 13. 
Briefly, limma uses linear models combined with methods for variance stabilization and 
post-hoc multiple correction (Benjamini-Hochberg at false discovery rate < 0.05) 14. As 
the absorption feature of molecules is given by a wavenumber region rather than a 
single wavenumber point, we considered wavenumber regions as significantly different 
when at least 10 neighboring wavenumber points had a p-value of less than 0.05. The 
width of these wavenumber regions is 0.5-1 cm-1. The choice of this width was based 
on the fact that the narrowest absorption features of small molecules like CO2 and H2O 
have a full width at half maximum (FWHM) of around 0.1 cm-1, but their full spectral line 
width is about 0.5 cm-1. All statistical calculations were performed using R version 3.1.2.
REsults
subject characteristics
We included 35 healthy children, 39 children with asthma and 15 children with CF. We 
successfully collected exhaled breath samples in all children. The clinical characteristics 
of the three groups are presented in Table 1 15.
Repeatability of exhaled breath profiles
We collected a 2nd exhaled breath sample 30 min after the 1st exhaled breath sample in 
35 healthy children, 31 children with asthma and 15 children with CF. In addition, we 
collected a 3rd exhaled breath sample after 24 hours and a 4th exhaled breath sample 
after 1 week in 34 healthy children. Each exhaled breath profile consists of 8612 indi-
vidual wavenumber points with each a width of 0.05 cm-1, in total covering a broadband 
spectral region from 832 cm-1 until 1262.55 cm-1. We found a poor overall correlation 
between the 1st and the 2nd exhaled breath profile in each group: Spearman’s rho = 0.46 
in healthy children, 0.43 in children with asthma and 0.43 in children with CF. Similar 
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table 1. Subject characteristics
Healthy (n=35) Asthma (n=39) CF (n=15)
Age (years) 9.9 (9.0-10.7) 10.9 (8.7-14.0) 11.0 (7.7-14.5)
sex (M:F) 15:20 26:13 4:11
height (cm) 141.5 (133.0-149.0) 150.0 (133.4-160.5) (n=38) 145.2 (129.3-164.9)
weight (kg) 33.0 (27.5-37.0) 42.9 (35.8-52.8) (n=38) 36.4 (27.4-59.1)
FEV1 (% predicted)a 94.6 (83.0-106.0) (n=32) 90.2 (84.7-99.8) (n=33) 95.7 (83.9-105.6)
Feno 15.0 (11.0-18.0) (n=33) 25.0 (12.0-39.0) (n=35) n.a.
Atopy 0/35 31/39 n.a.
Act score n.a. 22.0 (18.5-23.0) (n=29) n.a.
Definition of abbreviations: M: male; F: female; FEV1: forced expiratory volume in 1 s; FeNO: fractional ex-
haled nitric oxide; ACT: asthma control test; n.a.: not applicable.
Data are presented as median (interquartile range).
a Percentage predicted according to the GLI-2012 equations 15.
Figure 3. Bland and Altman plot showing moderate agreement between the 1st and the 2nd exhaled breath 
sample profile in 35 healthy children. Each dot represents the mean plotted against the difference of a 
single wavenumber point with a width of 0.05 cm-1 in all healthy children. The vertical axis depicts the dif-
ference between the 1st and the 2nd exhaled breath profile, the horizontal axis the mean of the 1st and the 
2nd exhaled breath profiles (parts per million volume, ppmv). The lines represents the mean and the 95% 
agreement limits.
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overall correlations were shown in healthy children between the 1st and the 3rd measure-
ment (Spearman’s rho = 0.39) and the 1st and the 4th measurement (Spearman’s rho = 
0.36). Bland and Altman plots for each group showed relatively good agreement when 
individual wavenumber points were assessed with a mean difference of -0.03 and limits 
of agreement between 0.60 and -0.65 in the healthy children (Figure 3).
Absorption spectra
Scatterplots depicting the separation between healthy children and children with 
asthma and between healthy children and children with CF by two principal compo-
nents are shown in Figure 4. We found significantly different wavenumber regions when 
we compared the mean of the first two exhaled breath profiles of asthmatic children 
with those of healthy controls in the wavenumber regions 1181.80–1182.55 cm-1 and 
1261.40–1262.05 cm-1. Between healthy children and CF patients we observed one 
significantly different wavenumber region between 1260.70 and 1261.65 cm-1.
chemical identification of Vocs
Using the Pacific Northwest National Laboratory (PNNL) database 16, we located mol-
ecules with their absorption signature in the wavenumber regions which differed sig-
nificantly between healthy children and the children with asthma or CF. We selected the 
molecules with an absorption signature corresponding to a minimum concentration of 
10 parts per million volume (ppmv) and compared these with VOCs previously reported 
to be present in human exhaled breath 17. In table 2 and 3 we summarize the VOCs which 
have their absorption spectra within the wavenumber regions that differentiated healthy 
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Figure 4. (a) 2D principal component plot showing the discrimination of the mean of the first two breath 
prints for each individual between healthy controls (circles) and children with asthma (triangles) and (b) 
between healthy controls (circles) and children with CF (squares) along two principal components with the 
greatest variance in spectroscopic data.
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children from children with stable asthma and stable CF, and that have been identified 
previously in exhaled breath. The complete results are given in the online supplement.
Discussion
We used broadband quantum cascade laser-based spectroscopy to detect VOC profiles 
in exhaled breath samples and tested this in healthy children and children with asthma 
or CF. We found an overall poor repeatability and limited agreement on the short and 
long term, of the complete exhaled breath profiles. We identified VOC profiles that 
discriminated healthy children from children with stable asthma or stable CF. Our results 
table 2. VOCs which have been identified earlier in exhaled breath, with absorption signatures in the 
wavenumber regions that differentiated healthy children from children with stable asthma
Compounds Wavenumber region (cm-1)
cAs number name 1181.80 - 1182.55 1261.40 - 1262.05
64-19-7 Acetic acid 
123-86-4 Acetic acid, butyl ester 
141-78-6 Acetic acid, ethyl ester / ethyl acetate 
110-19-0 Acetic acid, isobutyl ester / isobutyl acetate 
108-21-4 Acetic acid, isopropyl ester / isopropylacetate 
79-20-9 Acetic acid, methyl acetate 
111-15-9 1-acetoxy-2-ethoxyethane 
105-54-4 Butanoic acid, ethyl ester  
78-93-3 2-butanone 
107-92-6 Butyric acid 
123-91-1 1,4-diethylene dioxide 
616-38-6 Dimethyl carbonate 
115-10-6 Dimethyl ether 
108-39-4 1-hydroxy-3-methylbenzene 
109-94-4 Methanoic acid, ethyl ester/ ethyl formate 
107-31-3 Methanoic acid, methyl ester/ methyl formate 
34590-94-8 2-methoxymethylethoxy/ Propanol  
75-09-2 Methylene chloride / dichloromethane 
80-62-6 2-methylpropenoic acid, methyl ester / methyl 
methacrylate

554-12-1 Propanoic acid, methyl ester 
79-09-4 Propanoic acid / propionic acid 
140-88-5 2-proponic acid, ethyl ester  
79-01-6 1,1,2-trichloroethene / algylen 
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suggest that laser-based spectroscopy might be a useful technique for exhaled breath 
profiling.
This is the first study that investigates a laser-based spectroscopic method to detect VOC 
profiles in exhaled breath samples. Our method covered a broad wavenumber region 7. 
Previous studies, investigating laser-based spectroscopy as a method to analyze VOCs 
in exhaled breath, focused on narrow wavenumber regions (10-20 cm-1) representing 
absorption of only one or two specific molecules 18-20. With our technique, we were able 
to detect VOC profiles within a broader wavenumber range. In addition, VOC identifica-
tion was possible with the use of molecular databases such as the PNNL database. Iden-
tification of molecules is important to understand underlying inflammatory processes, 
which may be useful to develop new and/or personalized treatments. The advantages 
of detecting VOC profiles with our technique over GC-MS are the ability to detect whole 
molecules instead of fragmented molecules, the relatively fast and easy analysis and the 
potential for miniaturization.
We showed poor repeatability of complete exhaled breath profiles both on the short 
term and on the long term. However, we also showed a relatively good agreement of 
individual wavenumber points in the first and second breath sample. A previous study, 
in which 3 breath samples were collected with a 2 min interval, also showed high 
coefficients of variation for VOC profiles when compared to individual molecules 21. 
The limited repeatability might be explained by the fact that we investigated a large 
spectroscopic range comprising 8612 individual wavenumber points. Furthermore, we 
consider it plausible that a high variability of exhaled breath content could be the result 
table 3. VOCs which have been identified earlier in exhaled breath, with absorption signatures in the 
wavenumber region which differentiated healthy children from children with stable CF
Compound Wavenumber region (cm-1)
cAs number name 1260.70 - 1261.65
123-86-4 Acetic acid, butyl ester 
141-78-6 Acetic acid, ethyl ester / ethyl acetate 
110-19-0 Acetic acid, isobutyl ester / isobutyl acetate 
108-21-4 Acetic acid, isopropyl ester / isopropylacetate 
79-20-9 Acetic acid, methyl acetate 
111-15-9 1-acetoxy-2-ethoxyethane 
105-54-4 Butanoic acid, ethyl ester 
123-91-1 1,4-diethylene dioxide 
616-38-6 Dimethyl carbonate 
34590-94-8 2-methoxymethylethoxy/ Propanol 
75-09-2 Methylene chloride / dichloromethane 
140-88-5 2-proponic acid, ethyl ester 
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of multiple daily life factors, like eating, drinking, exercise and the variable composition 
of ambient air. All children in this study refrained from eating, drinking and exercise one 
hour prior to exhaled breath sampling. Surprisingly, the long term repeatability in the 
healthy children was similar to the short term repeatability. This suggested that VOCs 
reflecting the pulmonary condition may be relatively stable over time but comprise only 
a small amount of the complete profile.
Previous studies have shown that exhaled breath VOC profiles measured with GC-MS and 
the eNose could discriminate healthy controls from asthmatic children and from chil-
dren with CF with a relatively high sensitivity and specificity and limited intra-individual 
variability 2,3,22-24. We were also able to discriminate healthy children from children with 
stable asthma or stable CF, however, the limited separation between the groups in the 
PCA suggests that the majority of wavenumber points and spectra representing VOCs 
did not differ between healthy and diseased children. Previous studies all reported dif-
ferent sets of best-discriminative VOCs for specific diagnoses, and there clearly is a need 
for external validation 2-5,22-25. Since hydrocarbons have been found to be discriminative 
VOCs in several different studies regarding respiratory inflammatory diseases, we fo-
cused our setup on the detection of hydrocarbons and set the wavenumber range of our 
laser between 832 and 1262.55 cm-1 covering the complete absorption spectra of this 
group of molecules. Surprisingly, molecules with absorption spectra in the wavenumber 
regions that differed between healthy and diseased children in the present study in-
cluded carboxylic acids, esters and ethers, which can derive from hydrocarbons. A recent 
review showed that these molecules represent around 20% of all molecules found in 
exhaled breath samples 17. When we focused on molecules which have been described 
before in exhaled breath, we noticed overlap between those in asthma and CF. This is 
not unexpected, as CF is characterized by chronic neutrophilic airway inflammation, and 
varying degrees of neutrophilic inflammation have been observed in childhood asthma 
as well 26. Based on the current data it is not possible to quantify the amount of airway 
inflammation or the intensity of the disease.
The main limitations of our study and earlier breath profiling studies include lack of 
standardization of sample collection and analysis between studies, thereby hampering 
the overall comparability. For instance, the effect of expiratory flow remains unclear al-
though current data do not suggest that flow control is needed 24,27-29. Therefore, we did 
not standardize expiratory flow making our sampling technique technically easy and 
applicable for children of all ages. We cannot rule out contamination of exhaled breath 
samples by disposable plastic components (mouthpieces, tubes and valves). As we 
used the same type of disposables in all children, this would not affect between-group 
differences. Storage time in Tedlar bags was kept less than 12 h for all exhaled breath 
samples 30. In order to avoid contamination we cleaned the multipass cell after each 
measurement, and used the laser signal of the empty cell immediately after performing 
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the cleaning procedure as a reference for the following measurement, thereby we ruled 
out the influence of water, methane, acetone, ethanol and CO2 on our exhaled breath 
profiles. Another possible source of measurement variability is the fluctuations in the 
intensity of the laser. We have addressed this issue by monitoring the laser emission 
using a reference detector 7. The electronic noise is kept minimum by using thermally 
cooled detectors. Finally, our spectroscopic setup has a sensitivity in the order of parts 
per million volume (ppmv), which is less than the parts per trillion volume (pptv) sensi-
tivity of other laser-based techniques such as cavity ring down spectroscopy 31. To what 
extent higher sensitivity would result in better results remains to be shown.
In conclusion, we developed a broadband quantum cascade laser-based spectroscopy 
technique for the detection of VOC profiles in exhaled breath samples. We showed 
overall poor short- and long term repeatability of this technique, but found different 
exhaled breath profiles in healthy children versus children with airway inflammation 
due to asthma or CF. Additional validation and attempts to improve the repeatability are 
needed before further clinical studies can be undertaken. The combination of a relatively 
easy and fast method and the possibility of molecule identification makes broadband 
quantum cascade laser-based spectroscopy attractive to investigate the diagnostic and 
prognostic potential of volatiles in exhaled breath.
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suPPlEMEntAl tABlEs
table 1. VOCs with absorption signature in the wavenumber regions which differentiated healthy children 
from children with stable asthma
Compounds Wavenumber region (cm-1)
cAs number name 1181.80 - 1182.55 1261.40 - 1262.05
431-89-0 1,1,1,2,3,3,3-Heptafluoropropane (HFC227EA) 
75-68-3 1,1,1-Chlorodifluoroethane (Freon-142B) 
421-50-1 1,1,1-Trifluoroacetone 
420-46-2 1,1,1-Trifluoroethane (R143A) 
79-01-6 * 1,1,2-trichloroethene / algylen 
124-73-2 1,2-Dibomotetrafluoroethane (Freon-114B2) 
106-93-4 1,2-Dibromoethane (EDB) 
354-23-4 1,2-Dichloro-1,1,2-trifluoroethane (F132A) 
123-91-1 * 1,4-diethylene dioxide 
111-15-9 * 1-acetoxy-2-ethoxyethane 
354-25-6 1-Chloro-1,1,2,2-tetrafluoroethane (R124A)  
108-39-4 * 1-hydroxy-3-methylbenzene 
75-89-8 2,2,2-Trifluoroethanol  
25256-77-4 2,2,4-Trimethyl-1,3-pentanediol isobutyrate 
(Texanol)
 
306-83-2 2,2-Dichloro-1,1,1-trifluoroethane (Freon-123) 
76-11-9 2,2-Difluorotetrachloroethane (F112A) 
78-93-3 * 2-butanone 
75-88-7 2-Chloro-1,1,1-trifluoroethane (R133A) 
2837-89-0 2-Chlroro-1,1,1,2-tetrafluoroethane (HCFC-124) 
138495-42-8 2H, 3H-Perfluoropentane  
34590-94-8 * 2-methoxymethylethoxy / Propanol  
80-62-6 * 2-methylpropenoic acid, methyl ester / methyl 
methacrylate

140-88-5 * 2-proponic acid, ethyl ester  
64-19-7 * Acetic acid 
123-86-4 * Acetic acid, butyl ester 
141-78-6 * Acetic acid, ethyl ester / ethyl acetate 
110-19-0 * Acetic acid, isobutyl ester / isobutyl acetate 
108-21-4 * Acetic acid, isopropyl ester / isopropylacetate 
79-20-9 * Acetic acid, methyl acetate 
75-86-5 Acetone cyanohydrin 
105-54-4 * Butanoic acid, ethyl ester  
107-92-6 * Butyric acid 
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table 1. (continued)
Compounds Wavenumber region (cm-1)
cAs number name 1181.80 - 1182.55 1261.40 - 1262.05
353-50-4 Carbonyl fluoride 
107-30-2 Chloromethyl methyl ether 
76-15-3 Chloropentafluoroethane (R115) 
1189-71-5 Chlorosulfonyl isocyanate (CSI) 
108-20-3 Diisopropyl ether 
108-18-9 Diisopropylamine 
616-38-6 * Dimethyl carbonate 
115-10-6 * Dimethyl ether 
79-44-7 Dimethylcarbamoyl chloride 
541-41-3 Ethyl chloroformate 
383-63-1 Ethyl trifluoroacetate 
76-13-1 Freon-113 (1,1,2-Trichlorortrifluoroethane) 
76-14-2 Freon-114 (1,2-dichlorortetrafluoroethane)  
811-97-2 Freon-134a (1,1,1,2-tetrafluoroethane) 
76-19-7 Freon-218 (octafluoropropane) 
115-25-3 Freon-C318 (octafluorocyclobutane) 
684-16-2 Hexafluoroacetone 
76-16-4 Hexafluoroethane (Freon-116) 
381-10-5 Hexafluoroisobutylene  
116-15-4 Hexafluoropropene 
124-63-0 Methanesulfonyl chloride 
109-94-4 * Methanoic acid, ethyl ester/ ethyl formate 
107-31-3 * Methanoic acid, methyl ester/ methyl formate 
96-33-3 Methyl acrylate  
93-58-3 Methyl benzoate  
547-63-7 Methyl isobutyrate  
598-98-1 Methyl pivalate 
119-36-8 Methyl salicylate  
79-22-1 Methylchloroformate (MCF) 
Methyldichlorodisilanes (mixed isomers) 
75-09-2 * Methylene chloride / dichloromethane 
97-66-7 N,N-Diethylaniline 
628-63-7 n-Amyl acetate 
123-63-7 Paraldehyde 
355-25-9 Perfluorobutane  
382-21-8 Perfluoroisobutylene (PFIB) 
79-09-4 * Propanoic acid / propionic acid 
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table 1. (continued)
Compounds Wavenumber region (cm-1)
cAs number name 1181.80 - 1182.55 1261.40 - 1262.05
554-12-1 * Propanoic acid, methyl ester 
624-65-7 Propargyl chloride 
109-06-4 Propyl acetate 
7791-25-5 Sulfuryl chloride 
2699-79-8 Sulfuryl fluoride 
994-05-8 tert-Amyl methyl ether 
75-73-0 Tetrafluoromethane 
75-05-1 Trifluoroacetic acid  
407-25-0 Trifluoroacetic anhydride  
354-32-5 Trifluoroacetyl chloride  
75-46-7 Trifluoromethane (Freon-23) 
373-80-8 Trifluoromethylsulfur pentafluoride 
334-99-6 Trifluoronitrosomethane  
All VOCs identified with PNNL database, with absorption spectra within the significantly different wave-
number regions between healthy children and children with stable asthma.
* VOCs that have been identified before in exhaled breath and included in Table 2 of the main article.
table 2. VOCs with absorption signature in the wavenumber regions which differentiated healthy children 
from children with stable CF
Compound Wavenumber region (cm-1)
cAs number name 1260.70 - 1261.65
431-89-0 1,1,1,2,3,3,3-Heptafluoropropane (HFC227EA) 
421-50-1 1,1,1-Trifluoroacetone
420-46-2 1,1,1-Trifluoroethane (R143A) 
123-91-1 * 1,4-diethylene dioxide 
111-15-9 * 1-acetoxy-2-ethoxyethane 
354-25-6 1-Chloro-1,1,2,2-tetrafluoroethane (R124A) 
75-89-8 2,2,2-Trifluoroethanol 
25256-77-4 2,2,4-Trimethyl-1,3-pentanediol isobutyrate (Texanol) 
75-88-7 2-Chloro-1,1,1-trifluoroethane (R133A) 
138495-42-8 2H, 3H-Perfluoropentane 
34590-94-8 * 2-methoxymethylethoxy / Propanol 
140-88-5 * 2-proponic acid, ethyl ester 
123-86-4 * Acetic acid, butyl ester 
141-78-6 * Acetic acid, ethyl ester / ethyl acetate 
110-19-0 * Acetic acid, isobutyl ester / isobutyl acetate 
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table 2. (continued)
Compound Wavenumber region (cm-1)
cAs number name 1260.70 - 1261.65
108-21-4 * Acetic acid, isopropyl ester / isopropylacetate 
79-20-9 * Acetic acid, methyl acetate 
105-54-4 * Butanoic acid, ethyl ester 
353-50-4 Carbonyl fluoride 
616-38-6 * Dimethyl carbonate 
79-44-7 Dimethylcarbamoyl chloride 
76-19-7 Freon-218 (octafluoropropane) 
115-25-3 Freon-C318 (octafluorocyclobutane) 
684-16-2 Hexafluoroacetone 
76-16-4 Hexafluoroethane (Freon-116) 
381-10-5 Hexafluoroisobutylene 
93-58-3 Methyl benzoate 
547-63-7 Methyl isobutyrate 
119-36-8 Methyl salicylate 
Methyldichlorodisilanes (mixed isomers) 
75-09-2 * Methylene chloride / dichloromethane 
97-66-7 N,N-Diethylaniline 
628-63-7 n-Amyl acetate 
355-25-9 Perfluorobutane 
624-65-7 Propargyl chloride 
109-06-4 Propyl acetate 
2699-79-8 Sulfuryl fluoride 
75-73-0 Tetrafluoromethane 
75-05-1 Trifluoroacetic acid 
407-25-0 Trifluoroacetic anhydride 
354-32-5 Trifluoroacetyl chloride 
373-80-8 Trifluoromethylsulfur pentafluoride 
334-99-6 Trifluoronitrosomethane 
All VOCs identified with PNNL database, with absorption spectra within the significantly different wave-
number regions between healthy children and children with stable CF.
* VOCs that have been identified before in exhaled breath and are included in Table 3 of the main article.
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ABstRAct
Background
The mechanisms responsible for dysangiogenesis and alveolar simplification in bron-
chopulmonary dysplasia (BPD) are poorly understood. Subpopulations of macrophages 
may well contribute to dysangiogenesis in BPD.
Aim: The aim of this study was to investigate whether macrophages and their products 
in serial tracheal aspirates (TAs) of ventilated preterm children correlate with BPD devel-
opment.
Methods
We tested serial TAs of preterm infants who did or did not develop severe BPD on the 
presence of angiogenesis-related proteins and macrophages by proteome profiling, 
multiplex assay, cytological examination and RT-PCR. Second, we examined the overall 
angiogenic activity of TAs using pericyte human endothelial cell co-cultures.
Results
TAs contained a broad variety of alternative angiogenesis-related factors. We observed 
a wide range angiogenic activity on pericyte-human endothelial cell co-cultures by 
TAs. Tubule growth did not correlate with VEGF, but did correlate with some alternative 
angiogenesis-related factors. The proangiogenic factors EMMPRIN, GDF15 and HGF, 
the pro-inflammatory cytokines TNF-α, IL-1α and IL-1β, and the M2-type macrophage-
related proteins CCL17 and CCL24 were present at significantly higher levels in TAs of 
preterm infants without BPD compared to those with severe BPD. Additionally, we found 
significant higher gene expression of the M2-related genes MRC1 and CD206 in infants 
without BPD.
conclusion
We observed higher levels of pro-angiogenic growth factors, pro-inflammatory cyto-
kines and M2-type macrophage-related proteins in serial TAs of preterm infants who did 
not develop BPD. Our findings support a role for M2-like macrophages in angiogenesis 
and tissue homeostasis during alveolarisation. We speculate that M2 macrophages and 
their products may be potential therapeutic targets for prevention and treatment of 
BPD.
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intRoDuction
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that occurs in extremely 
preterm infants and is characterized by impaired alveolarisation 1-4. Currently, the exact 
pathogenesis of BPD is unclear and treatment is limited and symptomatic. Histology of 
lungs from patients who died from BPD show remarkable abnormalities in the pulmo-
nary vascular network with a reduction in small arteries, abnormal distribution of capil-
laries in the distal lung, and intrapulmonary arteriovenous connections 5-7. Disruption of 
microvascular development in immature lungs has been postulated as a critical factor in 
the abnormal alveolar development in BPD 6, 8, 9. The signals linking alveolar and vascular 
growth in the developing lung are not well understood. Decreased vascular endothelial 
growth factor (VEGF) concentrations have been found in bronchoalveolar lavage fluid 
(BALF) of infants developing BPD 10, although data are conflicting 11-13. More recent stud-
ies show an association between BPD and alternative regulators of angiogenesis, such as 
endoglin, endothelial monocyte activating polypeptide II (EMAP-II) and endostatin 14-16. 
Also chemokines with angiogenic effects such as monocyte chemoattractant proteins 
(MCP)-1, MCP-2 and MCP-3, and macrophage inflammatory proteins (MIP)-1α and MIP-
1β were found to be associated with the development of BPD 16, 17. Since many of these 
angiogenic growth factors are products of inflammatory cells (e.g., monocytes/macro-
phages, neutrophils), they may provide a link between inflammation and dysangiogen-
esis, independent of VEGF 6,17,18. Macrophages and their precursor monocytes are able to 
produce a wide array of angiogenic growth factors including endoglin, endostatin and 
EMAP-II. They belong to a heterogeneous group of myeloid cells with a high degree of 
plasticity in response to local micro-environmental stimuli and are important for tissue 
homeostasis 19-22. Monocytes/macrophages can be subdivided in different subsets (M1, 
M2a-d). The most polarized subsets express either M1 markers like tumor necrosis factor 
(TNF)-α and interleukin (IL)-1 or M2 markers like YM1 as well as multiple pro-angiogenic 
genes, but mixed phenotypes have also been described. M2-polarized macrophages 
have been demonstrated in neonatal lungs during the alveolarisation stage of lung 
development. Their localization to sites of branching morphogenesis suggests a role in 
normal lung growth and development 23.
The aim of the present study was to investigate the presence of angiogenic factors in 
serial tracheal aspirates (TAs) of preterm infants with a focus on macrophage-derived 
factors and to compare these between infants who did and did not develop severe BPD. 
We hypothesized that perinatal lung macrophages display an M2 phenotype and that 
changes in the M2-related protein expression profile correlates with BPD development.
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Patient inclusion
Preterm infants (≤ 32 weeks gestational age, GA) in need of mechanical ventilation in 
the first week of life were recruited at the neonatal intensive care unit of Erasmus MC-
Sophia Children’s Hospital. Children with a congenital disorder affecting lung structure 
and/or function and children who were intubated only to administer surfactant were 
excluded. BPD was defined as need for oxygen supplementation for ≥ 28 days 24. BPD 
severity was assessed by means of an oxygen reduction test at 36 weeks postmenstrual 
age (PMA) 25. Relevant maternal and neonatal characteristics were prospectively col-
lected from patient records. Two groups of infants were formed in this study: preterm 
infants who developed severe BPD at 36 weeks PMA (n=22), and preterm infants who 
did not develop BPD (n=23). Written informed consent was obtained from the parents. 
The study was approved by the medical ethical committee of Erasmus MC, Rotterdam 
(MEC-2013-062, NL43229.078.13).
tracheal aspirate collection and processing
We obtained TAs directly after intubation in the first week of life, and at consecutive 
days (1, 3, 5, and 7), during routine clinical suctioning procedures where 0.5 mL of sterile 
isotonic saline was instilled into the endotracheal tube, and after 5 s was suctioned with 
a 5F catheter positioned at the end of the endotracheal tube. After centrifugation for 5 
min at 300×g, the supernatant was collected, aliquoted in extra low binding Eppendorf 
tubes (BiozymTC, Landgraaf, the Netherlands), and stored at -80°C until analysis. Cyto-
spin preparations for morphological analysis were made with a cytocentrifuge (Cytospin 
4, Thermo Scientific, Breda, the Netherlands) at 680 rpm for 7 min with low acceleration. 
Cytospins with 50,000 cells per slide were stained with May-Grünwald Giemsa staining. 
A differential cell count was performed by two observers (EM and IK).
Proteome profiling, multiplexed fluorescent bead-based immunoassay 
(luminex) and ElisA
A set of 102 predefined growth factors and cytokines was analyzed with the proteome 
profiler array from R&D systems (Human XL Cytokine Array Kit, ARY022). Undiluted 
pooled TA samples (in total 1.5 ml) from the first 3 days of 4 patients with severe BPD 
were compared with undiluted pooled samples from the first 3 days of 6 patients with-
out BPD. This assay was performed a second time with pooled samples from 6 different 
severe BPD patients and 8 patients without BPD.
Next, we used a customized magnetic bead-based immunoassay (Luminex, custom 
made screening assay, R&D systems) in which we included angiogenic factors that 
showed high expression in the proteome analysis. These included: VEGF, angiopoietin 
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(Ang)1, Ang2, platelet-derived growth factor (PDGF)α, PDGFβ, extracellular matrix 
metalloproteinase inducer (EMMPRIN)/CD147, growth differentiation factor (GDF)15, 
hepatocyte growth factor (HGF), epidermal growth factor (EGF), C-X-C motif chemokine 
(CXCL)1/GROα, CXCL4/PF4, CXCL5/ENA78, CXCL8/ IL-8, CXCL9/MIG, CXCL10/IL-10, 
CXCL13/BLCBCA, CXCL14/BRAK, C-C motif chemokine (CCL)2/MCP-1, CCL21/6Ckine, 
MIF, TNF-α, IL-1α, IL-1β and IL-6. We quantified this large set of growth factors, chemo-
kines and cytokines in 139 serial TAs from 45 infants. CCL17 and CCL24 were additionally 
measured by ELISA (R&D systems, Quantikine ELISA). All assays were used according to 
the manufacturer’s protocol.
mRnA isolation and qPcR
Sorted cells from TAs were stored at -80˚C in RLT lysis buffer (QIAGENE, US) and mRNA 
was extracted using RNeasy Micro Kit from QIAGEN (QIAGENE, US) according to the 
manufacturer’s instructions. The mRNA concentration was measured on NanoDrop 
(Thermofisher, US). mRNA was amplified using Ovation® PART NO. 3312 PicoSL WTA Sys-
tem V2 (NuGENE, US) and purified with MinElute Reaction Cleanup Kit (QIAGENE, US). The 
following human primers were used: MRC1 forward 5’ -CCTCTGGTGAACGGAATGAT- ‘3 
and MRC1 reverse 5’-AGGCCAGCACCCGTTAAAAT-‘3, and CD68 forward 5’-GCTACATGGC-
GGTGGAGTACAA-‘3. CD68 reverse 5’-ATGATGAGAGGCAGCAAGATGG-‘3, CD206 forward 
5’-TTGGACGGATAGATGGAGGG, CD206 reverse 5’-CCAGGCAGTTGAGGAGGTTC, CD163 
forward 5’-CCAGTCCCAAACACTGTCCT-3, reverse 5’-ATGCCAGTGAGCTTCCCGTTCAGC-3’, 
and β-actin forward 5’-GCA CCA CAC CTT CTA CAA TG and reverse 5’- TGC TTG CTG ATC 
CAC ATC TG. Quantitative real-time PCR was carried out by Lightcycler 480 (Roche) with 
the Universal Probe Library system (Roche, West Sussex, UK). Gene expression was ana-
lyzed using the comparative Ct method with target gene mRNA levels being normalized 
to β-actin.
Pericyte huVEc co-culture
Human umbilical vein endothelial cells (HUVEC) were cultured in EGM-2 (EBM-2 basal 
medium supplemented with EGM-2 bullit kit; Lonza) till passage 6 under standard cul-
ture conditions (37˚C and 5% CO2). Human brain derived pericytes were cultured in 
DMEM with 10% FCS till passage 6 under standard culture conditions. We used HUVEC 
that express green fluorescent protein (GFR) and pericytes that express red fluorescent 
protein (RFP). For aspirate exposure, HUVEC GFP and pericytes RFP were diluted at a 5:1 
ratio (1.0*106 : 0.20*106/ml) in co-culture medium (EBM-2 basal medium with 2% FCS, 
ascorbic acid and FGF from the EGM-2 bullit kit; Lonza). For every condition, 0.2 µg/ml 
of feline/human/rhesus macaque CXCL12/SDF1α, human SCF/c-kit ligand and human 
IL-3 was added. Collagen type 1 was diluted in co-culture medium to a final concen-
tration of 2 mg/ml with the cell mix. This co-culture system constitutes a bioassay to 
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quantify angiogenesis, as angiogenic factors will cause outgrowth of tubules that can be 
measured. In this co-culture bioassay, we tested whether TAs influences angiogenesis in 
vitro. Aspirates from severe BPD (n=6), no BPD (n=6) patients or PBS (n=6) were added 
as 10% of the total mixture. From this mix, 50 µl was transferred to a single well of a 96 
wells flat bottom plate. After 1 hour incubation at 37˚C in 5% CO2, co-culture medium 
supplemented 1:1 with severe BPD, no BPD or PBS was added on top of the collagen co-
culture gel. Samples were incubated for 4 days at 37˚C in 5% CO2. On day 2 images were 
taken using Olympus IX51 fluorescence microscope with CellSenseDimension software. 
Images were analyzed using AngioSys.
statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD) for normally 
distributed data or median (interquartile range, IQR) for not normally distributed data, 
and categorical variables were expressed as n/N (%). We compared preterm infants who 
developed severe BPD with infants who did not develop BPD, using Fisher’s exact test for 
categorical variables and the Mann-Whitney U test for continuous variables. Cell counts 
between these two groups and between different time points were compared using the 
Kruskal-Wallis test. Concentrations of growth factors, chemokines and cytokines in TAs 
were compared between the two groups for each time point separately using the Mann-
Whitney U test. Concentrations below the detection limit were imputed as the lower 
detection limit as published by R&D 26. Concentrations were log transformed in order to 
obtain a near normal distribution. Linear mixed effects models with unstructured covari-
ance matrix were used to examine the change over time of growth factors, chemokines 
and cytokines concentrations in TAs, thereby providing estimates of the average change 
in the samples over time and compared between groups. Independent variables in the 
linear mixed effect models were birth weight corrected for GA, time between birth and 
intubation and time at which TAs were obtained (post intubation day 0, 1, 3, 5 and 7, as 
categorical variable with day 0 as reference level). Correlations between tubule growth 
and concentrations of growth factors, cytokines and chemokines were assessed with 
Spearman correlation coefficient. Two-sided significance level was 0.05 without cor-
rection for multiple testing. GraphPad Prism software (version 4.0, GraphPad) and SPSS 
version 21.0 software (SPSS, Inc., Chicago, IL) were used for statistical analyses.
REsults
subject characteristics
We included serial TAs from 23 preterm infants who did not develop BPD and 22 who 
developed severe BPD. Infants with BPD were born at significantly lower GA, with lower 
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birth weight, received more postnatal surfactant, experienced more complications like 
persistent ductus arteriosus, and had a significantly longer duration of invasive mechani-
cal ventilation and oxygen supplementation. Patient characteristics are given in Table 1.
table 1. Patient characteristics
No BPD Severe BPD p value
number of patients 23 22
number of tAs Day 0: 15 Day 0: 12
 Day 1: 17 Day 1: 17  
 Day 3: 15 Day 3: 13  
 Day 5: 11 Day 5: 19  
 Day 7: 6 Day 7: 14  
gestational age (weeks) 29.1 (26.7-30.4) 25.9 (24.9-26.3) < 0.001
Birth weight (gram) 1080 ± 374 762 ± 217 0.001
sex (male : female) 12 : 11 11 : 11 1.000
Antenatal corticosteroids No: 5 (21.7%)
Yes, not complete: 6 (26.1%)
Yes, complete: 12 (52.2%)
No: 2 (9.1%)
Yes, not complete: 8 (36.4%)
Yes, complete: 12 (54.5%)
0.516
Maternal preeclampsia 4 (17.4%) 5 (22.7%) 0.722
chorioamnionitis 2 (8.7%) 8 (36.4%) 0.072
Postnatal surfactant No: 6 (26.1%)
1 gift: 9 (39.1%)
≥ 2 gifts: 8 (34.8%)
No: 1 (4.5%)
1 gift: 6 (27.3%)
≥ 2 gifts: 15 (68.2%)
0.043
Early onset sepsis 0 (0.0%) 1 (4.5%) 0.489
late onset sepsis 7 (30.4%) 13 (59.1%) 0.075
PDA 10 (43.5%) 20 (90.9%) 0.001
total days invasive ventilation 6 (4-13) 22 (17-35) < 0.001
total days oxygen exposure 10 (0-18) 62 (46-69) < 0.001
Definition of abbreviations: BPD: bronchopulmonary dysplasia; TAs: tracheal aspirates; PDA: persistent duc-
tus arteriosus. Continuous variables are expressed as mean ± standard deviation (SD) for normally distrib-
uted data or median (interquartile range, IQR) for data that were not normally distributed. Categorical data 
are expressed as n (%).
Angiogenesis-related factors in tracheal aspirates
We explored which angiogenesis related factors are present in TAs, using an antibody 
mediated proteome-profiling assay. The proteome profiler detected all classical growth 
factors involved in angiogenesis in TAs of preterm infants, such as VEGF, Ang1 and -2, 
PDGFα, PDGFβ and fibroblast growth factor (FGF) (Figure 1A). Additionally TAs contained 
a variety of alternative angiogenesis-related proteins (Figure 1B). Amongst these were 
CXCR-chemokines and CC-chemokines and other angiogenic proteins like EGF, HGF, 
GDF15 and EMMPRIN. The TAs contained both products of M1 macrophages (TNF-α, 
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IL1-β, IL-6, CCL3/MIP-1alpha, CCL4/MIP-3α, CCL5/RANTES) and of M2 macrophages 
(chitinase-3-like-1, IL-10, IL-Ra, CCL17/TARC). TAs also contained cytokines known to be 
involved in the induction of M1 (interferon (IFN)-γ and granulocyte-macrophage colony-
stimulating factor (GM-CSF)), and M2 macrophages (IL-4, IL-6, IL-13, IL-33 and leukemia 
inhibitory factor (LIF)) (Figure 1C). Secretory IgA levels showed little variation between 
the samples, indicative of a low variance in dilution between diff erent patient samples 
(Figure S1). To judge variance we repeated the experiment on comparable samples of 
diff erent patients. Complete data of the two experiments are shown in Figure S2. We 
conclude that TAs of preterm infants, besides classical growth factors involved in angio-
genesis, contained a variety of alternative angiogenesis related factors, representatives 
of both M1 and M2-type macrophages.
Figure 1. Proteomic analysis of angiogenesis-related factors in TAs of preterm born infants who did or did 
not develop severe BPD. (A) Results of a semi-quantitative antibody mediated proteome-profi ling assay 
(R&D systems) on classical angiogenic growth factors, (B) other angiogenesis related growth factors and (c) 
proinfl ammatory cytokines in TAs of premature children. The data represents one of two experiments. To 
obtain enough material to perform the assay (1.5 ml per condition) we pooled TA samples obtained within 
the fi rst 3 days of life of 4 patients who later developed severe BPD (grey bars) and 6 matched patients who 
did not develop BPD (black bars). Due to pooling no SD values or indications of signifi cance could be given. 
Numbers on the Y-axis represent mean pixel density of the blot. Alternative growth factors that are either 
chemoattractants or products of monocytes/macrophages were marked with an asterix.
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Macrophage numbers and M2 gene expression in tracheal aspirates of preterm 
infants
Total cell numbers were lowest in the aspirates taken directly after intubation, and 
increased at later time points (Figure 2B). Diff erential cell counts showed that epithelial 
cells were highest on the day of intubation (day 0), while the percentage of neutrophils 
and macrophages increased later (Figure 2C-E). We found no diff erences in the cellular 
distribution patterns between infants who did and did not develop severe BPD (Figure 
2C-E).
Figure 2. Presence of M2-like macrophages in TAs of preterm infants without BPD. (A) May-Grünwald Gi-
emsa staining of three cytospin preparations (40X) from TAs of preterm born infants showing the predomi-
nant presence of epithelial cells (left panel), monocytes/macrophages (middle panel) and granulocytes 
(right panel). (B) Total cell counts and percentages of epithelial cells (c), granulocytes (D) and monocytes/
macrophages in TAs of preterm infants who developed severe BPD or did not develop BPD. (F) Gene expres-
sion of the M2 markers MRC1, CD206 (g) and CD163 (h) relative to CD68 in total cell lysates of TAs from 
children with and without BPD.
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Figure 3. Macrophage-derived growth factors and chemokines over time. (A) Classical growth factors, 
(B) chemokines, (c) pro-infl ammatory cytokines and (D) other alternative growth factors (ng/ml) in TAs 
of infants who developed bronchopulmonary dysplasia (BPD; ∙, continuous red line) and infants who did 
not develop BPD (no BPD; ○, dashed blue line), analyzed by Luminex assay. Dots represent median values, 
whiskers 25th and 75th percentiles, and group comparison by means of univariate analysis per time point, * 
= p < 0.05. Numbers of observations at diff erent time points are given in Table 1.
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To investigate whether macrophage profi les are diff erent between preterm infants 
with and without BPD we measured gene expression of the M2-macrophage specifi c 
markers MRC-1, CD206 and CD163 in TA total cell lysates by RT-PCR. We used CD68 as 
a macrophage specifi c housekeeping gene. We found signifi cantly higher MRC1/CD68 
and CD206/CD68 ratio’s in preterm children who did not develop BPD (Figure 2F-G), 
indicating the presence of higher numbers of M2-like macrophages in this group. CD163 
gene expression was not diff erent between the two groups (Figure 2H).
Figure 4. Monocyte/macrophage derived angiogenesis related factors in TAs of preterm born infants and 
eff ect on angiogenesis in vitro. (A) Representative pericyte-HUVEC co-culture showing endothelial cells in 
green and pericytes in red. Percent diff erence in number of tubules (B and c) and total tubule length (D 
and E) between pericyte-HUVEC co-cultures grown in the presence of medium diluted with PBS (1:1) or di-
luted with TAs (1:1) from preterm infants without BPD(n=6) or with severe BPD (n=6). Each bar represent the 
median of and individual patient, error bars are IQR of 6 measurements of a given TAs sample. No signifi cant 
diff erences were found between TAs of children with and without BPD.
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Difference in growth factors, cytokines and chemokines in serial tAs of  
preterm infants with and without BPD development
Concentrations of growth factors and cytokines in the Luminex assay and ELISA were 
above the detection limit in most TAs. Median concentrations (pg/mL) over time with 
25th and 75th percentiles in infants who did not develop BPD and those who developed 
severe BPD are presented in Figure 3 and S3. Linear mixed models with each factor as 
dependent variable found an overall significant difference over time for HGF, EMMPRIN, 
GDF15, IL-1α, IL-1β and TNF-α, the M2-chemokines CCL17/TARC and CCL22/MDC and 
the classical growth factors Ang1, Ang2 and PDGFα, with lower concentrations in TAs of 
patients who developed severe BPD and higher concentrations in TAs of patients who 
did not develop BPD. For none of the CXCL chemokines significant differences were 
found.
Effect of tracheal aspirates on angiogenesis in vitro
Average effects of TAs from infants with and without severe BPD on tubule growth, namely 
number and length of tubules, were not significantly different, respectively p=0.11 and 
p=0.15 (Figure 4). There was marked intersubject variation between samples: TAs from 
children without BPD (n=6) either inhibited (n=4) or enhanced (n=2) tubule formation, 
and TAs from infants with severe BPD (n=5) inhibited (n=2) or strongly enhanced (n=3) 
tubule formation. Tubule formation did not correlate with VEGF concentrations, but did 
correlate with several alternative growth factors. In infants with severe BPD the number 
and length of tubules correlated negatively with concentrations of endoglin (rs=-0.841, 
p=0.04 and rs=-0.841, p=0.04, respectively). In infants without BPD tubule growth cor-
related negatively with CXCL1/GROα, TNF-α and Ang1 (data not shown) and we found 
a positive correlation with GDF15 (rs=0.886, p=0.02 and rs=0.928, p=0.01, respectively).
Discussion
We showed that TAs of preterm infants contained classical angiogenic growth factors 
and a broad array of alternative angiogenesis-related proteins in relatively high concen-
trations. In a co-culture bioassay, the angiogenic effect of TAs was overall not different 
between infants who did or did not develop BPD, with marked interindividual variation. 
Tubule growth in these assays did not correlate with the classical angiogenic growth 
factor VEGF, but did correlate with several alternative growth factors. A selection of 
alternative proangiogenic factors including HGF, EMMPRIN and GDF15, M1/pro-inflam-
matory cytokines IL-1α, IL-1β and TNF-α, and M2-type factors CCL17/TARC and CCL22/
MDC were higher in serial TAs of preterm infants who did not develop BPD compared to 
children who developed severe BPD. In addition, we found higher expression of the M2-
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macrophage specific genes MRC1 and CD206 in those who did not develop BPD. These 
data support an effect of M2-type macrophage-derived angiogenic growth factors in 
the pathogenesis of BPD.
Previous studies focusing on the classical vascular growth factors VEGF and the Ang/Tie-2 
system in lungs of patients developing BPD have reported conflicting results 11, 12, 27. More 
recent studies postulated that inflammatory mediators like endoglin-1 and chemokines 
like MIP-1α and MCP-1 might cause a surge in inappropriate angiogenesis leading to 
aberrant alveolar capillaries in the developing lung 14-17, 28. Besides previously identi-
fied alternative factors, such as endoglin, HGF and MMP-9, we also found factors not 
described in BPD before, but with well-known effects on angiogenesis such as EMMPRIN 
and GDF15. EMMPRIN is known to promote angiogenesis through its protease-inducing 
function and by affecting paracrine regulation of the VEGF/VEGF-receptor (VEGFR) 
system in endothelial cells 29. GDF15, also known as MIC-1 (macrophage inhibitory cy-
tokine 1) has anti-inflammatory functions 30 and a pro-survival and anti-oxidant role in 
hyperoxia 31, 32. We found EMMPRIN and GDF15 in significantly higher concentrations in 
preterm children who did not develop BPD compared to those developing severe BPD.
We also noticed strong signals of CXCL5/ENA78, CXCL1/GROα and CXCL8/IL-8. These 
chemokines are well known for their effects on angiogenesis via ligation to the CXC che-
mokine receptor 2 (CXCR2), which is expressed on endothelial cells and epithelial cells, 
including the alveolar type II cell. The absence or inhibition of CXCR2 has been shown to 
reduce neutrophil accumulation, radical formation and lung injury caused by hyperoxia 
in adult mice and newborn rats 33. Antibodies to CXCR2 or gene knockout also preserved 
alveolarization in murine models of BPD 34. It has therefore been suggested that the 
CXCR2/CXCR2 ligand axis may be relevant in the pathogenesis of BPD. Similar data are 
present for the angiogenic CC-chemokines CCL2/MCP1, CCL3/MIP1α and CCL4/MIP2α, 
which also gave strong signals in our proteome assay. However, quantitative analysis of 
serial TAs only showed differences in infants with or without later BPD in ENA78/CXCL5 
and MCP1/CCL2 and in none of the other chemokines, questioning the relevance of the 
above findings in mice for the human situation.
Previous studies have described higher levels of pro-inflammatory cytokines in TAs of 
preterm children who developed BPD, as recently reviewed elsewhere 35, and this seems 
contradictory to the present findings of higher levels of IL-1α, IL-1β and TNF-α and a 
clear trend towards higher levels of IL-6 in preterm infants who did not develop BPD. 
Compared to our findings, most samples in previous studies were collected within 24 
hours after intubation and we observed differences at 5-7 days after intubation. Fur-
thermore, some studies investigated BALF, while we studied TAs. Although the origin of 
most factors expressed in the proteome-profiling assay can be heterogeneous, it is likely 
that most factors originate from epithelial cells or from the inflammatory cells present 
in TAs, i.e. neutrophils and macrophages. Since TAs were taken from the proximal air-
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ways, TA macrophages cannot be classified as alveolar macrophages. They most likely 
represent monocytes that migrated from the pulmonary interstitium into the tracheal 
lumen in response to chemoattractants, and differentiated into macrophages locally. 
This difference in cellular content between BALF and TAs may also explain the variance 
in concentrations of pro-inflammatory cytokines reported in different studies. Further-
more, evidence is also rising that coordinated expression of these cytokines during early 
immune responses plays a protective role as well. Fetal IL-6 is a regulatory cytokine of 
pulmonary surfactant proteins and plays an important role in lung maturity decreasing 
the incidence of respiratory distress syndrome in preterm neonates 36-39. Intra-amniotic 
administration of IL-1α or IL-1β also induces lung maturation in preterm animals 40. A 
recent study showed that absence of TNF-α strongly enhances inflammatory responses 
in newborn mouse lungs undergoing mechanical ventilation. Absence of TNF-α was as-
sociated with excess activation of TGF-β signaling, resulting in increased inflammation 
and apoptosis, and reduced NF-κB activity 41.
The relatively late increase in CCL17, CCL22 and pro-inflammatory cytokine concentra-
tions paralleled a late increase of monocytes/macrophages in TAs. The low cell count in 
TAs did not allow for cell sorting and precise characterization of macrophages. Although 
total numbers of monocytes/macrophages did not differ between patients who did or 
did not develop BPD, we did find higher gene expression of the M2-macrophage mark-
ers MRC1 and CD206 in TAs cells of preterm infants who did not develop BPD. Together 
with the higher soluble M2 markers (CCL17 and CCL24) and higher concentrations of 
cytokines important for the induction of M2 macrophages (IL-4, IL-5, IL-13 and IL-33) this 
suggests high M2-macrophage activity in children who did not develop BPD.
The combination of pro-angiogenic factors, pro-inflammatory cytokines and M2-related 
factors reflects a similar expression profile as embryogenic macrophages and tumor-
associated macrophages (TAMs), subsets of macrophages well-known for their function 
in angiogenesis. These factors were consistently higher in TAs of infants without BPD 
compared with TAs of infants with severe BPD. In addition, M2 macrophages have been 
found in neonatal lungs at the tips of alveolar septa where they seem to guide branching 
morphogenesis suggesting a role in ensuring normal lung growth and development 23. 
An improved understanding of the role of macrophages under homeostatic and inflam-
matory conditions is important, as modulation of monocytes and macrophages and 
their products in the context of lung development may provide new future prevention 
or treatment modalities for BPD.
Some limitations of our study should be considered. The infants who did and did not 
develop severe BPD differed with respect to GA at birth, birth weight, postnatal surfac-
tant, persistent ductus arteriosus and total days of invasive mechanical ventilation and 
oxygen supplementation, and the number of TA samples decreased over time, as many 
infants could be extubated within 7 days. This inevitably introduced selection bias. We 
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did not obtain TAs from preterm infants who did not need mechanical ventilation. There-
fore, one can argue that a proper control group is missing. Few TAs were macroscopically 
contaminated with blood. Growth factors, chemokines and cytokines are also present 
in plasma, and this might have influenced our results. We consider it unlikely that such 
contamination differed systematically between groups, and affected the comparisons. 
Finally, no formal correction for multiple testing of different growth factors, chemokines 
and cytokines was performed.
In conclusion, we found a wide spectrum of angiogenic factors in TAs of ventilated pre-
term children during the first week of life which influenced tubular growth in vitro. Some 
pro-angiogenic factors, pro-inflammatory cytokines and M2-related factors were higher 
in infants who did not develop BPD. Further studies to better understand macrophage-
related angiogenesis under inflammatory conditions in the newborn lung are warranted 
as they may lead to new prevention or treatment modalities for BPD.
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suPPlEMEntAl FiguREs
Figure 1. Secretory IgA in 28 randomly selected tracheal aspirates of preterm infants.
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Figure 2. Complete proteome profi ling data of two separate experiments on diff erent TA samples of pre-
term infants who later developed severe BPD (grey bars) or did not develop BPD (black bars). The legend 
indicates the number of patients per group. The experiments illustrate the variability between patient sam-
ples. Note that overall both experiments showed the same expression pattern.
Angiogenic growth factors in serial tracheal aspirates of preterm infants 123
5
Figure 3. Additional alternative growth factors (ng/ml) in TAs of infants who developed bronchopulmo-
nary dysplasia (BPD; ∙, continuous red line) and infants who did not develop BPD (no BPD; ○, dashed blue 
line) analyzed by Luminex. Dots represent median values, whiskers 25th and 75th percentiles, and group 
comparison by means of univariate analysis per time point, * = p < 0.05.
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ABstRAct
Background
In an experimental mouse model we showed that ceramides play a role in the patho-
genesis of bronchopulmonary dysplasia (BPD) and are a potential target for therapeutic 
intervention. We investigated whether ceramides are detectable in tracheal aspirates 
(TAs) of preterm infants and differ between infants with or without BPD.
Methods
Infants born ≤ 32 weeks of gestational age in need for mechanical ventilation in the first 
week of life were included. TAs were obtained directly after intubation and at day 1, 3, 
5, 7, and 14. Ceramide concentrations were measured by tandem mass spectrometry. 
At 36 weeks postmenstrual age BPD was defined as having had ≥ 28 days supplemental 
oxygen.
Results
122 infants were included, of which 14 died and 41 developed BPD. All infants showed 
an increase in ceramides after the first day of intubation. The ceramide profile differed 
significantly between preterm infants who did and did not develop BPD. However, the 
ceramide profile had no additional predictive value for BPD development over GA at 
birth, birth weight and total days of mechanical ventilation.
conclusions
Ceramides in TAs may be an early marker for BPD development and the ceramide path-
way is a potential new target for future therapeutic interventions.
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intRoDuction
Bronchopulmonary dysplasia (BPD) is a serious complication affecting preterm born 
infants, with an incidence ranging from 4% in infants born at a gestational age (GA) of 31 
weeks to 56% in infants born at a GA of < 26 weeks 1. BPD is defined as need for oxygen 
supplementation for ≥ 28 days at 36 weeks postmenstrual age 2. Genetic predisposition 
and exposure to environmental factors, such as chorio-amnionitis, preeclampsia, GA at 
birth, birth weight, mechanical ventilation, supplemental oxygen exposure, postnatal 
infections, persistent ductus arteriosus (PDA) and malnutrition, have been implicated 
in the etiology of BPD. To date, treatment is symptomatic and children with BPD are at 
increased risk of long term respiratory sequelae 3.
Sphingolipids are important structure-bearing constituents of the cell membrane that 
also function as regulatory molecules in cell proliferation and cell death, endothelial 
barrier function, angiogenesis, and immune response 4-6. Altered sphingolipid levels 
have been shown to play a role in asthma 7-9, cystic fibrosis 10, 11, and cigarette-smoke 
or radiation induced lung injury 12-14. This stresses the biological importance of the 
sphingolipid metabolism in lung disease 5. Two important sphingolipids are ceramides 
and sphingosine-1-phosphate (S1P). Ceramides act as a precursor for all other sphingo-
lipids; S1P is generated from ceramide via sphingosine 15. Ceramides and S1P play an 
important role in apoptosis, with ceramides stimulating apoptosis and cell cycle arrest 
and S1P stimulating cell survival and proliferation 16. Apoptosis may be critical in BPD as 
increased apoptosis has been found in pulmonary epithelial cells of BPD patients and 
in animal models of BPD 17, 18. Recently we observed a transient increase in ceramide 
concentrations in bronchoalveolar lavage (BAL) fluid of a mouse model of BPD during 
the first 2-4 weeks of hyperoxia. Supplementation of D-sphingosine, a synthetic precur-
sor of S1P, during normoxic recovery of hyperoxia-induced lung damage accelerated 
normalization of ceramide concentrations and improved the hyperoxia-induced alveolar 
arrest in this mouse model 19. These findings suggest that ceramides are involved in the 
development of BPD, may be used as an early biomarker for BPD, and might be a target 
for new therapeutic interventions.
The aim of the present study was to translate these findings to humans, by analyzing 
ceramide profiles in tracheal aspirates (TAs) of preterm infants. We hypothesized that 
ceramide concentrations in TAs were higher in preterm born infants who developed BPD 
compared to those who did not, and may be an early biomarker for BPD.
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MAtERiAls AnD MEthoDs
study subjects and design
Preterm infants (≤ 32 weeks GA) in need of mechanical ventilation in the first week of life 
were recruited at the Neonatal Intensive Care Unit of Erasmus MC-Sophia Children’s Hos-
pital. Children with a congenital disorder affecting lung structure and/or function and 
children who were intubated only to administer surfactant were excluded. We obtained 
TAs directly after intubation, and as long as children were intubated at consecutive days 
1, 3, 5, 7 and 14, during routine suctioning procedures. BPD was diagnosed according 
to criteria of Jobe and Bancalari 2. BPD severity was assessed by means of an oxygen 
reduction test at 36 weeks postmenstrual age 20. Relevant maternal and neonatal char-
acteristics including maternal age, preeclampsia, chorio-amnionitis, antenatal steroids, 
mode of delivery, GA at birth, birth weight, sex, surfactant treatment, early or late onset 
sepsis, persistent ductus arteriosus (PDA), postnatal systemic steroids, days on mechani-
cal ventilation and days on oxygen were prospectively collected from patients records. 
Written informed consent was obtained from the parents. The study was approved by 
the medical ethical committee of Erasmus MC, Rotterdam, The Netherlands (MEC-2013-
062, NL43229.078.13).
tracheal aspirate collection and processing
TAs were collected directly after intubation, and at days 1, 3, 5, 7, and 14 as long as the 
patient was intubated. TAs were obtained at least 6 h after surfactant administration. Dur-
ing the procedure 0.5 ml of sterile isotonic saline was instilled into the endotracheal tube, 
and after 5 s suctioning was performed with a 5F catheter positioned at the end of the 
endotracheal tube. TAs were directly stored at 4°C. After centrifugation for 5 min at 300×g, 
the supernatant was collected, aliquoted in 1.5 ml extra low binding Eppendorf tubes (Bio-
zymTC, Landgraaf, the Netherlands), and stored at -80°C until analysis. Subsequently, cell 
suspensions were stored in 100 μL 1x phosphate-buffered saline (PBS). Cells were counted 
and a maximum of 4 standardized cytospins with 50,000 cells per slide were prepared. 
Cytospin preparations were made with a cytocentrifuge (Cytospin 4, Thermo Scientific, 
Breda, the Netherlands) at 680 rpm for 7 min with low acceleration. The cytospins were air 
dried for at least 24 h and subsequently wrapped in aluminum foil and stored at -20°C. For 
each TA sample one cytospin was stained with May-Grünwald Giemsa staining. Per slide a 
differential cell count was performed by two observers (EM and IK) 21, 22.
liquid chromatography tandem mass spectrometry
Ceramide concentrations (ng/mL) in TAs were measured as previously described 19. 
Briefly, lipids were extracted from TA samples (200 μL) and ceramides were separated 
using high performance liquid chromatography (LC) and quantified by tandem mass 
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spectrometry (MS/MS). The analyses were performed at the Analytical Facility for Bioac-
tive Molecules of the Hospital for Sick Children, Toronto, ON, Canada.
statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD) for normally 
distributed data or median (interquartile range, IQR) for data that were not normally dis-
tributed, and categorical variables were expressed as n (%). We compared infants who did 
not develop BPD with those who did develop BPD or died because of respiratory failure 
before 36 weeks PMA using Fisher’s exact test for categorical variables or the Mann-Whit-
ney U test for continuous variables. Ceramide concentrations were compared for each 
time point separately using the Mann-Whitney U test. Ceramide concentrations below 
the detection limit were imputed as the lower detection limit (0.03 ng/ml). Ceramide 
concentrations were logarithmically transformed in order to obtain a near normal distri-
bution. Spearman’s rho was used to assess the correlation between individual ceramides 
and the correlation between ceramides and cell counts. Cell counts between different 
time points were compared using the Kruskal-Wallis test. Principal components analysis 
was applied to achieve a simpler structure combining ceramides that were highly cor-
related. Linear mixed effects models were used to examine the change over time of the 
mean logarithmically transformed ceramide concentrations, providing estimates of the 
average change in the samples. Independent variables in the linear mixed effect models 
were BPD outcome, GA at birth, birth weight SDS, time between birth and intubation and 
total days of invasive ventilation at 36 weeks PMA, and time at which TAs were obtained. 
Time at which TAs were obtained (post intubation day 0, 1, 3, 5, 7 and 14) was treated as 
categorical variable with day 0 as reference level. A random intercept was included in the 
linear mixed models to account for within-subject correlations.
To explore whether longitudinal observations of the ceramide profile or individual 
ceramides predicts the development of BPD we used a two-step approach. First, a linear 
regression of the log-transformed ceramides on time, coded as continuous variable, 
for each patient and ceramide was performed. The estimates of the intercept and the 
slope of the ceramide profile and individual ceramides were then included as indepen-
dent variables in a logistic regression for the development of BPD. Patients for whom 
ceramide concentrations were not available at two or more time points were excluded 
from this analysis, because no linear regression could be performed in that case. GA at 
birth, birth weight SDS, time between birth and intubation and total days of invasive 
ventilation were included as independent variables in this logistic regression model. The 
calibration of the logistic regression model was assessed using the Hosmer-Lemeshow 
test. All statistical tests used a two-sided significance level of 0.05, without correction 
for multiple testing. SPSS version 21.0 software (SPSS, Inc., Chicago, IL) and Excel version 
2010 software were used for statistical analyses.
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REsults
Patient characteristics
We included 122 preterm born infants with a median GA (IQR) of 27.2 (25.6-29.6) weeks 
and a mean birth weight (SD) of 1003 (371) grams between September 2013 and De-
cember 2014 (Table 1). Fourteen infants died before 36 weeks PMA, of whom 3 due to 
respiratory failure. Forty-one infants (33.6%) developed BPD, 16 mild-moderate and 25 
severe (Figure 1). Infants who developed BPD were born at significantly lower GA, with 
lower birth weight, received more antenatal corticosteroids and postnatal surfactant, 
experienced more complications like late onset sepsis and PDA, and had a significantly 
longer duration of mechanical ventilation and oxygen supplementation.
ceramides in tracheal aspirates of preterm born infants
We collected 341 TAs from 111 preterm infants included in our final analysis, of which 
84 TAs were collected at day 0, 87 at day 1, 52 at day 3, 47 at day 5, 39 at day 7, and 32 at 
day 14. All ceramides were highly correlated with each other (data not shown). The con-
centrations of each individual ceramide were above the detection limit in the majority 
of TAs, except for CerDiHy 18:1, of which 92.1% of the samples had concentrations below 
Figure 1. Flow diagram study population. Overview of the eligible and included patients between 
September 2013 and December 2014.
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the detection limit. Therefore, this ceramide was excluded from further analysis. Secre-
tory IgA levels showed little variation between the samples, indicative of a low variance 
in dilution between different patient samples (data not shown). All infants showed an 
increase in ceramides after the first day of intubation. Ceramides in infants who did not 
develop BPD generally showed a late rise in ceramides until day 14, and this was not seen 
in those who developed BPD. Median ceramide concentrations (ng/ml) over time with 
table 1. Patient characteristics
No BPD BPD or respiratory death p value
number of patients 67 44
number of tAs Day 0: 51 Day 0: 34
Day 1: 48 Day 1: 39  
Day 3: 18 Day 3: 34  
Day 5: 12 Day 5: 35  
Day 7: 8 Day 7: 31  
Day 14: 3 Day 14: 29  
gestational age (weeks) 29.4 (27.9-30.4) 25.9 (24.5-26.3) < 0.001
Birth weight (gram) 1205 ± 346 768 ± 230 < 0.001
sex (male : female) 33 : 34 25 : 19 0.446
Antenatal corticosteroids No: 17 (25.4%)
Not complete: 17 (25.4%)
Yes, complete: 33 (49.2%)
No: 3 (6.8%)
Not complete: 12 (17.9%)
Yes, complete: 29 (65.9%)
< 0.001
Maternal preeclampsia 14 (20.9%) 11 (25.0%) 0.647
chorioamnionitis 14 (20.9%) 15 (34.1%) 0.203
Postnatal surfactant No: 12 (17.9%) No: 4 (9.1%) < 0.001
1 dose: 36 (53.7%) 1 dose: 12 (27.3%)  
≥ 2 doses: 19 (28.4%) ≥ 2 doses: 28 (63.6%)  
Early onset sepsis 2 (3.0%) 2 (4.5%) 0.648
late onset sepsis 14 (20.9%) 23 (52.3%) 0.001
PDA 24 (35.8%) 38 (86.4%) < 0.001
total days mechanical ventilation 2 (1-6) 22 (11-33) < 0.001
total days supplemental oxygen exposure 3 (0-13) 55 (40-67) < 0.001
Definition of abbreviations: BPD: bronchopulmonary dysplasia; PDA: persistent ductus arteriosus. Maternal 
preeclampsia was defined as newly developed hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg) 
after 20 weeks of pregnancy and proteinuria (protein-creatinine ratio ≥ 30 mg/mmol or ≥ 300 mg/24u). 
Chorioamnionitis was determined based on placental pathology findings. Treatment with prenatal corti-
costeroids was considered adequate when infants were born at least 12 hours after the second antenatal 
corticosteroid administration. Early onset sepsis was defined as a positive blood culture in the first 72 hours 
after birth, late onset sepsis as a positive blood culture after the first 72 hours after birth and in the first 3 
months of life. Continuous variables are expressed as mean ± standard deviation (SD) for normally distrib-
uted data or median (interquartile range, IQR) for data that were not normally distributed. Categorical data 
are expressed as n (%).
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25th and 75th percentiles in infants who did and did not develop BPD are presented in 
Figure 2. Principal component analysis revealed that a single component was sufficient 
to represent the data of all ceramides, explaining 84.2% of all variance. We therefore 
computed a new variable representing the mean of the logarithmically transformed 
ceramides per patient and per time point, as this mean was similar to the single principal 
component. The linear mixed model performed with this new variable as dependent 
variable found an overall significant difference in ceramide profile between patients 
who did and did not develop BPD (p= 0.026) and a significant change in ceramide profile 
over time compared to the day of intubation (Table 2). Multivariable logistic regression 
analysis showed that the ceramide profile over time had no additional predictive value 
over known predictors of BPD outcome (GA at birth, birth weight, total days invasive 
ventilation) (Table 3). When we performed separate multivariable logistic regression 
analysis for all the individual ceramides for each time point, individual ceramides had no 
significant predictive value over the known predictors (Supplemental data).
cell count in tracheal aspirates
We found no difference in total cell count of TA samples between infants who did and 
who did not develop BPD or died because of respiratory failure. Overall, TAs acquired 
table 2. The change in overall ceramide profile
Ceramide profile level
Predictor coefficient (95% ci) p value
GA at birth -0.044 (-0.200 – 0.112) 0.575
Birth weight (SDS score) 0.177 (-0.049 – 0.403) 0.123
Total days invasive ventilation 0.014 (-0.009 – 0.037) 0.221
Time between birth and intubation (days) 0.002 (-0.003 – 0.007) 0.442
BPD diagnosis
No BPD 0a
BPD or respiratory death -0.797 (-1.497 – 0.098) 0.026b
Post intubation day
Day 0 0a
Day 1 1.019 (0.565 – 1.472) <0.001b
Day 3 0.458 (-0.083 – 1.000) 0.097
Day 5 0.871 (0.303 – 1.440) 0.003b
Day 7 0.634 (0.023 – 1.244) 0.042b
Day 14 0.410 (-0.257 – 1.076) 0.227
This linear mixed model investigates the association between GA, birth weight (SDS score), total days inva-
sive ventilation, time between birth and intubation, time of obtaining TA (post intubation day 0, 1, 3, 5, 7 or 
14) and the occurrence of BPD and respiratory death on rates of change in ceramide profile. a No BPD and 
post intubation day 0 are used as reference category, b p<0.05.
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at day 14 contained significantly more cells than TAs obtained at day 0, adjusted for 
multiple comparisons; 530,000 (207,000-1,044,000) versus 136,500 (45,000-354,750), 
respectively, p=0.003. Differential cell count showed a significant decrease of epithelial 
cells and a significant increase in granulocytes and macrophages and/or monocytes 
(Figure 3). Overall, there was a significant correlation between ceramide profile and total 
cell count, but no significant correlation between ceramide profile and percentage of 
granulocytes and macrophages or monocytes (data not shown).
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Figure 2. Ceramide patterns (ng/ml) in tracheal aspirates of preterm infants who developed bronchopul-
monary dysplasia (BPD; •, continuous line) and infants who did not developed BPD (○, dashed line). Dots 
represent median values, whiskers 25th and 75th percentiles, and group comparison by means of univariate 
analysis per time point, * = p < 0.05.
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Discussion
We showed an overall increase in ceramides in TAs of preterm infants after the fi rst day of 
mechanical ventilation. Infants who developed BPD had lower ceramide concentrations 
compared to those who did not, in particular at day 7 after intubation. Ceramide profi les 
changed over time, and were signifi cantly diff erent between infants who did or did not 
develop BPD. However, the combined ceramide profi les over time had no additional 
predictive value over known predictors of BPD.
table 3. Multivariable logistic regression analysis of BPD and respiratory death
Independent variable OR 95% CI p value
gA at birth 0.558a 0.327-0.954 0.033
Birth weight (sDs score) 0.884 0.424-1.846 0.486
total days mechanical ventilation 1.126a 1.002-1.265 0.046
time between birth and intubation 0.868 0.566-1.332 0.518
intercept ceramide profi le 0.836 0.493-1.420 0.508
slope ceramide profi le 0.604 0.205-1.776 0.359
The dependent variable in this analysis is BPD outcome (0 = did not develop BPD, 1= did develop BPD or 
died because of respiratory failure). n = 79, Hosmer-Lemeshow test (p= 0.468), a p< 0.05.
Figure 3. Cell distribution in TAs of preterm born infants. a) Total cell count for each time point between 
two groups (no BPD and BPD or respiratory death). b) Percentage of epithelial cells in TAs of infants who 
did not and who did develop BPD or died because of respiratory failure. c) Percentage of granulocytes in 
TAs of infants who did not and who did develop BPD or died because of respiratory failure. d) Percentage 
of macrophages or monocytes in TAs of infants who did not and who did develop BPD or died because of 
respiratory failure.
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This is the first study investigating ceramide profiles in TAs of preterm born infants. We 
recently showed in a mouse model of BPD that changes in ceramide levels may be a 
factor in hyperoxia- induced lung injury, and affect proper lung development and func-
tion 19. With this study we aimed to reproduce these findings in preterm infants. We 
collected TAs at multiple time points, which enabled us to observe the development of 
ceramide concentrations over time. The prospective design allowed us to investigate 
the predictive value of ceramide concentrations for BPD development when compared 
to known clinical risk factors.
Ceramides play an important role in apoptosis and lung inflammation 23 and mediate 
acute lung injury by increasing alveolar permeability and pro-inflammatory cytokine 
production 24. Long chain ceramides (Cer 16:0, Cer 18:0 and Cer 20:0) have anti-
proliferative and pro-apoptotic effects, whereas very long chain ceramides (Cer 22:0, 
Cer 24:0 and Cer 24:1) promote cell proliferation 25. In the present study, we observed 
an early increase in both long chain and very long chain ceramides in TAs of preterm 
born infants after 1 day of mechanical ventilation and oxygen supplementation. This 
is consistent with our results obtained in the mouse model showing an early increase 
of ceramides after start of exposure to hyperoxia. In infants, we found a late increase of 
both long chain and very long chain ceramides in those who did not develop BPD. These 
results at first seem to be in contrast with our earlier findings of increased ceramides 
in hyperoxia-exposed mice 19. However, in our study all preterm infants were exposed 
to both mechanical ventilation and supplemental oxygen. Therefore, we speculate that 
infants in our study were comparable to hyperoxia-exposed mice, as they showed an in-
crease in ceramides directly after intubation and exposure to oxygen supplementation. 
Due to medical ethical reasons it was not possible to include a control group of infants 
who were not intubated. When we combined the individual ceramides into a ceramide 
profile we indeed found a significant change in the profile over time and a significant dif-
ferent profile in those infants who did develop BPD compared to the infants who did not 
develop BPD. In a multivariable analysis the ceramide profile over time had no additional 
predictive value over GA at birth, birth weight, and total days mechanical ventilation. 
However, when we considered the individual ceramides we found borderline significant 
additional predictive value of the very long chain ceramides (Cer 22:0, Cer 24:0 and Cer 
24:1) that are known to promote cell proliferation (supplemental data). Altogether, an 
increased initial ceramide-triggered apoptotic signaling is present in all preterm infants 
exposed to mechanical ventilation and hyperoxia. Apoptosis of alveolar epithelial cells 
has been found before in the lungs of preterm infants that were subjected to ventilation 
and oxygen treatment 17 and in mouse models of BPD 26. Secondly, our results suggest 
that a reduced late increase in ceramides that may function as a proliferation signal, 
may predispose preterm infants to develop BPD. Given these findings, it is worthwhile 
to investigate the role of ventilation and hyperoxia-induced ceramide production in 
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epithelial apoptosis as a mechanism responsible for pulmonary apoptosis and inhibition 
of alveolar development in preterm infants with BPD.
Snoek et al. investigated ceramide concentrations in infants born > 32 weeks GA with a 
congenital diaphragmatic hernia (CDH) and did not find a difference in ceramide con-
centrations between infants with and without BPD 27. This discrepancy may be explained 
by the fact that the pathophysiology of BPD development in neonates with CDH is dif-
ferent from that in preterm infants. Patients with CDH are not surfactant deficient 28 and 
inflammatory processes seem to play a less important role. It should be noted that the 
ceramide concentrations in TAs of infants with CDH were in the same range as in the 
present study. Therefore, lower ceramide concentrations might predispose for BPD both 
in infants with lung hypoplasia due to CDH and in ventilated preterm infants.
Ceramides can be increased by increased sphingomyelin metabolism via sphingomy-
elinases, by increased production via de novo synthesis or from sphingosine by ceramide 
synthase 5. For this reason, it would be interesting to analyze the quantity of sphingo-
myelins in the TAs in our preterm infants. However, this was not feasible as most infants 
were treated with exogenous surfactant, which contains abundant sphingomyelins.
Pulmonary inflammation has always been considered a hallmark of BPD development. 
Previous studies showed an association between increased pro-inflammatory cytokine 
concentrations in blood and lung derived fluid and development of BPD 29. In the current 
study, we found a significant increase in granulocytes and macrophages or monocytes 
in TAs over time; however, this increase did not significantly differ between infants with 
or without later BPD. Furthermore, the overall ceramide profile did not correlate with 
the percentage of granulocytes and macrophages or monocytes, suggesting that the 
concentrations of ceramides might not be influenced by local inflammation in the lungs.
A few limitations of our study should be considered. We analyzed ceramides in TAs 
obtained from routine suctioning procedures, and not in BAL fluid which might yield 
larger samples and better standardization, but is more invasive. However, there is evi-
dence that TAs are suitable substitutes for BAL samples in newborns 30. Second, it was 
impossible to obtain TAs from preterm infants who did not need mechanical ventilation. 
Therefore, one can argue that a proper control group is missing. Few TAs (18%) were 
macroscopically contaminated with blood. Ceramides are present in plasma, and this 
might have influenced our results 31. However, sensitivity analysis after excluding these 
specimens, yielded similar results (data not shown). Patient characteristics between 
the infants who did and did not develop BPD differed with respect to GA at birth, birth 
weight, antenatal corticosteroids, postnatal surfactant, late onset sepsis, PDA and total 
days of mechanical ventilation. Based on a recent review regarding clinical predictors 
for BPD we chose only to correct for GA at birth, birth weight and total days of mechani-
cal ventilation 32. Correcting for all differentially expressed variables shown in Table 1 
did not change the results, but yielded not enough statistical power due to the small 
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sample size. The number of TA samples decreased over time, as many infants could be 
extubated within 14 days. This inevitably introduced selection bias. However, again 
sensitivity analysis including only those infants with at least one late TA sample available 
(13 infants without and 36 infants with BPD), yielded similar results (data not shown). 
Also, one could argue about the fact that BPD development is a continuum and a binary 
division based on the 36 weeks definition will introduce loss of power. In the future, it 
will be interesting to relate ceramides to BPD severity based on for example structural 
lung abnormalities and lung function. Finally, no formal correction for multiple testing 
of different ceramides was performed.
In conclusion, a pattern with early increase and subsequent decrease in ceramides in 
preterm infants exposed to mechanical ventilation and supplemental oxygen seems to 
predispose for BPD development. Therefore, ceramide profiles in TAs may be a new early 
marker for BPD and the ceramide pathway in general might be a potential new target for 
future prevention or treatment of BPD.
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ABstRAct
Background
Bronchopulmonary dysplasia (BPD) is a common respiratory complication of preterm 
birth and associated with long term respiratory sequelae. Chest computed tomography 
(CT) is a sensitive tool to obtain insight in structural lung abnormalities and may be a 
predictor for later symptoms.
objectives
To give an overview of chest CT scoring methods that are used to evaluate chest CT 
scans of BPD patients. To review which structural lung abnormalities are described in 
children and adults with BPD and whether these are related to clinical outcomes.
Methods
An extensive literature search was conducted for relevant studies on chest CT imaging 
in patients born preterm with BPD.
Results
We retrieved 316 original papers of which 16 articles and 3 abstracts fulfilled our inclu-
sion criteria. Overall, we identified nine different semi-quantitative scoring methods. 
Chest CT scans revealed structural abnormalities in > 85% of BPD patients. These abnor-
malities are decreased pulmonary attenuation, opacities, bronchial wall thickening, and 
consolidations. Some have been found to be negatively correlated with lung function 
and respiratory symptoms.
conclusions
None of the currently described scoring systems are appropriately validated or superior 
over another. Future studies are needed to generate a validated and universal chest CT 
quantitative scoring method for patients with BPD.
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intRoDuction
Lung damage is an important sequela of extreme preterm birth. In Europe, 4-56% of 
surviving preterm infants, depending on gestational age at birth, are suffering from 
bronchopulmonary dysplasia (BPD) 1. BPD is a lifelong condition associated with long 
term respiratory sequelae like lower lung function, severe obstructive airways disease 
and pulmonary hypertension, but also neurological and cognitive impairment, which all 
have a major impact on the quality of life and on survival 2.
BPD was first described in 1967 by Northway et al. and defined as persistent respiratory 
symptoms and need for oxygen supplementation in the first 28 days of life 3. BPD devel-
opment was mostly related to the severity of respiratory distress syndrome and chest 
radiographs showed especially hyperinflation and cystic areas. Lung histology from 
autopsy specimens of patients diagnosed with BPD as a result of preterm birth showed 
extensive inflammatory and fibrotic changes in both airways and lung parenchyma. 
Since the initial description by Northway et al., major changes in neonatal care have led 
to increased survival of more extremely preterm born infants (< 28 weeks of gestational 
age). Parallel to the changes in care and the younger gestational age, the spectrum of 
lung abnormalities in these surviving preterm infants has changed and is often referred 
to as 'new' BPD. Lung histology of infants who died from this new BPD show changes 
suggestive of impairment in normal lung development with reduced alveolar septation 
and abnormal vasculature and chest radiographs with particularly less cystic areas 4.
Chest computed tomography (CT) is considered the most sensitive imaging modality 
to detect structural abnormalities in patients with BPD 5. Chest CT has the potential to 
play an important role as outcome measure for clinical studies aiming to reduce the inci-
dence of BPD. In addition, chest CT could provide insight in the pathophysiology of BPD 
and might be a predictor for later symptoms and impairments. However, before chest CT 
can play a role as outcome measure in clinical studies, sensitive and reproducible image 
analysis methods need to be developed to quantify and characterize the morphological 
lung changes. Ideally such imaging analysis method should be automated. A consider-
able number of CT protocols and scoring methods have been described over the last 
30 years to characterize and quantify the structural abnormalities on chest CT scans of 
preterm born patients with BPD. However, to date there are no validated and universally 
accepted CT protocols and scoring systems for quantifying structural changes.
The primary aim of this systematic review is to identify all different scoring systems which 
have been used to evaluate chest CT scans of BPD patients. We aimed to investigate 
which structural lung abnormalities on chest CT are observed in children and adults 
with BPD, and whether these structural abnormalities have been described to relate to 
clinical outcomes like lung function and other respiratory sequelae. Finally, based on the 
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results of this review, we propose a universal chest CT quantitative scoring method for 
patients diagnosed with BPD that has the potential to be automated.
MEthoDs
A systematic literature search was conducted in cooperation with experienced medical 
librarians (WB and GJ) on the application of chest CT performed in patients with BPD. 
We searched Embase, Medline, Web-of-Science, Scopus, Cochrane, Google scholar, and 
PubMed databases for relevant publications. The last search was run on July 23, 2015. 
Key words included: chronic lung disease OR bronchopulmonary dysplasia OR BPD OR 
infant OR premature AND X-ray computed tomography AND scoring OR scale OR grad-
ing OR classification. Titles and abstracts were screened by two independent reviewers 
(EM and KL). We only included articles published in English that described original 
research, and addressed chest CT findings in patients born preterm with BPD. Reference 
lists of included articles were reviewed for additional references.
REsults
In total 316 articles were retrieved. Figure 1 shows the flow chart for all harvested 
papers. Finally, 16 articles met the inclusion criteria, and three additional articles were 
retrieved from their reference lists. In total, we included 19 original articles, of which 
three were only published as abstracts. Table 1 summarizes the 19 included articles. Year 
of publication varied between 1994 and 2013. The year of birth of the included preterm 
born infants in the studies varied between 1974 and 2008 and subsequently different 
diagnostic criteria for BPD were used. The age at which the chest CT scan was made 
varied between 34.9 weeks postmenstrual age and 33 years of age. Table 2 outlines the 
structural components scored using semi-quantitative scoring systems. In eight studies 
both inspiratory and expiratory chest CT scans were made. In total, nine different scor-
ing systems were identified. Intra-observer and inter-observer variability were described 
in, respectively, 5 and 12 of the 19 articles and showed kappa’s for different components 
scored between 0.45 and 0.95 6-10 and between 0.18 and 0.99 6-17. The most commonly 
scored structural components were hyperlucency, emphysema, opacities (both linear 
and subpleural), bronchial wall thickening and collapse, consolidation, or atelectasis 
(Table 2). Overall, emphysema scored the best intra-observer and inter-observer agree-
ment. The scoring systems assessed the extent of structural lung damage based on 
either the number of affected segments or lobes or on the number of lesions present. 
None of the scoring systems were fully quantitative.
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All studies showed abnormal CT findings in patients with BPD, both in the neonatal 
period and later in life 5-23. Furthermore, most studies which assessed the clinical sever-
ity of BPD (mild, moderate, severe) found an increase in CT abnormalities within the 
patients with more severe BPD 8, 10-12, 17, 19. Long et al. defined a clinical severity score at 
36 weeks (mean airway pressure x FiO2 at 36 weeks) and also found significant positive 
correlation with architectural distortion, linear and triangular opacities and air trapping 
on CT scans 21. In seven studies, CT findings of BPD patients were compared with control 
patients, which were either healthy term born 9, 16 or preterm born without BPD 6, 7, 15, 19, 23. 
The studies in which patients > 1 year of age were investigated found higher CT scores in 
the BPD patients compared with control patients 9, 16, 19, 23. In contrast, studies performing 
chest CT during the neonatal period found abnormal CT findings in almost all preterm 
infants exposed to mechanical ventilation and oxygen exposure irrespective of whether 
they had a clinical BPD diagnosis 6, 7, 15.
In 8 out of the 19 articles the correlation between scoring parameters and lung function 
parameters were described. All studies assessed different lung function parameters with 
Figure 1. Flow chart of included articles.
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diverse techniques at various ages. However, all but one study found significant correla-
tions between CT abnormalities and lung function parameters 9, 15, 17-22. Before the age of 
2 years both lower compliance and forced residual capacity (FRC) were found in those 
children with more CT abnormalities present 15, 17. At a later age, the severity of hypo 
attenuation, air trapping and architectural distortion correlated most with obstructive 
lung function, especially low forced expiratory volume in 1 s (FEV1) 18-22. Only one study 
assessed the diffusion capacity and found a reduction in 84% of adults with moderate to 
severe BPD, but this was not associated with the presence of emphysema 22.
Multiple perinatal factors are known to play a role in BPD development and might 
influence type and extent of structural lung damage. However, imaging studies usu-
ally only describe gestational age, birth weight, days of oxygen and days of ventilation. 
Some studies investigated the correlation between these neonatal factors and CT 
scores 11, 12, 17, 19, 21, 22. Most studies found a significant correlation between the duration 
of oxygen treatment and CT scores at a later age, and higher CT scores in those infants 
who were discharged home on oxygen 12, 17, 19. Wong et al. found an association between 
birth weight and severity of emphysema in adulthood 22. Some studies also investigated 
the correlation between CT scores and long term respiratory outcome. Both Shin and 
Boechat et al. showed higher CT scores in infants with later respiratory morbidity, in-
cluding persistent wheezing, hospitalization, or pneumonia in the 1st year of life 7, 10. 
In contrast, Mahut et al. found no difference in CT scores at a mean age of 16 months 
between infants with and without frequent respiratory symptoms 17.
In only two studies, a second CT scan was made during follow up of BPD patients. Le 
Tour et al. describes four patients in which a second CT scan was made between 10.6 
and 43.2 months after the first scan, in which the different lesions remained fairly stable 
over time 11. Also the study of Broström et al. shows persistent abnormalities at 6-8 years 
of age, mainly in the children who were diagnosed with moderate or severe BPD 20. In 
addition, Aukland et al. who investigated two cohorts with BPD patients born respec-
tively between 1982-1984 ('old' BPD) and between 1991 and 1992 ('new' BPD), found no 
significant differences in CT scores between both cohorts at a later age of, respectively, 
18 and 10 years 19. Indeed, despite the difference in pathology, most chest CT findings 
found in patients with 'old' BPD are similar to those observed in patients with 'new' BPD. 
Mahut et al. described a relative absence of bronchial involvement in their BPD popula-
tion at a mean age of 16 months 17. However, others did find bronchial wall thickening in 
patients with 'new' BPD 11, 20. Besides the study of La Tour et al. who included moderate 
to severe BPD patients, the presence of emphysema and bronchial wall thickening has 
only been found in children above the age of 8 years 14, 16, 20, 22.
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Discussion
In this review, we included 19 studies which evaluated chest CT imaging in infants, 
children and adults with BPD. Nine different semi-quantitative scoring methods were 
used in these 19 studies. Overall, chest CT scans revealed abnormalities in > 85% of the 
patients. We found many similarities in the components being scored, with almost all 
studies reporting patterns of hypo attenuation on inspiratory and/or expiratory scans, 
linear or subpleural opacities, bronchial wall thickening and collapse, consolidation or 
atelectasis. Furthermore, both lower lung function and increased respiratory symptoms 
have been found associated with chest CT abnormalities.
The most sensitive structural abnormality associated with BPD severity is low attenu-
ation on inspiratory or tidal breathing CT scans. The terminology used in the various 
studies to describe this hypo attenuation varies from decreased pulmonary attenuation, 
mosaic perfusion, emphysema, and abnormal or decreased density. This component 
seems to make up a large proportion of the lungs in BPD patients. These regions of low 
attenuation at inspiratory scans represent either hypo perfusion and/or hypoventilation, 
both contributing to impaired gas exchange and therefore highly relevant. When these 
regions of low attenuation persist in expiration they are often described as trapped 
air. Accurate quantification of the volume fraction of the lung of these low attenuation 
regions on the in- and expiratory scan, as was done for cystic fibrosis (CF), may be a 
promising predictor for future impaired lung function and symptoms 24, 25. Long-term 
follow up of these changes is required to understand whether there is reversibility of 
this low attenuation and whether these changes negatively affect the long-term lung 
structure and respiratory morbidity. Currently, in- and expiratory scans are not possible 
before the age of 4-5 years, unless anesthesia is used, which may limit the usefulness of 
this parameter in young children. However, third generation scanners have also over-
come the limitation of anesthesia in infants, by providing high quality images in free 
breathing conditions 26, 27.
The second most frequent structural abnormality scored in 15 of the 19 studies is opaci-
ties, with strands of atelectasis extending to the pleura (linear opacities) and creating 
pleural grooves (triangular or subpleural opacities). These abnormalities probably reflect 
alveolar septal fibrosis. In the few longitudinal studies these opacities did not change 
over time and may be considered a marker of acute and irreversible damage in patients 
with BPD 11, 20. Both the presence of hypo attenuation and opacities are consistent with 
the hypothesis that the predominant abnormality in BPD is in the peripheral lung.
The third most often scored structural component is bronchial wall thickening. Again 
various terms have been used, like peribronchial thickening and thickening of the bron-
chovascular bundle. These regions of bronchial wall thickening most likely reflect peri-
bronchial and peribronchiolar fibrosis or inflammation, both are likely to have a negative 
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impact on the work of breathing. It is unclear if bronchial wall thickening, observed in CT 
scans from term age to adulthood, represents ongoing disease or whether it is the end 
stage of acute damage in the neonatal period. To resolve this question bronchoscopy 
studies examining inflammatory markers in lavage fluid, which may be correlated with 
CT abnormalities, are needed as was done for CF 28. To monitor the reversibility of long-
term changes a sensitive objective method to determine airway dimensions is needed. 
Recently, such a system has been developed in our group 29.
Other structural changes such as bronchiectasis and mucus plugging, often reported on 
CT images of patients with CF were reported less frequent in patients with BPD. There-
fore, it is unlikely that these structural abnormalities play a role in the pathophysiology 
of long-term symptoms in BPD patients. Taken together, all studies indicate persistent 
abnormalities in the lungs of patients born preterm irrespective of when in the evolu-
tionary path of preterm neonatal care these patients were born ('old' versus 'new' BPD) 
and regardless of age at the time of chest CT imaging.
A striking finding of our review was that in only few studies a detailed description of the 
CT protocol was given. CT protocol has a major impact on the image quality, especially 
factors such as control of lung volume during acquisition, slice thickness and reconstruc-
tion kernel. These parameters influence the sensitivity of scoring methods and of future 
semi-automated image analysis systems 27. There is clearly a need for standardization of 
chest CT and image analysis protocols in BPD patients. Of key importance is to use a chest 
CT protocol using the lowest possible radiation dose to generate images that will be of 
diagnostic quality. To give detailed recommendations for such a protocol is beyond the 
scope of this review. Amongst other such a protocol should take into account patient’s age 
and cooperation, technical qualities of the CT scanner, and image analysis techniques to 
be used. In Supplemental Table S1, we give some general recommendations that could be 
used as starting point for a consensus meeting or task force addressing this issue.
Furthermore, the clinical information reported in these imaging studies of preterm born 
patients with BPD is inconsistent. And because most studies were retrospective, data col-
lection may have been incomplete. Collection of perinatal data will allow us to improve 
our understanding of the pathophysiology of today’s BPD and may lead to new preven-
tive measures or adaption of treatment protocols. Therefore, standardized prospective 
collection of key data at relevant time points should be aimed for, including maternal 
(e.g., age mother, preeclampsia, premature rupture of membranes, chorio-amnionitis, 
mode of delivery), fetal (e.g., growth) and neonatal data (e.g., gestational age at birth, 
birth weight, postnatal infection, persistent ductus arteriosus, duration of respiratory 
support modes, treatment with oxygen supplementation, treatment with surfactant, 
and antenatal steroids). Besides standardization of protocols and complete collection 
of perinatal data, it is also important to compare CT to other monitoring modalities like 
quality of life, lung function and survival, if CT is to be used as primary endpoint or pre-
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dictor in clinical trials. Of the studies included in this review, eight studies investigated 
the relation between chest CT findings and lung function. These studies showed that an 
increase in CT abnormalities is associated with lower flow rates suggesting that radio-
graphic findings indeed reflect some fundamental aspects of the pulmonary sequelae 
from preterm birth 9, 15, 17-22. Until now no intervention studies included chest CT as an 
outcome measure in BPD patients.
In 8 of the 19 studies, chest CT was performed in the first 2 years of life and in three 
studies even at term age (Table 1) 7-12, 15, 21. In these three studies chest CT abnormalities 
reflect the short-term effects of BPD, which are amongst others caused by abnormal lung 
development and acute damage due to high oxygen and exposure to high pressure or 
volume ventilation 10, 12, 15. The structural abnormalities described on CT scans of older 
children and adults with 'old' BPD seem to be associated with the amount of oxygen 
exposure during neonatal life. This association between CT abnormalities and oxygen 
duration is not per se causal, the oxygen duration may be just an indicator of severe lung 
disease. Although 'new' BPD seems to have a different histopathological background, 
CT findings in infants with 'new' BPD show similar abnormalities and are still found to 
be associated with both mechanical ventilation and oxygen exposure. Only two stud-
ies performed longitudinal chest CT imaging in few patients born between 1992 and 
2007 and revealed that structural changes remain fairly stable over time 11, 20. How lung 
structure changes related to 'new' BPD in former extremely preterm born infants will 
affect the normal lung function decline related to aging in adult life remains unknown. 
Therefore, there is a need for longitudinal follow up studies to investigate how these 
early structural abnormalities on CT scans will evolve. For example, how they relate to 
neonatal treatment, what they can learn us on pathophysiology, whether regions of low 
density are a risk factor for progressive emphysema in the long term, and if these early 
structural abnormalities may be a predictor of respiratory morbidity, such as chronic 
obstructive pulmonary disease (COPD), in later life.
A disadvantage of chest CT is its ionizing radiation exposure, and therefore it is less 
appropriate for frequent longitudinal assessment. However, for the follow up of BPD it 
is likely that only few CT scans are needed throughout life. Therefore the risks related to 
this extra radiation burden will be low 30. Chest Magnetic Resonance Imaging (MRI) is a 
potential radiation free alternative for chest CT. Currently, MRI proves technically chal-
lenging because of several factors, particularly low 1H density of the lung parenchyma, 
air-tissue interfaces that lead to rapid signal decay, and motion artefacts. Recently, 
Walkup et al. demonstrated a diagnostic-quality, quantitative pulmonary MRI in neo-
nates and found increased signal, probably due to combinations of fibrosis, edema and 
atelectasis, in all preterm born infants, although more pronounced in infants diagnosed 
with BPD 26. Decreased signal, presumably reflecting alveolar simplification, was only 
present in chest MRI of the most severe BPD cases. Standardized follow up that includes 
156 Chapter 7
chest imaging allows continuous evaluation of the effect of therapy changes in the neo-
natal period on the structural lung changes later in life. Therefore, efforts should also be 
directed towards further optimization of imaging quality of chest MRI.
The most striking observation of this review is the variable terminology used to describe 
the structural components scored. Hence, there is no gold standard to describe the 
structural abnormalities demonstrated in patients with BPD. Therefore it is not pos-
sible to reliably compare results between studies, between patients of different ages 
and between 'old' BPD and 'new' BPD populations. In addition, all scoring methods are 
semi-quantitative which currently makes it impossible to make direct comparisons of 
the extent of the BPD defects between studies. Therefore, based on the results of this 
systematic review, we suggest a new CT scoring method for BPD, the Perth-Rotterdam 
Annotated Grid Morphometric Analysis, PRAGMA-BPD scoring method, which is based 
upon the methodology of the recently developed PRAGMA-CF and which is both quali-
tative and quantitative (Table 3) 25, 31. PRAGMA-BPD is in design and training strategy 
similar as the PRAGMA-CF score; however, the pulmonary features which are scored are 
specific for BPD. Based upon our literature search we have included in the PRAGMA-BPD 
score the three most distinguishing features for BPD, namely decreased pulmonary at-
tenuation (including mosaic perfusion, emphysema and bullae), opacities (linear and/or 
subpleural triangular), consolidations (collapse and/or atelectasis), and bronchial wall 
thickening. Each feature represents non-functional lung tissue and is likely to influence 
the respiratory prognosis to some extent. Besides PRAGMA-BPD being a qualitative score 
it is also quantitative. The volume fraction of each of the four components is expressed 
as a percentage of total lung volume which is highly relevant for statistical analysis in 
clinical studies, but probably also for the clinical outcome of BPD patients (Figure 2). 
In addition, the amount of architectural distortion of the lung, meaning an abnormal 
displacement of bronchi, vessels, fissures and/or septa caused by diffuse or localized 
lung disease, is scored. We distinguish in four categories (normal, mild, moderate and 
severe) based on the amounts of affected segments (Table 3). Clearly, our PRAGMA-BPD 
scoring method requires validation before it can be used for future clinical trials, for 
example, assessing intra-observer and inter-observer reliability, cross validation to other 
outcomes, like quality of life and lung function, and standardization within and across 
different centers. The ultimate goal of such a quantitative scoring system is to improve 
clinical and pathophysiological phenotyping of individual BPD patients, enabling de-
velopment of new preventive measures to optimize lung development in early life and 
minimize respiratory morbidity at later age.
In summary, chest CT scans of BPD patients revealed unique structural abnormalities 
and the extent of these abnormalities correlates with BPD severity and lung function. 
Additionally, there clearly is a need for a standardized CT protocol and quantitative scor-
ing method before chest CT can be used as a clinical outcome measure and predictor 
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for long-term structural abnormalities and respiratory morbidity in BPD patients. We 
propose our newly developed PRAGMA-BPD method as such a scoring method.
table 3. PRAGMA-BPD score
Structural component PRAGMA-BDP score Scoring method
Normal lung Normal lung (GREEN) Percentage of total lung volume
Decreased pulmonary attenuation
- hypo attenuation (inspiratory/ 
expiratory)
- mosaic perfusion
- emphysema
- bullae
Hypo attenuation (BLUE) Percentage of total lung volume
Opacities
- linear
- subpleural triangular
Hyper attenuation (RED) Percentage of total lung volume
Consolidations
- collapse
- atelectasis
Hyper attenuation (RED) Percentage of total lung volume
Bronchial wall thickening Bronchial wall thickening (PURPLE) Percentage of total lung volume
Architectural distortion Scored according the number of segments 
presenting architectural distortion
-  Normal: no architectural distortion
- Mild: less than 6 segments
-  Moderate: between 6 and 13 segments
- Severe: more than 13 segments
Percentage of total lung 
segments
 
 
Figure 2. Apical (A) and basal (c) slices from inspiratory computed tomography scan in 1 years old female 
preterm born patient with severe BPD. (B-D) Slices annotated with PRAGMA-BPD: 1) red = opacities (linear 
an subpleural triangular) and consolidation; 2) purple = bronchial wall thickening; 3) blue = decreased pul-
monary attenuation (bullae, emphysema, mosaic perfusion, trapped air); 4) green = no abnormality seen. In 
this patient, the assessment of the four components was as follow: 1) 5.81 ml (1.5%); 5.23 ml (1.3%), 3) 13.08 
ml (3.4%) and 4) 364.97 ml (93.8%). Architectural distortion was deemed mild.
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suPPlEMEntAl tABlE
table 1. Concept proposal CT protocol for BPD patients
Data acquisition mode Volumetric, helical scan technique
Patient positioning Supine, with arms above the head
Volume control < 3 years Free breathing
Volume control 3-6 years Technician guided to obtain a breath hold at maximum 
voluntary inspiration and expiration
Volume control ≥ 6 years Spirometer controlled procedure to obtain an 
inspiratory chest CT at a volume level ≥ 95 inspiratory 
vital capacity and an expiratory chest CT at ≥ 95 vital 
capacity
CTDIvol (in 32 cm body phantom) for inspiratory scan
1 year old
5 years old
young adult
Optimal dose for BPD needs to be determined for 
each CT scanner to generate an image with sufficient 
parenchymal detail. Dose needed should probably be 
slightly higher than what has been recommended for 
cystic fibrosis. Doses below are the average doses used 
for clinical scan in 42 BPD patients in the ErasmusMC-
Sophia (data on file).
≥ 0.6 mGy
≥ 1.0 mGy
≥ 2.2 mGy
Field of view As close as possible to the entirety of the lungs, without 
cutting of the lung borders
CTDIvol for expiratory scan 50% lower than inspiratory scan
Tube voltage Low enough such that the recommended CTDIvol can be 
reached, e.g. 80 kV
Tube current Adapt to recommended CTDIvol
Pitch <1; lower limit determined by maximum scan time 
allowed
Slice thickness Thinnest slice thickness e.g. 1 mm
Reconstruction increment 50% overlap e.g. 0.5 mm with 1 mm slice thickness
Kernel for automated analysis Sharp reconstruction filter without under- or overshoot 
at edges preferably a dedicated kernel for quantitative 
image analysis
Iterative reconstruction technique If available, iterative reconstruction techniques can 
be applied in addition to the requested filtered back 
projection techniques
Shielding Breast shielding by bismuth for example is discouraged
This proposal is based upon guidelines for CT protocols for cystic fibrosis patients. These recommendations 
are based on the SCIFI CF project (W. Kuo, M. Kemner-van de Corput, A. Perez-Rovira, M. de Bruijne, I. Fajac, 
H. Tiddens, M. van straten. Multicenter chest CT standardization in children and adolescent with CF: The 
way forward. Submitted to ERJ 2016). The CTDIvol (CT dose index volume) represents the radiation dose for 
a 32 cm body phantom.
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ABstRAct
Background
Bronchopulmonary dysplasia (BPD) is the most frequent serious complication in pre-
term infants. We aimed to describe lung structure and ventilatory function of preterm 
infants with severe BPD and explored the association between early postnatal growth 
and these outcomes.
Methods
We included preterm infants born ≤ 32 weeks gestational age (GA) with severe BPD. 
Lung structure was assessed on chest CT with the PRAGMA-BPD scoring system and 
ventilatory function by polysomnography (PSG) at 6 months corrected age. Postnatal 
growth was assessed by weight measured at birth, and at 2 and 6 months corrected age.
Results
We included 49 infants (median (IQR) GA of 25.7 (24.6-26.3) weeks and mean (SD) birth 
weight of 760 (210) gram). 95.5% of the chest CT scans showed architectural distortion 
of the lung, and an oxygen desaturation index (ODI) > 5 was found in 74% of the infants. 
An increase in GA of 1 week was associated with higher total and normal lung volume 
(β coefficient (95% CI): 1.86 (0.15, 3.57) and 2.03 (0.41, 3.65) respectively), less hypoat-
tenuation (-4.30 (-7.70, 0.90)%) and lower ODI (-36.70 (-64.20, -9.10)%). Higher weight 
at 6 months was independently associated with higher total and normal lung volume, 
and with less severe desaturations. Increased weight gain between 2 and 6 months of 
corrected age was associated with less severe desaturations during sleep (β coefficient 
(95% CI): 2.09 (0.49, 3.70)).
conclusion
Most preterm infants with severe BPD have structural lung abnormalities and impaired 
ventilatory function early in life, partly explained by birth characteristics and infant 
growth.
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intRoDuction
Over the last decades improved perinatal care has resulted in an increased survival of 
infants born extremely preterm. However, the incidence of severe bronchopulmonary 
dysplasia (BPD) did not decrease as more immature babies survive the neonatal period. 
In Europe, the incidence of BPD ranges from 4% in infants born at a gestational age (GA) 
of 31 weeks to 56% in infants born before 26 weeks GA 1. Children with BPD are at in-
creased risk of long-term respiratory morbidity. Early assessment of both lung structure 
and ventilatory function may help to detect those children who are more likely to have 
severe respiratory problems and are at risk for serious respiratory morbidity in later life.
Chest computed tomography (CT) studies revealed structural lung abnormalities in up 
to 85% of patients with BPD with worse CT abnormalities in patients with more severe 
BPD, both in the neonatal period and later in life 2. Long-term outcome of children with 
BPD showed lower forced expiratory volume in 1 s (FEV1) than age-matched children 
without BPD 3. Data on lung function in preschool children with BPD are scarce given the 
low feasibility of most lung function tests in this age group. Moreover, most studies on 
long-term consequences of BPD included children born before 1990 and do not reflect 
current BPD population.
Polysomnography (PSG) has been used as a proxy marker for ventilatory reserve and can 
be performed early in life 4. However, data on PSG findings in preterm infants with BPD 
are scarce 4-6. Importantly, to date the relation between structural lung abnormalities 
and ventilatory function in the first year of life has not been established. In addition, pre-
term born infants with BPD are at risk of reduced postnatal growth, which might further 
contribute to impaired lung development, thereby influencing both lung structure and 
ventilatory function in later life 7-9.
Therefore, the aims of the present study were: 1) to assess lung structure on chest CT 
scans and ventilatory function by means of PSG in children with severe BPD at 6 months 
corrected age, 2) to examine how lung structure and function are related, and 3) to study 
the impact of GA at birth, birth weight and postnatal growth in the first months of life 
on these outcomes.
MEthoDs
study design
Preterm infants (≤ 32 weeks GA) with severe BPD who were born at Erasmus MC-Sophia 
Children’s Hospital or referred to us by other hospitals were included in our standardized 
multidisciplinary follow-up program from September 2013 onwards. Severe BPD was 
defined as oxygen supplementation for ≥ 28 days and need for either more than 30% 
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oxygen, more than 1L/min flow, continuous positive airway pressure (CPAP) or ventilator 
support at 36 weeks postmenstrual age (PMA) 10. Children with congenital diseases that 
might affect lung structure or function were excluded. Our routine follow-up program 
includes consultation by a multidisciplinary team of a neonatologist, pediatric pul-
monologist and pediatric cardiologist, physical examination and assessment of lung 
structure by chest CT scan, and ventilatory function by overnight PSG. In the current 
cross sectional study, we included all consecutive patients with a clinical follow up visit 
at 6 months corrected age. Written informed consent to use these data for research 
purposes was obtained from both parents of all infants. The study was approved by the 
medical ethical committee of Erasmus MC, Rotterdam, the Netherlands (MEC-2016-016).
chest ct imaging
Volumetric chest CT scans were acquired during free breathing in infants without seda-
tion at 6 months of corrected age using a standardized protocol (online supplement). All 
CT scans were de-identified and analyzed in random order by an experienced thoracic 
radiologist (PC) using the quantitative Perth-Rotterdam Annotated Grid Morphometric 
Analysis (PRAGMA)-BPD scoring method 2. This scoring system identifies lung tissue with 
a normal appearance, hypoattenuation, hyperattenuation and bronchial wall thickening 
and expresses their volume in ml and as percentage of total lung volume. In addition, 
the severity of architectural distortion of the lung, meaning an abnormal displacement 
of bronchi, vessels, fissures and/or septa caused by diffuse or localized lung disease, 
was scored. We distinguished four categories of architectural distortion (normal, mild, 
moderate, and severe) based on the number of affected segments (for details, see online 
supplemental data).
Polysomnography measurements
Overnight PSG was performed at 6 months corrected age for at least 9 hours in a dark, 
quiet room. The following physiologic signals were recorded using BrainRT Shell+ (OSG 
BVBA, Rumst, Belgium): limited electroencephalogram (EEG), heart rate by electrocar-
diogram (ECG), chest and abdominal breathing movements by induction plethysmogra-
phy, oronasal airflow by thermistor and oxygen saturation (SaO2) by pulse oximetry. The 
recordings were analyzed by a trained researcher (EK). All PSG outcomes were scored 
according to the American Academy of Sleep Medicine (AASM) criteria 11. We considered 
breathing rate, oxygen saturation and deepest desaturation, apnea hypopnea index 
(AHI), central apnea index (CAI) and oxygen desaturation index (ODI) as the most im-
portant representative measures for ventilatory function. Normal values were obtained 
from literature 12-15 and cutoff values defined as mean oxygen saturation (SaO2) > 95%, 
deepest oxygen desaturation (SaO2 nadir) > 92%, AHI ≤ 1, ODI < 5, and CAI ≤ 1.
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Postnatal growth
We assessed weight at birth, and at 2 and 6 months corrected age according to local 
standardized protocols. GA-adjusted birth weight SD scores (SDS) were constructed 
using reference growth standards 16. Infant growth characteristics were converted into 
SDS using reference growth charts 17. Infant weight gain was defined as the difference 
between weight at 6 months corrected age and weight at birth divided by the exact 
number of months between these two measurements. Similarly, weight gain between 
various other age intervals were calculated.
covariates
The following parameters were obtained from medical records: maternal age, pre-
eclampsia, chorio-amnionitis, antenatal corticosteroids, mode of delivery, and child’s 
sex, surfactant treatment, respiratory distress syndrome stage, early or late onset sepsis, 
persistent ductus arteriosus (PDA), days on mechanical ventilation (conventional or high 
frequency), days on supplemental oxygen, respiratory support at 36 weeks PMA, treat-
ment at 6 months corrected age (e.g. (inhaled) corticosteroids, diuretics, supplemental 
oxygen, enteral tube feeding).
statistical analysis
For descriptive analyses of patient characteristics, lung structure and respiratory func-
tion, continuous variables were expressed as mean ± standard deviation (SD) for normally 
distributed data or median (interquartile range, IQR) for not normally distributed data, 
and categorical variables were expressed as n (%). We used multivariate linear regression 
models to examine the associations of lung structure with ventilatory function, and of 
birth and infant growth characteristics with parameters of lung structure and ventilatory 
function. Not normally distributed variables were transformed by log transformation for 
positively skewed data or arcsine transformation for negatively skewed data. Regres-
sion models were used to examine the association of weight gain as a change in SDS 
between various age intervals with lung structure and ventilatory function measures. 
To account for the correlation between birth and infant growth characteristics, we used 
conditional regression analyses to examine associations of weight and weight gain 
with lung structure and function. We constructed variables for sequential weight and 
weight gain, which are statistically independent from each other, allowing simultaneous 
inclusion in multiple regression models 18. Thus, the associations of weight at a specific 
moment can be assessed in comparison with, and adjusted for, weight at other measur-
ing moments. Selection of covariates was based on literature, if a covariate changed the 
effect estimate of the unadjusted analyses by ≥ 10% or if covariates were strongly re-
lated to the outcomes of interest. Based on this, sex, preeclampsia and age at time of CT 
scan and PSG were included as confounders in the models. All measures of association 
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are presented as beta coefficients or sympercent for log transformed outcomes with 
corresponding 95% confidence intervals. Analyses were performed using SPSS version 
21.0 for Windows (IBM, Chicago, IL, USA).
REsults
subject characteristics
49 infants were included with a median (IQR) GA of 25.7 (24.6-26.3) weeks with a mean 
(SD) birth weight of 760 (210) grams (Table 1). Chest CT was performed successfully in 45 
infants at a corrected age of 6.2 (5.9-6.9) months. Architectural distortion was identified 
table 1. Patient characteristics
Severe BPD (n=49)
gestational age (weeks) 25.7 (24.6-26.3)
Birth weight (gram) 760 ± 210
sex (female) 20 (40.8%)
Age mother (years) 31.5 (27.5-35.0)
Antenatal corticosteroids None: 2 (4.3%)
Yes, not complete: 12 (25.5%)
Yes, complete: 33 (70.2%)
Maternal preeclampsia 11 (23.4%)
chorioamnionitis 20 (43.5%)
Mode of delivery Vaginal: 16 (32.7%)
Cesarean section: 33 (67.3%)
Postnatal surfactant None: 6 (12.2%)
1 gift: 12 (24.5%)
≥ 2 gifts: 31 (63.3%)
Early onset sepsis 4 (8.2%)
late onset sepsis 30 (61.2%)
PDA 44 (89.8%)
total days invasive ventilation 30 ± 16
total days oxygen exposure 60 ± 15
oxygen supplementation at
6 months corrected age
12 (24.5%)
use of diuretics at 6 months corrected age 15 (30.6%)
use of ics at 6 months corrected age 7 (14.3%)
use of enteral tube feeding at 6 months corrected age 16 (32.7%)
Definition of abbreviations: BPD: bronchopulmonary dysplasia; PDA: persistent ductus arteriosus. Data 
were missing for antenatal corticosteroids (n=2), maternal preeclampsia (n = 2), chorio-amnionitis (n=3), 
total days invasive ventilation (n=2), total days oxygen exposure (n=8). Continuous variables are expressed 
as mean ± standard deviation (SD) for normally distributed data or median (interquartile range, IQR) for 
data that were not normally distributed. Categorical data are expressed as n (%).
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in 95.5% of all CT scans (Table 2). Median (IQR) total lung volume was 264 (219-327) ml, 
of which 1.6 (0.5-3.8) % showed hypoattenuation, 4.2 (2.0-9.1)% hyperattenuation and 
2.1 (0.8-2.9) % bronchial wall thickening, while 89.7 (85.6-93.2)% had a normal appear-
ance using the PRAGMA-BPD scoring method.
PSG was performed successfully in 47 infants at a corrected age of 6.2 (5.8-6.6) months 
(Table 3). The median total sleep time (TST) for overnight PSG was 534 (489-579) min 
with a mean (SD) sleep efficiency of 80.4 (14.7)% (n=45). The median (IQR) breathing 
rate was 30 (24-36) per min, the mean (SD) oxygen saturation (SaO2) was 96 (2) %, with 
a mean (SD) deepest oxygen desaturation (SaO2 nadir) of 85 (4)%. The median (IQR) AHI 
was 8.08 (4.59-11.60) (n=42) and the median (IQR) ODI was 10.30 (4.78-18.95) (n=45), 
with 74% of the infants having an abnormal ODI above 5.
Relation lung structure and ventilatory function
Associations of chest CT scores and PSG parameters are presented in Table 4. We found 
per 10 ml increase of hypoattenuation a 3.3 (0.4, 6.3)% lower mean SaO2, and an in-
crease with one affected segment was associated with a 10.2 (0.9-19.5)% increase in 
ODI. However, when we adjusted for GA at birth, birth weight SDS and sex the associa-
tions became non-significant (data not shown). No other associations of lung structure 
measures with ventilatory function was observed.
table 2. PRAGMA-BPD chest CT scores
Severe BPD (n=45)
total lung volume (ml) 264 (219-327)
normal lung volume (ml/ % total volume) 231 (197-307)/ 89.7 (85.6-93.2)
hypoattenuation (ml/ % total volume) 4 (1-10)/ 1.6 (0.5-3.8)
hyperattenuation (ml/ % total volume) 11 (5-27)/ 4.2 (2.0-9.1)
Bronchial wall thickening (ml/ % total volume) 5 (2-9)/ 2.1 (0.8-2.9)
number of affected segments 6 ± 3
Percentage of affected segments of total number of segments 29.8 ± 16.8
Architectural distortion
- Absent 2 (4.5%) 
- Mild 24 (53.3%) 
- Moderate 18 (40.0%) 
- severe 1 (2.2%) 
Definition of abbreviations: CT: computed tomography; ml: millilitre. Continuous variables are expressed as 
mean ± standard deviation (SD) for normally distributed data or median (interquartile range, IQR) for data 
that were not normally distributed. Categorical data are expressed as n (%).
170 Chapter 8
Relation birth characteristics and infant growth with lung structure and 
ventilatory function
An increase in GA of 1 week and 100 grams of weight at birth was associated with 
higher total lung volume (β coefficient (95% CI): 1.86 (0.15, 3.57) and 0.99 (0.06, 1.92)), 
higher normal lung volume (β coefficient (95% CI): 2.03 (0.41, 3.65) and 1.05 (0.17, 1.94)), 
less hypoattenuation (-4.30 (-7.70, -0.90) and -2.50 (-4.40, -0.70) and lower ODI (-36.70 
(-64.20, -9.10) and -19.10 (-35.00, -3.10) (Table 6a and b). The effect estimates of birth 
weight with lung structure and ventilatory function became non-significant when GA 
was taken into account.
Conditional analyses showed that higher weight at 6 months corrected age only, was 
associated with higher total and normal lung volume (β coefficient (95% CI): 2.36 
table 3. Polysomnography outcomes
Severe BPD (n=47)
corrected age at Psg (months) 6.2 (5.8-6.6)
tst (min) 534 (489-579)
tiB (min) 642 (579-703)
sPt (min) 614 (559-650)
Mean breathing rate (/min) 30 (24-36)
Mean heart rate (/min) 113 (106-121)
Bradycardia events 1 (0-14)
tachycardia events 1 (0-14)
Mean sao2 (%) 96 ± 2
sao2-nadir (%) 85 ± 4
oAhi 1.51 (0.77-3.13)
Ahi 8.08 (4.59-11.60)
oDi 10.30 (4.78-18.95)
oAi 0.00 (0.00-0.11)
cAi 2.82 (1.15-4.56)
MAi 0.00 (0.00-0.00)
Definition of abbreviations: TST: total sleep time; TIB: time in bed; SPT: sleep period time; mean SaO2: mean 
oxygen saturation; SaO2-nadir: deepest oxygen desaturation. Obstructive apnea hypopnea index (oAHI) 
was defined as the sum of obstructive apneas (OAs); mixed apneas (MAs) and obstructive hypopneas (OHs) 
per hour of sleep. Apnea hypopnea index (AHI) was defined as the number of apneas and hypopneas per 
hour of sleep. Oxygen desaturation index (ODI) was defined as the sum of all desaturations ≥3% per hour of 
sleep. Obstructive apnea index (OAI) was calculated as the number of OAs per hour of sleep. Central apnea 
index (CAI) as the number of central apneas (CAs) per hour of sleep. Mixed apnea index (MAI) as the number 
of MAs per hour of sleep. oAHI≥1, AHI>1, ODI>5, OAI≥1, CAI≥1 and MAI≥1 were defined as abnormal. Data 
were missing for TIB (n=1), Mean breathing rate (n=2), Bradycardia events (n=1), Tachycardia events (n=1), 
oAHI (n=5), AHI (n=5), ODI (n=2), OAI (n=5), CAI (n=5), MAI (n=5), and AI (n=5). Continuous variables are 
expressed as mean ± standard deviation (SD) for normally distributed data or median (interquartile range, 
IQR) for data that were not normally distributed.
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(0.14,  4.59) and 2.53 (0.28, 4.78), respectively, per SDS increase in weight) (Table 5a). 
Higher weight at 6 months corrected age was also independently associated with less 
severe oxygen desaturations (β coefficient (95% CI): 1.25 (0.08, 2.43), per SDS increase in 
weight) (Table 5b). Infant weight gain across all various time intervals did not affect lung 
structure at 6 months corrected age (Table 6a). Only infant weight gain between 2 and 
6 months corrected age was associated with less severe oxygen desaturations during 
overnight PSG (β coefficient (95% CI): 2.09 (0.49, 3.70)) (Table 6b).
Discussion
Our findings show that among preterm infants with severe BPD almost all had lung 
architectural distortion and the majority had abnormal PSG at 6 months corrected age. 
The volume fraction of hypoattenuation was associated with mean SaO2 measured dur-
ing overnight PSG and the number of affected segments with ventilatory function as 
reflected by ODI, but results were explained by birth characteristics. A lower GA at birth 
was associated with a lower total and normal lung volume, more hypoattenuation and 
higher ODI. An increased weight gain in the first 6 months was associated with higher 
total and normal lung volume and with less ventilatory deficits.
It is well known that chest CT scans reveal structural abnormalities in most patients with 
BPD, with the most common abnormalities being pulmonary hypoattenuation, linear 
and pleural opacities, bronchial wall thickening and consolidations 2. These findings 
derive from studies which have been performed in older children or adults and do not 
reflect current BPD population. Although in this study almost all infants with severe BPD 
showed architectural distortion, the lung volume which had a macroscopically normal 
appearance was high, namely 89.7 (85.6-93.2)%. The overall relatively high percentage of 
normal lung volume fits the reported high quality of life which is generally experienced 
by patients with BPD 19. However, some children had less than 45% normal lung volume, 
which is likely to have a negative impact on long-term prognosis. In our opinion, it is 
important to recognize abnormal lung structure early in life in order to identify those 
children with the most severe disease, who are at risk for future severe respiratory mor-
bidity and should be monitored more strictly. 
Preterm birth affects later lung function. A systematic review showed lower mean FEV1 
in preterm born infants, with the lowest FEV1 of 79.1 (76.9-81.3)% in infants with severe 
BPD defined as oxygen dependency at 36 weeks PMA 3. As a proxy for ventilatory and 
respiratory function we performed overnight PSG, because with PSG the whole ventila-
tory system can be assessed. Studies with PSG results of preterm infants are scarce 4-6, 12, 20. 
Infants with BPD may have normal oxygen saturation and respiratory rate during an 
outpatient clinic visit while awake, but still having desaturations during sleep along with 
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sleep-disordered breathing overnight 4, 6, 21. Previously, Sekar et al. reported that preterm 
infants with BPD have more episodes of hypoxemia, central apneas and periodic breath-
ing than preterm infants without BPD 20. In the present study, we also found abnormal 
AHI and abnormal ODI in the majority of infants with severe BPD. Furthermore, while 
the mean SaO2 during overnight PSG was within normal ranges, the deepest oxygen 
desaturation was below normal values with a mean of 85%. These results indicate that 
infants with severe BPD might be more vulnerable for desaturation during apneas, per-
haps because of decreased ventilatory reserve, and overnight PSG registration before 
cessation of supplemental oxygen may be recommended.
Only few studies assessed both lung structure and ventilatory function in infants with 
BPD below 1 year of age 22, 23. We found that hypoattenuation was associated with mean 
SaO2 during overnight PSG and the extent of structural abnormalities showed an as-
sociation with ventilatory function as reflected by ODI. In previous studies performed in 
the first year of life, chest CT scores correlated significantly with the clinical severity of 
BPD and with respiratory symptoms 22-26. Only 2 studies performed both chest CT and 
respiratory function before the age of 2 years. In these studies a lower lung compliance 
and lower functional residual capacity (FRC) was reported for those children with most 
abnormal CT scans 22, 27. The effect of these early abnormalities on respiratory health in 
later life is not clear. Most studies have examined lung structure and function at a later 
age and all but one study 28 reported significant correlations between CT abnormalities 
and lung function parameters. After infancy, specifically the volume of hypoattenuation 
and architectural distortion is correlated with obstructive lung function, mainly low 
FEV1  23, 29-32. Studies are difficult to compare because lung function was assessed with 
diverse techniques at various ages. 
Another important finding of our study was that both lower GA at birth and lower 
birthweight were associated with worse structural and functional respiratory outcomes 
at 6 months of corrected age, although only GA was independently associated. Previous 
research also showed that both lower GA at birth and lower birth weight were associ-
ated with lower lung function 33. Preterm infants are born when lung development is still 
in the canalicular or saccular stage, resulting in vascular and alveolar simplification. This 
suggests that poor lung development especially at the time of preterm birth is crucial 
for the development of BPD. Our data indeed showed that GA at birth influences both 
lung structure and ventilatory function at later age.
Last, in our study we showed that early postnatal weight gain positively influenced both 
lung structure and ventilatory function in preterm infants with severe BPD. The associa-
tion between infant growth and lung function in the first year of life has been assessed 
extensively in the context of early risk factors for asthma, and infant weight gain was 
consistently associated with higher FEV1 and forced vital capacity (FVC), but lower FEV1/
FVC and forced expiratory flow after 75% of vital capacity (FEF75) 34-36. The underlying 
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mechanisms for the associations between infant weight gain and lung structure and 
function are unclear. The lower FEV1/FVC ratio and FEF75 might be explained by smaller 
airways in preterm born infants. In addition, animal studies showed that growth restric-
tion might affect airway compliance and lead to impaired growth of bronchial walls, 
alterations in mucus producing tissues, a decrease in number of alveoli, thicker interal-
veolar septa and a greater volume density of lung tissue 37. Another possible explanation 
for the observed associations between infant weight gain and lung structure and func-
tion is low grade systemic inflammation, associated with obesity. Both the increased 
amount of pro-inflammatory cytokines producing macrophages present in adipose 
tissue and the adipokines and leptin secreted by adipose tissue itself could lead to sys-
temic low grade inflammation 38. Recently, it was shown that a coordinated expression 
of pro-inflammatory cytokines like interleukin (IL)-6 and tumor necrosis factor (TNF)-α 
plays a protective role and might positively influence lung maturation 39-42. In our study, 
we found an association between increased infant weight gain from 2 to 6 months cor-
rected age and less severe oxygen desaturations. Furthermore, also weight at 6 months 
corrected age was independently associated with more healthy lung volume and less 
severe oxygen desaturations during sleep. We did not find an association between early 
growth and other parameters from PSG like breathing rate, mean oxygen saturation, 
AHI, CAI and ODI, suggesting that alveolar growth might be better reflected by oxygen 
desaturations than by other aspects of ventilation during sleep. This can be explained by 
the fact that AHI, CAI and ODI may also be influenced by central apneas and superficial 
breathing patterns which may occur in preterm infants. We can only speculate whether 
postnatal growth would have been better when prolonged supplemental oxygen was 
given to these preterm born infants and the influence on both total and normal lung 
volume and ventilatory function.
Our prospective cohort provides the opportunity to follow preterm born infants with 
severe BPD in a multidisciplinary team, with detailed measurements of both lung 
structure and function and detailed information on prenatal and postnatal exposures. 
There are some limitations to the present study. We perform chest CT scans during free 
breathing, acquiring CT scans at a volume level around FRC plus or minus tidal volume. 
The alternative would be to acquire chest CT scans at total lung capacity (TLC) level and 
at FRC level using a pressure-controlled protocol, but then general anesthesia is needed. 
Hence a free breathing protocol creates some noise in relation to the lack of volume 
standardization during CT acquisition. 
PSG measurements reflect an important aspect of ventilatory and respiratory function. 
However, we lacked information on infant lung function as may be obtained by multiple 
breath washout (MBW) techniques. Recent studies suggest that the lung clearance 
index (LCI) as obtained with MBW is a sensitive marker of small airway disease 43. Of 
the 49 infants, we had reproducible MBW measurements in only 18 (36.7%), mainly due 
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to standardization problems, and practical problems with using the equipment and 
software. We plan to repeat MBW tests at 12 months and spirometry from 5 years of age 
onwards, which will make it possible to correlate early structural abnormalities with later 
lung function.
Lastly, the clinical definition of BPD remains under debate. Previous research showed 
that preterm born infants who did not fulfill the criteria for BPD also showed struc-
tural and functional respiratory abnormalities 44, 45. Therefore, it should be considered to 
screen all preterm infants born before 28 weeks GA in the first year of life for structural 
and functional respiratory impairment.
In conclusion, our results suggest that structural abnormalities of the lung and ventila-
tory impairment are present in most preterm born infants with severe BPD at a corrected 
age of 6 months. These outcomes are mainly affected by GA at birth and infant weight 
gain between 2 and 6 months corrected age. The long-term effect of these early im-
pairments for respiratory morbidity in later life is not clear, stressing the importance of 
long-term follow up of all preterm born infants.
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suPPlEMEntAl MEthoDs
PRAgMA-BPD scoring method
The PRAGMA-BPD scoring is system is a quantitative structural lung disease computed 
tomography scoring system for BPD derived by the PRAGMA-CF scoring system (Am J 
Respir Crit Care Med. 2015 May 15;191(10):1158-65). The PRAGMA-BPD score assesses 
lung structure according to five major categories and according to the following scoring 
priority order: hypoattenuation, hyperattenuation, bronchial wall thickening, normal 
lung structure and architectural distortion. Hypoattenuation refers to lung parenchyma 
with reduced CT attenuation (dark appearance) either in the inspiratory or expiratory 
scans. This category includes mosaic perfusion, emphysema, trapped air, bullae and 
cysts. Hyperattenuation refers to lung parenchyma with increased CT attenuation (white 
appearance) either in the inspiratory or expiratory scans. This category includes consoli-
dation, atelectasis, linear and subpleural triangular opacities. Bronchial wall thickening 
is defined when the ratio between bronchial wall thickness and outer diameter of the 
adjacent pulmonary artery is greater than 33% (J Pediatr 2004;144:154-161). The lung 
parenchyma not fulfilling the criteria of these three categories falls within the fourth 
category of normal lung structure. Finally architectural distortion, defined as abnormal 
displacement of bronchi, vessels, fissures and/or septa caused by diffuse or localized 
lung disease, is scored per lung segment. Each lung consists of 10 segments, where the 
medial basal segment is considered a separate segment on the left side. According to 
the number of lung segments involved, the architectural distortion is defined as mild 
(less than 7 lung segments), moderate (7-13 lung segments) and severe (more than 13 
lung segments).
ct BPD protocol
BPD protocol was performed using the 256-rows SOMATOM Definition Flash or 384-rows 
SOMATOM Force scanners (Siemens, Erlangen, Germany) with the following parameters: 
kV 90, 10-20 reference mAs, pitch 3, CAREDose4D. The following reconstructions were 
acquired: axial 1 and 3 mm lung window (kernels BI57 and Br64), axial 3 mm mediastinal 
window (Br40) and 2 mm sagittal and coronal multiplanar reformats. Computer tomog-
raphy index (CTDI) ranged between 0.2 to 0.5 mGy.
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Today’s children will grow up to be the adults of tomorrow, and the management of re-
spiratory diseases in children will influence adult lung health 1. In this thesis we focused 
on three groups of patients: children with asthma, cystic fibrosis (CF) and bronchopul-
monary dysplasia (BPD). These diseases have in common that inflammation, destruction 
and (defective) repair mechanisms play a central role in their pathogenesis. Impairment 
of lung development has lifelong consequences on lung function. Consequently if we 
are able to improve respiratory health in a very early phase of life, this will have lifelong 
benefits.
There are several approaches possible to accomplish this goal. First, prediction and early 
diagnosis offers the opportunity of early treatment and maybe prevention of progres-
sion towards more severe disease. This has been the case in CF where newborn screening 
led to better lung function, nutritional status and improved survival in screened patients 
in early adulthood 2. Second, more insight in the underlying pathophysiology of pedi-
atric respiratory diseases is needed to develop new treatments or preventive strategies. 
Third, disease phenotyping may lead to personalized treatment. Last, better monitoring 
of disease progression with timely interventions may lead to better outcomes.
In this thesis we focused on biomarker identification as biomarkers may be essential 
in prediction and early diagnosis of respiratory diseases, but can also contribute to 
insight in underlying pathophysiology, disease phenotyping and monitoring of disease 
progression and treatment effect. To identify biomarkers we used different approaches. 
In chapter 3 and 4 we investigated biomarkers in exhaled breath of children with 
asthma and CF with the use of a newly developed technique enabling both fast de-
tection and molecule identification. In chapter 5 and 6 we investigated biomarkers in 
tracheal aspirates (TAs) of preterm infants by means of liquid chromatography tandem 
mass spectrometry (LC-MS/MS), proteome assay and multiplex immunoassay (Luminex). 
We choose to detect biomarkers in exhaled breath and TAs, as both can be obtained 
routinely in a clinical setting and are minimally invasive which is particularly important 
in children. Finally, in chapter 7 and 8 chest CT scans and polysomnography have been 
studied as outcomes in infants with severe BPD, which may however also be ‘alternative 
biomarkers’ that may predict outcome of BPD. The main findings of each chapters are 
discussed below, as well as the challenges that we encountered while working in an 
interdisciplinary field of research. In addition, the relevance of our findings and their 
potential scientific and clinical implications are placed in a broader context. Finally, 
future research perspectives with respect to biomarker research in pediatric respiratory 
diseases will be discussed.
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DiFFEREnt APPRoAchEs to tEst BioMARkERs in PEDiAtRic REsPiRAtoRy 
DisEAsEs
Biomarkers are broadly defined as "any substance, structure, or process that can be 
measured in the body or its products and influence or predict the incidence of out-
come or disease". The ideal biomarker is easy to obtain with minimal discomfort or risk 
to the patient, is cheap, has high sensitivity and specificity, good reproducibility and 
repeatability, and can be used for one or preferably more clinical applications such as 
diagnosis, disease phenotyping, prognosis, or monitoring. Biomarkers in respiratory 
diseases can be measured systemically (e.g. in blood) or locally in the lung and airways 
(e.g. in endobronchial biopsies, bronchoalveolar lavage fluid (BALF), sputum, exhaled 
breath and exhaled breath condensate). To investigate a specific aspect of a disease, 
single biomarkers can be useful, like the fraction of exhaled nitric oxide (FeNO) which 
reflects eosinophilic airway inflammation in asthma 3. However, single markers do not 
reflect the complexity of most respiratory diseases in which genetic, environmental and 
epigenetic factors interact with each other and may lead to inflammation, infection, 
damage and repair. Therefore, the last decade a systems biology approach including 
genomics, proteomics and metabolomics, has become popular to enable the analysis 
of numerous potential biomarkers at the same time and allow for the discovery of new 
pathophysiological pathways without a priori hypothesis.
In this thesis we investigated biomarkers in exhaled breath and TAs by using techniques 
which enabled us to detect multiple biomarkers at the same time. For identification of 
multiple biomarkers at once two approaches may be followed. First, one might use an 
unselected approach to study biomarker profiles which offers the possibility to discover 
new pathophysiological processes of lung health and disease. The disadvantage of such 
a ‘fishing expedition’ is that it is time consuming, costly and may lead to side paths that 
are not relevant. The second approach is preselection of biomarkers based on current 
knowledge. This approach, which we used in our studies, enables to investigate bio-
markers in specific pathways, previously shown to contribute to the disease in question. 
In chapter 4 we investigated volatile exhaled compounds (VOCs) present in exhaled 
breath of children with asthma and CF. We studied a specific broad wavelength spectrum 
containing the absorption profiles of hydrocarbons, since previous studies have identi-
fied hydrocarbons as the most discriminating VOCs between patients with and without 
asthma or CF. In chapter 5 we used a proteome profiling and Luminex assay to measure 
multiple cytokines, chemokines and growth factors in TAs of preterm infants. Both as-
says contained a preselected set of biomarkers known to be important in angiogenesis, 
since angiogenesis is a driving force of alveolarisation and disruption of microvascular 
development in premature lungs has recently been postulated as a critical factor in the 
alveolar development in BPD. In chapter 6 we measured a specific set of sphingolipids in 
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TAs of preterm infants using liquid chromatography tandem mass spectrometry (LC-MS/
MS). Previous studies in mice indicated the importance of ceramides in inflammation 
and repair processes in the developing lung.
We speculate that the use of ‘omics’ techniques, measuring multiple biomarkers at once 
with or without a priori hypothesis, may improve stratification of patient groups to a 
level of individual decision making, contributing to personalized medicine.
ExhAlED BREAth AnAlysis in DiAgnosis AnD MonitoRing oF AsthMA 
AnD cystic FiBRosis
Exhaled breath analysis is a noninvasive method to assess potential biomarkers for 
diagnosis and management of respiratory diseases in childhood, and exhaled breath 
can be very easily obtained in children of all ages.
Broadband quantum cascade laser-based spectroscopy
chapter 3 describes how we developed a broadband quantum cascade laser-based 
spectroscopic system for exhaled breath analysis, in cooperation with the Optics research 
group at the Delft University of Technology, the Netherlands. This technique allows for 
detection of VOCs in exhaled breath samples, with an absorption spectrum in a specific, 
broad wavelength region. Advantages of this technique over the more commonly used 
gas chromatography-mass spectrometry (GC-MS) technique are especially the limited 
need for preprocessing and the relatively fast detection without the need for highly 
trained personnel. The main advantage over the use of sensor-based detection meth-
ods, like the electronic nose (eNose), is the possibility of VOC identification with the use 
of molecular databases. VOC identification may be helpful for further understanding of 
underlying pathophysiological processes of respiratory disease. Current disadvantages 
of this new method are the still bulky equipment and the relatively low sensitivity.
We performed a first pilot study, in which we analyzed exhaled breath samples of 
healthy children, children with stable asthma and children with stable CF (chapter 4). 
We found overall poor short- and long-term repeatability. This could be explained by the 
fact that we investigated a large spectroscopic range comprising 8612 individual wave-
number points, and because daily life factors (e.g. eating, drinking, exercise, variable 
composition of ambient air) influence exhaled breath content and were not standard-
ized. However, despite the variability of the spectra we were able to detect differences 
between exhaled breath profiles from healthy children and from children with chronic 
airway inflammation due to asthma or CF.
We propose that, before further clinical studies can be undertaken, the sensitivity and 
repeatability of this technique need to be improved. In general, laser-based methods for 
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trace gas detection, in our case in exhaled breath samples, are based on de Beer-Lambert 
law and the absorbance, which is determined by the wavenumber corresponding to the 
highest molar absorption coefficient, the interaction distance and the concentration. 
During the development of our set-up we mainly focused on increasing the interaction 
distance within the multipass cell in order to improve the sensitivity. To further increase 
the sensitivity it is also possible to apply preconcentration of samples, as was done with 
GC-MS. However, whether or not a higher sensitivity will lead to better performance re-
mains to be shown. Improving the repeatability with regards to exhaled breath analysis 
is far more challenging, since this is due to numerous factors, including the width of the 
wavelength spectrum, the amount of noise, and the variability of the composition of 
exhaled breath due to numerous environmental factors. Furthermore, there is a need 
for further validation of this technique by internal validation, mainly comparing this 
technique with other exhaled breath techniques such as GC-MS and the eNose, and 
by external validation, by demonstrating the reproducibility of this technique in other 
target populations. Finally, the equipment needs to be adapted to make it applicable in 
a clinical setting. Key element in this process of miniaturization is the multipass cell used 
to increase the interaction distance. The use of hollow waveguides (HWG) is an attractive 
alternative allowing to confine the laser light in thin channels where small volumes of 
the exhaled breath sample can be introduced 4. HWGs are available with internal diam-
eters of 1 mm and volumes lower than 100 microliters. They allow interactions distances 
of up to 4 meters 5. This relatively small interaction distance is not a limitation because in 
the HWGs the laser fills the complete volume of the cell, which increases the probability 
of interaction between the laser light and the molecules 4,6. As an example, Charlton et 
al.4 reported an effective increase in the sensitivity of their absorption system by a factor 
1.2 when compared to their results obtained with a 3 meter long multipass cell. Taken 
together, when preconcentration can be combined with broadband quantum cascade 
laser-based spectroscopy with the use of HWGs, in order to reduce the equipment in size 
for practical use in a clinical setting, this might proof to be an attractive technique for 
exhaled breath profiling with the possibility to characterize the individual VOCs.
clinical application of exhaled breath analysis
The analysis of VOC profiles in exhaled breath, ‘breathomics’, is a potential tool in respira-
tory medicine. Yet, despite decades of research, ‘breathomics’ is still not incorporated in 
clinical practice, and the biological origin of most VOCs is largely unknown.
In chapter 2 we summarized the methodological issues and clinical applications of 
exhaled breath and EBC analysis in children with respiratory diseases. Lack of standard-
ization of the collection- and measurement procedures and differences in the selection 
of subjects probably explains the high variability and low reproducibility of exhaled 
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biomarkers between studies. Currently, analysis of biomarkers in exhaled breath and 
exhaled breath condensate (EBC) is still a research tool and not validated for clinical use.
Several steps are required before exhaled breath analysis can be implemented into clini-
cal practice 7,8. First, there is a need for longitudinal studies investigating exhaled breath 
biomarkers in real life, to validate their diagnostic potential. Second, the lack of standard 
collection and analysis methods clearly hampers the validation that is necessary before 
clinical application. Standardization of both collection and analysis techniques will al-
low for pooling of data and will facilitate external validation. An attempt to standardize 
these factors between studies is currently underway by a European Respiratory Society 
Task Force and a collaborative open-source development project (www.breathe-free.
org). Last, identifying the biological sources of individual VOCs, (e.g. systemic, upper or 
lower respiratory tract, environmental, instrumental) and knowledge of the factors that 
influence their levels in exhaled air may further improve their diagnostic accuracy.
Future directions
In clinical practice, diagnosis and monitoring relies on complex integration of different 
parameters, including clinical history, physical examination, functional tests, imaging, 
blood tests and histopathology. Integrating clinical knowledge with data from basic 
research is a complex process, but is now being developed as ‘systems medicine’ 9. 
Current health care is moving from being reactive to preventive and the aim of system 
medicine is to intervene at an early stage to control symptoms and prevent or reduce 
future risks. Since many diseases have their origin in childhood, in other words during 
growth and development, the pediatric field can be a pioneer in the development of 
a systems medicine approach. This requires interdisciplinary collaboration between 
various disciplines who not always speak the same language, and integration of data 
from molecular and cell biology, physiology, clinical medicine, and epidemiology. In the 
near future, also personal health profiles acquired through e-health, wearable devices 
and health apps will potentially produce a wealth of personal data and contribute to 
individualized treatment and monitoring. Furthermore, a systems medicine approach 
stresses the need for computational and bioinformatics infrastructures to deal with 
proper management and interpretation of large scale multidimensional data sets and 
to incorporate the temporal dimension of both biological and clinical data. It will be a 
major challenge to select those patients who are likely to benefit from such a multidis-
ciplinary systems medicine approach, and to educate clinicians to work with them and 
keep a keen eye on possible flaws and drawbacks.
As an example, in September 2015, a population-based study started in the Nether-
lands, using the spiroNose, a standardized method which integrates eNose technology 
with spirometry 10, with the primary aim to gather exhaled breath profiles in a central 
database together with anonymized patient characteristics. This database will be 
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coupled to a self-learning algorithm with an accessory app (www.breathcloud.org). This 
project uses a ‘systems medicine’ approach combining clinical data with lung function 
and breathomics. However, whether or not this kind of technically demanding ap-
proaches will pay off in terms of feasibility, discriminatory power, reproducibility and 
costs, remains to be shown. In order to bring forward metabolomics of exhaled breath 
and EBC, international research networks should urgently work together to standardize 
collection methods, analysis techniques and interpretation.
BioMARkERs FoR BRonchoPulMonARy DysPlAsiA DEVEloPMEnt:  
two tARgEtED APPRoAchEs
The second part of this thesis focused on biomarkers in preterm born children with bron-
chopulmonary dysplasia (BPD). Currently, the two best established clinical risk factors 
for BPD are gestational age (GA) at birth and birth weight 11. However, for an individual 
preterm born child it remains difficult to predict whether he or she will develop BPD. 
Therefore, there is a clear need to identify biomarkers or predictors that discriminate 
between preterm children who will or will not develop BPD. Such biomarkers may 
also give new insights in the pathophysiology of the disease and guide the design of 
new preventive and/or therapeutic strategies. The last decades various inflammatory 
biomarkers in TAs or blood have been investigated for their predictive value for BPD, 
but so far results have been negative or could not be reproduced 12. Biomarkers could 
be detected in amniotic fluid, cord blood, blood and/or in samples from the respiratory 
tract, specifically bronchoalveolar lavage fluid (BALF) or TAs. In chapter 5 and 6 we have 
investigated multiple biomarkers in TAs of preterm infants. We evaluated the levels of 
cytokines and growth factors (chapter 5), and sphingolipids (chapter 6) in TAs over 
time. This longitudinal aspect is a strength of our studies since lung development, injury 
and repair are dynamic processes. We focused on the first postnatal week, because we 
aimed to identify early markers of BPD with the main goal to enable the development of 
early intervention and prevention strategies.
RolE oF MAcRoPhAgE-DERiVED AngiogEnic gRowth FActoRs in 
BRonchoPulMonARy DysPlAsiA
Histology of lungs from patients who died from BPD show impaired alveolarisation but 
also remarkable abnormalities in the pulmonary vascular network with a reduction in 
small arteries, abnormal distribution of capillaries in the distal lung, and intrapulmonary 
arteriovenous connections 13-15. Disruption of microvascular development in very imma-
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ture lungs has been postulated as a critical factor in the abnormal alveolar development 
in BPD 13,16,17. Traditionally, the classical angiogenic pathways associated with vascular 
morphogenesis, such as vascular endothelial growth factor (VEGF) and Angiopoietin-1 
(Ang-1), have been implicated in BPD pathogenesis 18. Although VEGF was shown to be a 
key mediator of lung angiogenesis and alveolarisation in mice 19,20, human studies on the 
correlation between these factors and clinical outcome show more variable results 21,22.
Placenta-mediated pregnancy complications like pregnancy induced hypertension 
(PIH) and preeclampsia with fetal growth restriction have been found to be associated 
with BPD in very preterm infants independently of GA and birth weight 23. Maternal 
blood levels of antiangiogenic factors like soluble fms-like tyrosine kinase 1 (sFlt-1) 
arising from the placenta are increased in PIH and preeclampsia 24. These factors might 
also play a role in impaired angiogenesis in the fetus. Furthermore, in mice, overexpres-
sion of proangiogenic factors like placental growth factor (PlGF) resulted in increasing 
type II alveolar cell apoptosis causing enlarged airspaces and pulmonary emphysema 
similar to BPD pathology 25. In humans, higher PlGF cord blood levels have been found 
in preterm infants who developed BPD 26. Unfortunately PlGF was not analyzed in our 
studies. The current paradigm suggests that imbalanced circulating proangiogenic and 
antiangiogenic factors could impair vasculogenesis in fetal lungs, which may lead to 
general disorders in lung development. However, the signals linking alveolar and vascu-
lar growth in the developing lung are still not well understood.
In chapter 5 we performed a targeted biomarker search within angiogenesis related 
factors using a proteome profiling assay. We measured multiple both classical and alter-
native growth factors known to be involved in physiological and aberrant angiogenesis. 
The proteome profiling assay is an easy method to quickly screen samples on the pres-
ence of multiple factors. However, this assay only allows semi-quantitative measurement 
and needs a lot of material (1.5 ml per membrane). Therefore in our study we had to pool 
multiple aliquots. Using this screening assay we identified the presence of multiple both 
classical and alternative angiogenic growth factors of which some were not described 
before in BPD. To further investigate differences between children with and without BPD 
we measured exact concentrations of a selected group of angiogenesis related growth 
factors, chemokines and cytokines in TAs of preterm born infants using a multiplex 
assay (Luminex) and ELISA. We found that TAs of preterm infants who do not develop 
BPD contain higher concentrations of M2-related chemokines, M1/pro-inflammatory 
cytokines and of a selection of proangiogenic factors including EMMPRIN, GDF15 and 
HGF, compared to TAs of infants who later developed severe BPD. The high expression 
of EMMPRIN  27, GDF15 28, and HGF are of special interest since these factors promote 
angiogenesis via modulating hypoxia-inducible factor (HIF) family. In utero, lung devel-
opment occurs under hypoxic conditions and HIF has shown to play an important role 
in branching of the epithelium and in the development of the pulmonary vasculature. 
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Under hypoxic conditions in utero, HIF activates proangiogenic factors including VEGF 
and Ang 1 and 2 29. After birth the hypoxic environment is acutely exchanged for 
a normoxic and in case of preterm birth often hyperoxic environment causing acute 
downregulation of HIF. The presence of high numbers of HIF inducing factors such as 
GDF15 and EMMPRIN may therefore play an important role in preservation of postnatal 
angiogenesis independent of oxygen tension.
We next studied cell number and phenotype present in TAs. Differential cell count on 
cytospins showed a significant different distribution of epithelial cells, granulocytes and 
monocytes/macrophages over time. The monocytes/macrophages were abundantly 
present in TAs of preterm infants especially at later time points, day 5 and 7 after intuba-
tion. We found that the macrophages in TAs express both CD68 and intermediate levels of 
CD14, and therefore recently differentiated from monocytes. Subsets of monocytes and 
macrophages, which express so-called M2 markers, are well-known for their functions 
in angiogenesis. These subsets were consistently higher in TAs of children without BPD 
than of those with severe BPD. Of interest M2 macrophages have been found in neonatal 
lungs at the tips of alveolar septa where they seem to guide branching morphogenesis 
suggesting a role in ensuring normal lung growth and development 30. We therefore for-
mulated a new hypothesis: M2-proangiogenic macrophages and their products protect 
preterm born infants from BPD development. To test this hypothesis we set up a more 
mechanistic study and investigated monocytes/macrophages in the lungs of neonatal 
mice during the alveolarisation phase of lung development using flowcytometry, RT-
PCR and functional studies. We found that neonatal pulmonary monocytes during al-
veolarisation display a similar gene expression profile as embryonic macrophages and/
or tumor-associated macrophages (TAMs) with strong gene expression of M2-related 
factors, pro-inflammatory cytokines and proangiogenic genes. This indicates that M2 
immunity is a default immune state during postnatal lung development and that the 
M2 profile in TAs of children without BPD reflects the normal microenvironment in the 
lung during postnatal alveolarisation, although a more efficient and active response 
to injury is not excluded. An improved understanding of the role of these monocytes/
macrophages under homeostatic and inflammatory conditions is of clinical relevance. 
It supports research into modulation of monocytes and macrophages and their derived 
products in the context of lung development to provide new future prevention or treat-
ment modalities for BPD.
Role of sphingolipids in bronchopulmonary dysplasia
The sphingolipid metabolism is suggested to be involved in various lung diseases 31. 
Sphingolipids are important structure-bearing constituents of the cell membrane and 
function as regulatory molecules in cell proliferation and cell death, endothelial barrier 
function, angiogenesis, and immune response 32,33. Previously, we observed a transient 
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increase in ceramide concentrations in BALF of a mouse model of BPD during the first 
2-4 weeks of hyperoxia. Supplementation of D-sphingosine, a synthetic precursor of 
sphingosine-1-phosphate (S1P), during normoxic recovery of hyperoxia-induced lung 
damage accelerated normalization of ceramide concentrations and improved the 
hyperoxia-induced alveolar arrest in this mouse model 34. These findings suggest that ce-
ramides are involved in the development of BPD and might be early biomarkers for BPD, 
and a target for therapeutic intervention. We translated our findings from this preclinical 
study into a human exploratory study and showed that ceramide profiles were indeed 
detectable in TAs of preterm infants, changed over time, and were significantly different 
between infants who did and did not develop BPD (chapter 6). However, a multivari-
able analysis showed that ceramide profiles over time had no additional predictive value 
over known clinical predictors of BPD like GA at birth, birth weight, and total days of 
mechanical ventilation. An increased initial ceramide-triggered apoptotic signal seemed 
to be present in all preterm infants exposed to mechanical ventilation and hyperoxia. 
Furthermore, a late increase in ceramides was present in those preterm infants who did 
not develop BPD, suggesting that this increase might function as a proliferation signal. 
These results suggest a potential role of ceramides in BPD development. It is therefore 
worthwhile to further investigate the role of ventilation- and hyperoxia-induced ce-
ramide production in epithelial apoptosis as a mechanism playing a role in pulmonary 
apoptosis and inhibition of alveolar development in preterm infants with BPD. Further 
research should also focus on discovering which enzymes in the sphingolipid pathway 
are responsible for the differences in ceramide levels. Specific enzyme inhibitors may be 
studied in mouse models for their potential to prevent hyperoxia induced lung injury, 
like acid sphingomyelinase inhibitors have shown to normalize ceramides and inflam-
mation in cystic fibrosis 35.
new potential pathways in BPD development
In chapter 5 and 6 of this thesis we described potential new pathways playing a role in 
BPD development. The pathogenesis of BPD is heterogeneous and complex and involves 
interaction among many genes, proteins and their environment. Interestingly, cytokines, 
growth factors (chapter 5) and sphingolipids (chapter 6) have been shown to interfere 
in the regulation of S1P. Numerous cytokines and growth factors are able to influence 
the sphingolipid signaling pathway, mainly through regulation of either the expression 
or activation of sphingosine kinase 36. For example, endothelin-1 is able to activate the 
sphingomyelin pathway, thereby increasing the amount of ceramides and subsequently 
induce apoptosis 37. On the contrary, both hepatocyte growth factor (HGF) and epider-
mal growth factor (EGF) attenuated ceramide-induced apoptosis 38,39.Conversely, S1P 
can also trans activate growth factor and cytokine signaling cascades 40-42. For example, 
an increase in ceramides disrupted the S1P/ceramide homeostasis and resulted in a re-
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duction of HIF-1α and VEGF expression, inducing lung cell apoptosis, whereas increased 
S1P restored the expression of HIF-1α and VEGF and prevented lung cell apoptosis in a 
rat model 42. In addition, inhibition of sphingosine kinase 1(SphK1) blocked TNF-α induc-
tion of IL-8 in lung epithelial cells, also supporting a role for the interaction between 
sphingolipids and cytokines in the initiation of lung inflammation  43. Furthermore, it 
has been shown that S1P regulates macrophage function 44. Recently, a potential link 
between S1P signaling system and defective monocyte-derived or alveolar macrophage 
phagocytic function and resultant chronic inflammation was suggested in patients with 
COPD 45. In chapter 5 we also found a major role for alternatively activated monocytes 
and monocyte-derived macrophages and their produced cytokines, chemokines and 
growth factors in BPD development. These interactions between S1P, macrophages and 
their derived cytokines, chemokines and growth factors may also potentiate an effect on 
angiogenesis and alveolarisation in the developing lung.
Our results described in chapter 5 and 6 consistently suggest a role for early apop-
tosis and late proliferation in the development of BPD. However, the alterations in 
expression of these factors that we observed in patients who developed BPD do not 
necessarily imply causality. Furthermore, the presence of these factors in TAs might not 
be a direct reflection of mechanisms occurring in the alveoli or lung tissue. Currently, 
studies examining lung tissue of BPD patients are scarce and only involve postmortem 
studies 46. Endobronchial biopsies have been shown to be feasible and safe in children 
with asthma 47. However, endobronchial biopsies in children with BPD will probably not 
contribute to further understanding of the underlying pathology since the structural 
abnormalities are present in the peripheral part of the lungs. For this purpose more 
postmortem studies in preterm infants who died because of respiratory insufficiency are 
needed. To gain better insight in the regulation of inflammation, angiogenesis, apopto-
sis and proliferation, and their effects and interactions during normal and impaired lung 
growth as seen in preterm birth we still depend on in vitro models and animal studies.
In vitro models like pericyte-endothelial cell co-cultures (chapter 5) can be used to study 
the mechanisms by which the identified factors affect angiogenesis and/or epithelial 
repair. In addition, wound healing studies can be used, where human lung epithelial 
cells are grown in a monolayer and scratched to create a 'wound' to monitor through 
time-lapse microscopy the speed of wound closure in the presence of the introduced 
factors. In addition, epithelial cell proliferation assays can be performed to indicate 
whether observed effects are due to proliferation or migration. Besides these known in 
vitro models the laboratory of Pediatric Surgery of the Erasmus MC (dr. R.J. Rottier and 
dr. I.M. de Kleer) are currently involved in a consortium with the University of Twente 
(dr. A.A. Poot and prof. dr. D.F. Stamatialis), Maastricht University (dr. R.K. Truckenmuller) 
and Leiden University Medical Centre (prof. dr. P.S. Hiemstra) collaborating on the devel-
opment of micro engineered 3D alveolar tissue using organ-on-a-chip technology, to 
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create a ‘lung-on-a-chip’. In contrast to currently used 2D lung models, lung cells in this 
model are cultured on curved membranes, allowing exposure to air and liquid flow as 
well as mechanical forces. The model allows alveolar epithelial cells to be grown on one 
side of the porous membrane and microvascular endothelial cells on the other side. They 
are currently successful in growing alveolar cell lines into the lung-on-a-chip device. In 
the near future they aim to add human umbilical vein endothelial cells (HUVECs) and to 
use human induced pluripotent stem cells to generate both alveolar and endothelial 
cells for implementation. This lung-on-a-chip model can also be used to explore the 
effects of the identified growth factors on lung tissue repair. Finally the therapeutic 
potential of the most promising growth factors and their sources can only be studied 
in animal models. However current animal models for BPD, like the hyperoxia mediated 
mouse model, need further refinement to better mimic the human condition. Current 
animal models have relatively normal lungs, while the lungs of preterm born infants are 
exposed to intrauterine inflammation, growth abnormalities, antenatal corticosteroids 
and postnatal effects of for example mechanical ventilation, oxygen supplementation, 
persistent ductus arteriosus and infections.
current clinical outcome of preterm born infants with severe BPD
The improved survival of extremely preterm born infants (< 28 weeks GA) results in 
an increasing incidence of BPD. Survivors of preterm birth and BPD have an increased 
risk for long term respiratory morbidity. These children experience more respiratory 
symptoms, such as wheeze, cough, dyspnea, and reduced exercise capacity, than chil-
dren without BPD 48-51. Furthermore, severe BPD has been associated with persistent 
pulmonary hypertension in preterm infants 52,53 and severe BPD may be a risk factor 
for developing pulmonary hypertension at a later age 54. Also, neurological and cogni-
tive impairment persisting into adulthood are common in preterm infants with BPD 55. 
Chest computed tomography (CT) studies show structural abnormalities in up to 85% of 
BPD patients (chapter 7). A recent meta-analysis showed that preterm infants with BPD 
have lower forced expiratory volume in 1 s (FEV1) compared to children without BPD 56. 
However, despite this significant morbidity and physical limitations adolescents with 
BPD experience a quality of life similar to that of healthy controls, which is in contrast 
to adolescents with asthma 57. Most of the earlier studies included children who were 
born before 1990 and do not reflect todays BPD population. Furthermore, the relation 
between structural abnormalities of the lungs and airways and lung function in patients 
with BPD early and later in life is not clear. Since lung function tracks throughout life, 
it is important to recognize both structural and functional impairment early in life in 
order to identify those at risk for future respiratory morbidity, and to develop targeted 
preventive strategies. Therefore, there is a need for long-term follow up of preterm born 
infants and since children with BPD might have a higher risk for early development of 
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COPD-like disease in adulthood, we have the obligation to follow these children into 
adulthood and guarantee transition to a pulmonologist.
the use of chest ct as a possible outcome measure for bronchopulmonary 
dysplasia
Chest CT is the most sensitive imaging technique to detect structural abnormalities in 
patients with BPD 58 and has been used as the primary endpoint in clinical studies on 
cystic fibrosis. In BPD there are no standardized universal CT scoring systems, and there-
fore we developed such a standardized CT protocol and quantitative scoring method, 
the PRAGMA-BPD scoring method (chapter 7). Our PRAGMA-BPD scoring method re-
quires validation, including assessing intra-observer and inter-observer reliability, cross 
validation to other outcomes like quality of life and lung function, and standardization 
within and between different centers, before it can be used for future clinical trials. The 
ultimate goal of such a quantitative scoring system for BPD would be to improve clinical 
and pathophysiological phenotyping of individual patients, to predict long term respi-
ratory morbidity, and to help developing new preventive measures to optimize lung 
development in early life. In our follow up study (chapter 8) we found structural lung 
abnormalities in almost all preterm infants with severe BPD at 6 months corrected age. 
However, we also found that overall around 90% of the total lung volume was still scored 
as normal, which can explain the relatively good lung functions found in some studies 
and the reported high quality of life. Still, BPD is a heterogeneous disorder and there 
are also a substantial number of preterm born children with BPD who do have severe 
structural damage and experience severe respiratory complications.
structural and functional abnormalities in infants with severe BPD
In chapter 8 we present the first results of our prospective hospital-based cohort 
which includes preterm infants born ≤ 32 weeks GA diagnosed with severe BPD from 
September 2013 onwards. These children will be followed from birth until adulthood 
by a multidisciplinary team of pediatric specialists and undergo several investigations 
including chest CT scans to assess structural abnormalities and lung function tests to 
evaluate functional abnormalities (Table 1). In chapter 8 we present data from 49 infants 
in whom we assessed lung structure on chest CT scans using the PRAGMA-BPD scoring 
system and performed overnight polysomnography (PSG) at 6 months corrected age.
We found that 95.5% of the infants had abnormal lung structure at 6 months corrected 
age. Although almost all infants with severe BPD in our study showed architectural 
distortion, the amount of normal lung volume was still quite high, namely 89.7 (85.6-
93.2)%. However, some children had less than 45% normal lung volume. In the future 
chest CT may be used as an outcome measure for BPD. It is important to recognize 
abnormal lung structure early in life in order to identify those children with the most 
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severe disease, who are at risk for future severe respiratory morbidity and should be 
monitored more strictly.
We found that 74% of the infants had an abnormal oxygen desaturation index (ODI) 
at 6 months corrected age. Our PSG results are consistent with previous studies 59 and 
indicate that infants with severe BPD might be more vulnerable for rapid desaturation 
during apneas, perhaps because of decreased ventilatory reserve. We speculate that 
increased ODI may be unfavorable for lung development, growth and neurocognitive 
development and suggest overnight PSG registration before cessation of supplemental 
oxygen.
Associations of lung structure measures with ventilatory function were only weak and 
disappeared after correction for GA. Also in CF studies weak correlations between 
lung structure and lung function were shown, probably due to the localized and in-
homogeneous aspect of the disease. In BPD we find a similar inhomogeneous picture. 
Furthermore, lung imaging techniques are not able to detect functional changes and 
lung morphometrics are probably not sensitive enough to demonstrate relative small 
structural changes. Multiple breath washout techniques, body plethysmography and 
compliance measurements might be more sensitive to pick up subtle changes in lung 
function.
Our data showed that especially GA at birth influences both lung structure and ventila-
tory function at later age. Preterm infants are born when lung development is still in the 
canalicular or saccular stage, characterized by vascular and alveolar simplification. This 
suggests that poor lung development at the time of preterm birth and during exposure 
to mechanical ventilation and supplemental oxygen is crucial for the development of 
BPD.
Finally, in addition to higher GA at birth also increased early postnatal growth positively 
influenced both the total and normal lung volume, and ventilatory function reflected 
in less severe oxygen desaturations in preterm infants with severe BPD. These results 
suggest that postnatal alveolar growth is positively influenced by overall weight gain. 
The underlying mechanisms for the associations between infant weight growth and 
lung structure and function are unclear. The lower lung function might be explained 
by smaller airways in preterm born infants. Another possible explanation for the ob-
served associations between infant weight gain and lung structure and function is low 
grade systemic inflammation, associated with obesity. Both the increased amount of 
pro-inflammatory cytokines producing macrophages present in adipose tissue and the 
adipokines and leptin secreted by adipose tissue itself could lead to this systemic low 
grade inflammation 60. Recently, it was shown that a coordinated expression of pro-
inflammatory cytokines like interleukin (IL)-6 and tumor necrosis factor (TNF)-α plays 
a protective role and might positively influence lung maturation 61-63. In chapter 5 we 
also found higher concentrations of pro-inflammatory cytokines in preterm infants pro-
202 Chapter 9
tected from BPD, which is in line with this hypothesis. Besides the influence of postnatal 
growth it would be interesting to evaluate whether intrauterine growth patterns are 
also associated with lung structure and function impairment. It has recently been found 
that fetal growth restriction, more than birth weight, predisposes for impaired lung de-
velopment 23. Furthermore, the question remains whether postnatal growth would have 
been better when prolonged supplemental oxygen was given to these preterm born 
infants with a positive influence on both total and normal lung volume and ventilatory 
function at 6 months corrected age.
Our prospective cohort provides the opportunity to follow preterm born infants with 
severe BPD until adult age in a multidisciplinary team, assessing both lung structure 
and respiratory function and their clinical consequences over time. Detailed information 
on prenatal and postnatal environmental factors is collected prospectively. These data 
allow us to gain more insight in structural and functional lung development of preterm 
infants with severe BPD and the influence of postnatal growth until adulthood. When we 
will continue to track these individuals trough their adult life’s, in the future we might be 
able to answer that question whether today’s children with severe BPD will grow up to 
be the early COPD-like patients of tomorrow.
Future directions
BPD is a serious complication of preterm birth with long-term respiratory morbidity.
BPD is a multifactorial disease, but the exact pathophysiology is still unclear. Therefore, 
for an individual preterm born child it remains difficult to predict whether he or she will 
develop BPD. A lot of different pathways seem to be involved in postnatal alveolarisa-
tion, including growth factors involved in angiogenesis, inflammatory cells and cyto-
kines, and the sphingolipid pathway. Biomarker research may lead to more insight in the 
underlying pathophysiology of BPD and may guide the design of new preventive and/
or therapeutic strategies.
The most important factor in the prevention of BPD is the prevention of preterm birth 
and prenatal etiological factors for preterm birth like pregnancy induced hypertension 
(PIH), preeclampsia and chorio-amnionitis. Since GA at birth, birth weight and intrauter-
ine growth restriction are important clinical risk factors for BPD development, it would 
be interesting to investigate prenatal treatments which interfere with poor placenta-
tion. Currently, there is no treatment for poor placentation once it has developed. A few 
promising interventions are now emerging such as nitric oxide donors (organic nitrates, 
S-nitrosogluthathione), sildenafil citrate, maternal VEGF gene therapy injected locally 
into the uterine arteries, hydrogen sulphide donors, statins and plasma exchange or 
plasmapheresis 64. In the absence of real treatment, current obstetric practice focuses 
on prevention of poor placentation and preterm birth. For example, maternal smok-
ing has been associated with preterm birth and subsequently BPD development 65 and 
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smoke-free legislation has been shown to be associated with a 10% reduction in preterm 
births 66. Studies in mice have suggested that also maternal diet, mainly a high fat diet, 
during pregnancy can cause placental inflammation and result in alveolar simplification, 
thereby increasing the risk of BPD development 67.
Besides prevention of preterm birth, a lot of research focused on postnatal measures 
to prevent BPD development. Since invasive mechanical ventilation is one of the major 
contributors to the development of BPD in preterm infants less invasive ventilation was 
thought to reduce the incidence of BPD 68. A recent trial of CPAP instead of invasive 
mechanical ventilation in the first day of life resulted in a significant reduction of BPD or 
death of very low birth weight infants 69. Other strategies of gentle ventilation include 
intubation solely to administer surfactant, early extubation and nasal intermittent 
mandatory ventilation. Given the fact that less invasive ventilator strategies are often 
successful, TAs will not be feasible anymore to obtain and alternative methods to sample 
the newborn airways, like exhaled breath and EBC, should be explored.
The introduction of antenatal corticosteroids have shown positive effects on lung 
development: reducing inflammation and stimulating surfactant synthesis and lung 
epithelial differentiation in the developing lung 70. Postnatal dexamethasone has been 
used for some time to prevent BPD development, however, in 2001 a meta-analysis 
revealed a relation between the use of early dexamethasone and poor neurodevelop-
mental outcome, especially cerebral palsy 71. This resulted in a general concern about 
the use of steroids in preterm infants even for late targeted use. Recently, animal data 
have suggested that hydrocortisone might have a less detrimental effect on the brain 
than dexamethasone 72. Retrospective studies seem to indicate that hydrocortisone is 
indeed effective in reducing BPD, without causing serious adverse effects in humans 73. 
Currently, a randomized double-blind placebo-controlled trial investigating if hydro-
cortisone is safe and effective in reducing the incidence of the combined outcome 
death or BPD at 36 weeks PMA in chronically ventilated preterm infants is conducted in 
15 NICUs in the Netherlands and Belgium (SToP BPD trial, www.neonatologiestudies.nl/
stopbpd/). Also local administration of budesonide by either intratracheal instillation or 
inhalation has been studied in the prevention of BPD 74. Animal models confirmed that 
local delivery of budesonide may have favorable effects on the developing lung without 
the neurodevelopmental side effects 75.
Studies on how to treat children with established BPD are scarce and current treatment 
options are limited and symptomatic. Ideally, a new treatment for BPD should promote 
postnatal lung growth and target the repair of lung injury. There are a number of inter-
esting emerging therapies focusing on treatment for BPD:
First, stem cell therapy: stem cellls, primitive multipotent cells with the ability to self-
renew and give rise to several differentiated cellular phenotypes, are currently a ‘hot 
topic’ in BPD research. Over the last years, animal studies using mesenchymal stem 
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cells (MSCs) as treatment for BPD showed positive results, which have led to the first 
trial in humans 76. In this study no serious adverse events or acute toxicity of stem cell 
treatment were observed. Currently, a major problem is the lack of standardization of 
preparing MSCs populations which makes it difficult to compare studies. Data on long 
term outcome of stem cell therapy are lacking.
Second, microbiome: another new field of research is exploring the role of the respira-
tory microbiome, the community of micro-organisms colonizing the upper and lower 
airways, in respiratory diseases. Molecular methods such as 16S rRNA gene sequencing 
provide improved sensitivity to detect micro-organisms compared with traditional 
culture-based techniques 77. Current evidence shows that the colonization of the airways 
begins very early in life, probably already in utero 78. Decreased diversity of the respira-
tory microbiome in preterm infants has been associated with BPD 79. The microbiome 
might influence the development of BPD by stimulating pro- or anti-inflammatory re-
sponses. Prophylactic azithromycin therapy was found to be associated with a significant 
reduction in BPD in preterm infants 80. However, further studies are needed to provide 
more information on pharmacokinetics and potential harmful effects, before routine use 
of azithromycin in the neonatal population. Most likely, the respiratory microbiome is 
influenced by the same environmental factors that have been shown to influence the 
gut microbiome like delivery mode, breastfeeding and the use of antibiotics 81. Further 
studies are needed to improve our understanding about the bacteria-host interactions 
playing a role in BPD development.
In BPD research, the movement of potential preventive and therapeutic measures from 
bench to bedside is complicated due to the difficulty of extrapolating animal data to hu-
man preterm infants, the complex multifactorial etiology, and the fact that most human 
studies are of small sample size 82. In this respect, a biobank may be extremely helpful. 
Collection of maternal blood, placental material, amniotic fluid, umbilical cord blood, 
and blood, urine and TAs obtained from the infants after birth, together with prospec-
tive clinical data regarding pregnancy, delivery and postnatal environmental factors 
could contribute to future research of BPD prevention. There is also a need for adequate 
long-term clinical follow-up studies of preterm infants. Due to treatment changes and 
increasing survival over time, outcome will constantly change, necessitating the con-
tinuous collection of new data in order to evaluate the long-term outcome of present 
treatment strategies. In addition, careful documentation of the clinical evolution might 
facilitate the identification of different phenotypes and the association with (epi)genetic 
markers 83-86.
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To summarize, biomarkers may help in the diagnosis, monitoring and management of 
respiratory diseases in childhood. The continuous search for new biomarkers as part of 
a systems medicine approach may help to identify new pathways and possibly develop 
new treatments. There is a need for integration of basic and clinical data requiring in-
teraction between various disciplines. Last, long term follow-up from childhood until 
adulthood is needed to document the course of respiratory diseases, and unravel the 
influence of preventive measures, treatment, and exposures.
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suMMARy
Today’s children will grow up to be the adults of tomorrow and respiratory diseases in 
children and their management will have impact on adult lung health. Biomarkers can 
play a role in the prediction and early diagnosis of respiratory diseases, but can also 
contribute to gaining more insight in underlying pathophysiology, disease phenotyping 
and monitoring of disease progression and treatment effect. In this thesis, we focused 
on these different aspects with the ultimate goal to improve the outcome of pediatric 
respiratory diseases.
Asthma and cystic fibrosis: exhaled breath analysis with laser-based 
spectroscopy
Previous studies on exhaled breath analysis in diagnosis and management of children 
with respiratory disorders are reviewed in chapter 2. In this review methodological is-
sues and clinical applications of exhaled breath and exhaled breath condensate (EBC) 
analysis in children with respiratory diseases are discussed. Methodological issues can 
be divided in precollection (e.g. physiological and environmental factors), collection 
(e.g. breathing maneuvers and devices), and postcollection (e.g. storage and analysis 
techniques) conditions. Lack of standardization of the collection- and measurement pro-
cedures and differences in the selection of subjects probably explain the high variability 
and low reproducibility of exhaled biomarkers between studies. Currently, besides the 
fraction of exhaled nitric oxide (FeNO), analysis of biomarkers in exhaled breath and EBC 
is still a research tool and not validated for clinical use.
In chapter 3 we present a new technique to detect volatile organic compounds (VOCs) in 
exhaled breath: broadband quantum cascade laser-based spectroscopy. This technique 
was developed in cooperation with the Optics research group at the Delft University of 
Technology, the Netherlands. Broadband quantum cascade laser-based spectroscopy 
allows for detection of VOCs in exhaled breath samples, with an absorption spectrum 
in a specific, broad wavelength spectrum. Advantages of this technique over the most 
commonly used gas chromatography-mass spectrometry (GC-MS) technique are espe-
cially the limited need for preprocessing and the relatively fast detection without the 
need for highly trained personnel. The main advantage over the use of sensor-based 
detection methods, like the electronic nose (eNose), is the possibility of VOC identifica-
tion with the use of molecular databases.
The pilot study described in chapter 4 explored the clinical applicability of this new 
technique in healthy children and children with asthma and cystic fibrosis (CF). We 
found overall poor short- and long term repeatability. However, despite the variability of 
the spectra we were still able to detect differences between exhaled breath profiles from 
healthy children and from children with chronic airways inflammation due to asthma or 
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CF. We propose that, before further clinical studies can be undertaken, the sensitivity 
and repeatability of this technique need to be improved.
Bronchopulmonary dysplasia: early markers in tracheal aspirates and clinical 
follow up
The improved survival of extremely preterm born infants (< 28 weeks gestational age, 
GA) may result in an increasing incidence of bronchopulmonary dysplasia (BPD). In 
Europe, the current incidence of BPD ranges from 4% in infants born at a GA of 31 weeks 
to 56% in infants born before 26 weeks GA. Children with BPD are at increased risk of 
long-term respiratory morbidity as a result of impaired lung development. The exact 
pathogenesis of BPD remains unclear and treatment modalities are limited and only 
treat symptoms. Altogether, it is important to gain more insight in the pathophysiol-
ogy of this chronic lung disease. Identification of biomarkers for BPD development may 
result in future early prediction and diagnosis and the development of new prevention 
and intervention strategies. In addition, since BPD is a heterogeneous disease it is also 
important to recognize both structural and functional impairment early in life and iden-
tify those children most at risk for future respiratory morbidity.
In chapter 5 and 6, we investigated potential biomarkers in tracheal aspirates (TAs) of 
preterm born infants with and without BPD. Recently, disruption of microvascular devel-
opment in very immature lungs has been postulated as a critical factor in the abnormal 
alveolar development in BPD. In chapter 5 we used a proteome profiling and Luminex 
assay to measure multiple growth factors, cytokines and chemokines in TAs of preterm 
infants. We found higher levels of several M2-type macrophage-related angiogenic 
growth factors and pro-inflammatory cytokines in serial TAs of preterm infants who did 
not develop BPD. Furthermore, we found significantly higher gene expression of the 
M2-related genes MRC1 and CD206 in infants without BPD. Our findings support a role 
for M2-like macrophages in angiogenesis and tissue homeostasis during alveolarisation. 
We speculate that M2 macrophages and their products may be potential therapeutic 
targets for prevention and treatment of BPD. In chapter 6 we focused on a specific set 
of sphingolipids in TAs of preterm infants using liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Previous studies in mice indicated the importance of cerami-
des in inflammation and repair processes in the developing lung. We found that an early 
increase and subsequent decrease in ceramides in TAs of preterm infants exposed to 
mechanical ventilation and supplemental oxygen seems to predispose for BPD develop-
ment. Therefore, ceramide profiles in TAs may be a new early marker for BPD and the 
ceramide pathway in general might also be a potential new target for future prevention 
or treatment of BPD.
In addition, we evaluated the results of an improved clinical monitoring program for 
preterm children with severe BPD. Chest computed tomography (CT) scans and poly-
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somnography have been studied as ‘alternative biomarkers’ that may predict outcome of 
BPD. In chapter 7 we reviewed the literature regarding chest CT studies in patients with 
BPD. We found that structural abnormalities are present in up to 85% of BPD patients 
and the extent of these abnormalities seem to correlate with BPD severity and lung 
function. There are no standardized universal CT scoring systems available for assess-
ment of structural pulmonary abnormalities in BPD patients. Therefore, we developed 
such a standardized CT protocol and quantitative scoring method, the PRAGMA-BPD 
scoring method, with the primary aim to enable the use of chest CT scans as a clinical 
outcome measure and predictor for long-term structural abnormalities and respiratory 
morbidity in BPD patients.
In chapter 8 we described the results of chest CT scans and polysomnography mea-
surements in children with severe BPD at 6 months corrected age and showed that the 
extent of structural abnormality was associated with ventilatory function impairment 
during sleep. Both higher GA at birth and higher birth weight were associated with 
better lung structural outcomes and ventilatory function. Also, increased weight gain 
between 2 and 6 months of corrected age was associated with better oxygenation and 
weight at 6 months was independently associated with more healthy lung volume and 
less severe oxygen desaturations during sleep.
In chapter 9 the main findings of our studies and their scientific and clinical implica-
tions are discussed and recommendations for future research are given. We conclude 
that biomarkers may be helpful not only in the diagnosis, monitoring and management 
of respiratory disease in childhood, but also in identifying new pathways which may 
eventually result in new preventive or therapeutic measures. Furthermore, long-term 
follow up from childhood until adulthood is necessary in order to document the course 
of respiratory diseases, and to evaluate the influence of preventive measures, treatment, 
and exposures. In order to reach these goals there is a need for integration of basic and 
clinical data requiring collaboration and interaction of various disciplines.
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sAMEnVAtting
Aandoeningen van longen en luchtwegen op kinderleeftijd en de behandeling daarvan 
kunnen van grote invloed zijn op de gezondheid van volwassenen. Biomarkers, of wel 
meetbare indicatoren van een bepaalde biologische toestand of ziekte, kunnen helpen 
bij het stellen van een vroege diagnose en bij het monitoren van longziekten. Daarnaast 
kunnen biomarkers bijdragen aan de kennis over de pathofysiologie van longziekten en 
daarmee ook aan nieuwe behandelingen. In dit proefschrift worden deze verschillende 
aspecten van het gebruik van biomarkers toegepast met als doel het verbeteren van de 
toekomst van kinderen met longziekten.
Astma en taaislijmziekte: analyse van uitademingslucht met behulp van  
laser spectroscopie
hoofdstuk 2 geeft een overzicht van de literatuur op het gebied van het gebruik van 
uitademingslucht voor het diagnosticeren en behandelen van kinderen met longziek-
ten. In dit hoofdstuk worden de methodologische uitdagingen en klinische toepasbaar-
heid van uitademingslucht en -condensaat (afgekoelde druppeltjes uitademingslucht) 
bediscussieerd. Methodologische uitdagingen kunnen worden onderverdeeld in 
uitdagingen vóór de verzameling van uitgeademde lucht en -condensaat (zoals fysio-
logische en omgevingsfactoren), tijdens de verzameling (zoals ademhalingsmaneuvers 
en verzamelapparatuur) en na de verzameling (zoals opslagmethoden en techniek van 
analyseren) gerelateerde condities. De hoge variabiliteit en lage reproduceerbaarheid 
van de resultaten van huidige studies kunnen worden verklaard door het gebrek aan 
standardisatie van verzamel- en analysemethoden en de selectie van proefpersonen. 
Momenteel is behalve het meten van de fractie van stikstofmonoxide (FeNO), de analyse 
van biomarkers in uitademingslucht en -condensaat niet gevalideerd voor gebruik in de 
dagelijkse praktijk.
In hoofdstuk 3 beschrijven we een nieuwe techniek om vluchtige organische com-
ponenten (VOCs) in uitgeademde lucht te meten: breedband quantum cascade laser 
spectroscopie. Deze techniek maakt gebruik van het feit dat elk molecuul licht van een 
bepaalde specifieke golflengte absorbeert. De opstelling werd ontwikkeld in samenwer-
king met de afdeling Optica van de Technische Universiteit Delft, Nederland. Met behulp 
van deze breedband laser spectroscopie techniek is het mogelijk om een breed scala 
aan VOCs te detecteren en te identificeren in uitgeademende lucht. Voordelen van deze 
nieuwe techniek over de huidig meest toegepaste techniek, gas chromotografische 
scheiding van de verschillende componenten en detectie met behulp van massa spec-
trometrie (GC-MS), zijn dat voorbehandeling van de monsters niet nodig is, en dat de 
techniek relatief snel en makkelijk is. Het voordeel ten opzichte van het gebruik van de 
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electronische neus (eNOse), is de mogelijkheid tot het identificeren van de verschillende 
VOCs door gebruik te maken van moleculaire databanken.
Het onderzoek beschreven in hoofdstuk 4 laat de eerste resultaten zien van de klinische 
toepasbaarheid van deze nieuwe techniek in het detecteren van VOCs in uitgeademde 
lucht van gezonde kinderen en kinderen met astma en taaislijmziekte. Er bleek sprake 
van een matige reproduceerbaarheid op zowel de korte als de lange termijn. Ondanks 
de variabiliteit waren we wel in staat verschillen te detecteren tussen de uitgeademde 
lucht van gezonde kinderen en kinderen met chronische luchtwegontsteking als gevolg 
van astma of taaislijmziekte. Echter, de sensitiviteit en de reproduceerbaarheid van deze 
techniek moet worden verbeterd, alvorens er klinische vervolgstudies kunnen worden 
gedaan.
Bronchopulmonale dysplasie: vroege biomarkers in luchtwegaspiraten en 
klinische follow up
De incidentie van bronchopulmonale dysplasie (BPD) is de laatste jaren niet gedaald, 
ondanks betere behandelmethodes van te vroeggeboren kinderen. Dit komt waarschijn-
lijk doordat meer extreem vroeg geboren kinderen (< 26 weken zwangerschapsduur) 
overleven. De huidige Europese incidentie van BPD varieert tussen 4% van de kinderen 
geboren bij een zwangerschapsduur van 31 weken, tot 56% van de kinderen geboren 
bij een zwangerschapsduur van 26 weken. Kinderen met BPD hebben een hoger risico 
op lange termijn longgerelateerde problemen ten gevolge van een afwijkende longont-
wikkeling. De exacte pathogenese van BPD is tot nu toe onduidelijk en behandeling is 
beperkt tot het bestrijden van symptomen. Het is belangrijk om meer inzicht te krijgen in 
het ontstaan van deze chronische longziekte. Het gebruik van biomarkers kan bijdragen 
aan een vroege detectie van te vroeggeboren kinderen die een hoger risico hebben op 
het ontwikkelen van BPD, en mogelijk ook in de ontwikkeling van nieuwe preventieve 
en behandelstrategieën. Daarnaast is het belangrijk om zowel structurele als functio-
nele longafwijkingen vroeg in het leven vast te stellen en daarmee de kinderen met het 
hoogste risico op longproblemen in het latere leven te identificeren.
In hoofdstuk 5 en 6 hebben we potentiële biomarkers onderzocht in luchtwegaspi-
raten van te vroeggeboren kinderen met en zonder BPD. Recent werd geopperd dat 
een verstoorde ontwikkeling van het vaatbed in onderontwikkelde longen een kritische 
factor is in het ontstaan van een abnormale ontwikkeling van longweefsel zoals gezien 
wordt bij BPD. In hoofdstuk 5 hebben we gebruik gemaakt van proteome profiling, 
Luminex en ELISA technieken om multipele groeifactoren, chemokines en cytokines 
die van invloed kunnen zijn op vaatontwikkeling te meten in luchtwegaspiraten van 
vroeggeboren kinderen. Te vroeggeboren kinderen die geen BPD ontwikkelen bleken 
hogere waardes van M2-type macrofagen gerelateerde groeifactoren en cytokines in 
luchtwegaspiraten te hebben dan te vroeggeboren kinderen die wel BPD ontwikkelen. 
Samenvatting 221
10
Daarnaast kwamen ook bepaalde M2-gerelateerde genen (MRC1 en CD206) hoger tot 
expressie in luchtwegaspiraten van te vroeggeboren kinder zonder BPD. Deze bevindin-
gen suggereren een potentiële rol van M2-type macrofagen in de vaatontwikkeling en 
daarmee de ontwikkeling van longweefsel. We speculeren dat M2-type macrofagen en 
hun gerelateerde groeifactoren en cytokines potentiële nieuwe aangrijpingspunten zijn 
voor preventie en behandeling van BPD. In hoofdstuk 6 hebben we ons gericht op het 
meten van sfingolipiden, bestandsdelen van celmembranen, in luchtwegaspiraten van 
te vroeggeboren kinderen met behulp van vloeistof chromotografische scheiding van 
de verschillende componenten en detectie met behulp van tandem massa spectrome-
trie techniek (LC-MS/MS). Eerder werd bij muizen aangetoond dat met name ceramides, 
een bepaald soort sfingolipide, een belangrijke rol spelen in zowel onstekings- als 
herstelprocessen gedurende de longontwikkeling. Wij hebben aangetoond dat een 
vroege toename en daaropvolgende afname in ceramides in luchtwegaspiraten van te 
vroeg geboren kinderen voorspellend zijn voor het ontwikkelen van BPD. Het ceramide 
profiel in luchtwegaspiraten lijkt een nieuwe vroege marker voor BPD ontwikkeling 
en interventies gericht op ceramides kunnen in de toekomst mogelijk ook leiden tot 
nieuwe preventieve of behandelstrategieën voor BPD.
In de hoofdstukken 7 en 8 bespreken we de eerste resultaten van een nieuw klinisch 
follow up programma voor te vroeggeboren kinderen met ernstige BPD. In dit klinische 
follow up programma wordt op de leeftijd van 6 maanden, gecorrigeerd voor de vroeg-
geboorte, een CT-scan van de longen gemaakt en een slaap-ademhalingsonderzoek 
(polysomnografie) verricht, als ‘alternatieve’ biomarkers die mogelijk inzicht kunnen 
geven in de lange termijn uitkomst van BPD. hoofdstuk 7 geeft een overzicht van de 
literatuur op het gebied van CT-scans van de longen bij patiënten met BPD: structurele 
longafwijkingen zijn aantoonbaar in 85% van de BPD patiënten en de uitgebreidheid 
van de afwijkingen correleert met de ernst van de BPD en longfunctieafwijkingen. Er 
is momenteel geen gestandaardiseerde universele CT-scoringsmethode beschikbaar 
voor de beoordeling van structurele longafwijkingen bij patiënten met BPD. Daarom 
hebben wij de PRAGMA-BPD scoringsmethode ontwikkeld, met als primaire doel om 
CT-scans van BPD patiënten in de toekomst te kunnen gebruiken als uitkomstparameter 
in klinische studies. Daarbij kunnen CT-scans van de longen mogelijk ook lange termijn 
structurele longafwijkingen en daarmee geassocieerde respiratoire morbiditeit voor-
spellen.
In hoofdstuk 8 beschrijven we de resultaten van long CT-scans en polysomnografie in 
kinderen met ernstige BPD op de gecorrigeerde leeftijd van 6 maanden oud. De uitge-
breidheid van de structurele afwijkingen op de CT-scans is geassocieerd met de mate 
van beperking in ademhalingsfunctie zoals gemeten met behulp van polysomnografie. 
Een grotere gewichtstoename tussen de gecorrigeerde leeftijd van 2 en 6 maanden 
bleek geassocieerd met betere zuurstofvoorziening. Een hoger gewicht op de gecor-
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rigeerde leeftijd van 6 maanden was geassocieerd met meer gezond longweefsel en 
minder dalingen in zuurstofverzadiging tijdens slaap.
In hoofdstuk 9 worden de resultaten van onze studies bediscussieerd en aanbevelingen 
voor toekomstig onderzoek gedaan. We concluderen dat biomarkers een rol kunnen 
spelen in de diagnose, monitoring en behandeling van kinderlongziekten. Daarnaast 
kunnen biomarkers ook belangrijk zijn in het ontrafelen van onderliggende pathofysio-
logische processen en daarmee een bijdrage leveren aan het ontwikkelen van nieuwe 
preventieve en behandelmethodes. De lange termijn follow- up van kinderen met 
longziekten tot in het latere volwassen leven is van groot belang om inzicht te krijgen 
in het beloop van longziekten over de tijd en de invloed van preventieve en behan-
delstrategieën daarop. Om deze algemene doelen te kunnen bereiken is het belangrijk 
fundamentele en klinische onderzoeksgegevens met elkaar te integreren, dit vereist 
nauwe samenwerking tussen onderzoekers in het laboratorium, klinische onderzoekers, 
artsen en (ouders van) patiënten.
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Ang Angiopoietin
ADMA Asymmetric dimethylarginine
AHI Apnea hypopnea index
AMP Adenosine monophosphate
ATP Adenosine triphosphate
BAL Bronchoalveolar lavage
BALF Bronchoalveolar lavage fluid
BPD Bronchopulmonary dysplasia
CAI Central apnea index
CAs Central apneas
CCL C-C motif chemokine
CDH Congenital diaphragmatic hernia
Cer Ceramide
CerDiHy Dihydroceramides
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance regulator
COPD Chronic obstructive pulmonary disease
CPAP Continuous positive airway pressure
CT Computed tomography
CXCL C-X-C motif chemokine
CXCR2 CXC chemokine receptor 2
cysLT Cysteinyl leukotrienes
EB Exhaled breath
EBC Exhaled breath condensate
EGF Epidermal growth factor
EMAP-II Endothelial monocyte activating polypeptide-II
EMMPRIN Extracellular matrix metalloproteinase inducer
eNO Exhaled nitric oxide
eNose Electronic nose
FeNO Fractional exhaled nitric oxide
FEF75 Forced expiratory flow after 75% of vital capacity
FEV1 Forced expiratory volume in 1 second
FGF Fibroblast growth factor
FRC Functional residual capacity
FVC Forced vital capacity
GA Gestational age
GC-FID Gas chromatography-flame ionization detection
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GC-MS Gas chromatography-mass spectrometry
GC-ToFMS Gas chromatography-time of flight mass spectrometry
GDF15 Growth differentiation factor 15
GFR Green fluorescent protein
GM-CSF Granulocyte-macrophage colony-stimulating factor
H2O2 Hydrogen peroxide
HELLP Hemolysis elevated liver enzymes and low platelets
HETE Hydroxyeicosatetraenoic acids
HGF Hepatocyt growth factor
HIF Hypoxia inducible factor
HUVEC Human umbilical vein endothelial cells
HWG Hollow waveguides
ICS Inhaled corticosteroids
IGF-1 Insulin-like growth factor 1
IL Interleukine
IQR Interquartile range
LCI Lung clearance index
LC-MS/MS Liquid chromatography tandem mass spectrometry
LIF Leukemia inhibitory factor
LT Leukotriene
LTRA Leukotriene receptor antagonist
LX Lipoxin
MAI Mixed apnea index
MAs Mixed apneas
MBW Multiple breath washout
MCP Monocyte chemoattractant proteins
MCT Mercury cadmium telluride
MDApp Minimum detectable absorption per point
MDAps Minimum detectable absorption per scan
MIP Macrophage inflammatory proteins
MMP Metallomatrix protease
MRI Magnetic resonance imaging
MSCs Mesenchymal stem cells
3-NT 3-nitrotyrosine
NO Nitric oxide
NOS Nitric oxide synthase
NOx Metabolites of nitrogen oxides
NREM Non-rapid eye movement sleep
oAHI Obstructive apnea hypopnea index
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OAI Obstructive apnea index
OAs Obstructive apneas
ODI Oxygen desaturation index
OHs Obstructive hypopneas
PCD Primary ciliary dyskinesia
PDA Persistent ductus arteriosus
PDGF Platelet derived growth factor
PEF Peak expiratory flow
PGD Prostaglandin
PIH Pregnancy induced hypertension
PlGF Placenta growth factor
PMA Postmenstrual age
PNNL Pacific northwest national laboratory
ppmv Parts per million by volume
ppbv Parts per billion by volume
pptv Parts per trillion by volume
PRAGMA-BPD  Perth-Rotterdam Annotated Grid Morphometric Analysis -  
Bronchopulmonary dysplasia
PSG Polysomnography
PTR-MS Proton transfer reaction-mass spectrometry
QCL Quantum cascade lasers
RAST Radioallergosorbent test
REM Rapid eye movement sleep
RFP Red fluorescent protein
RNS Reactive nitrogen species
rms Root mean square
ROS Reactive oxygen species
RT-PCR Reverse transcription polymerase chain reaction
SaO2 Mean oxygen saturation
SaO2 nadir Deepest oxygen desaturation
SD Standard deviation
S1P Sphingosine-1-phosphate
sFLT-1 Soluble fms-like tyrosine kinase-1
sICAM-1 Soluble intracellular adhesion molecule-1
SIFT-MS Selected ion flow tube-mass spectrometry
SphK1 Sphingosine kinase 1
SPT Sleep period time
TAMs Tumor-associated macrophages
TAs Tracheal aspirates
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TEC Thermo-electric cooled
TGF-β Transforming growth factor beta
Th T helper
TIB Time in bed
TIMP-1 Tissue inhibitors metalloproteinase-1
TLC Total lung capacity
TNF-α Tumor necrosis factor alpha
TST Total sleep time
TURBO DECCS  Transportable unit for research on biomarkers obtained from 
disposable exhaled condensate collection systems
VEGF Vascular endothelial growth factor
VOC(s) Volatile organic compound(s)
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2011 0.4
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De afgelopen jaren stond mijn leven in het teken van de combinatie van 3 onderdelen: onderzoek, 
klinische opleiding en privé. In feite redelijk vergelijkbaar met het trainen voor een triatlon. Drie 
verschillende disciplines, die je alle drie in perfectie wilt uitvoeren. Iets wat ik niet altijd als even 
makkelijk heb ervaren.
Allereerst het zwemmen, een technisch onderdeel waarbij veel komt kijken, net als bij het doen 
van onderzoek. Het uitdenken van een studie-opzet, het aanvragen van de financiering, de 
daadwerkelijke uitvoering met het includeren van patiënten en het verzamelen en verwerken van 
studiematerialen, het analyseren en interpreteren van alle gegevens, en uiteindelijk het schrijven 
van een artikel.
Dan het fietsen, leren door veel te doen, met vallen en opstaan, te vergelijken met een klinische 
opleiding tot kinderarts. Door in een groep van verpleegkundigen, arts-assistenten en kinderart-
sen te fietsen, leer je van elkaar, kan je elkaar van tijd tot tijd uit de wind houden, en kan je samen 
accelereren.
In de triatlon sport wordt hardlopen, het laatste onderdeel, gezien als het belangrijkste onderdeel 
voor succes. Net zoals ik de afgelopen jaren heb geleerd dat balans in je persoonlijke leven het 
belangrijkste is voor het behalen van welke eindstreep dan ook.
In een triatlonwedstrijd komen alle drie de disciplines samen, volgen ze elkaar op, op weg naar 
de eindstreep. Vandaag is het dan zover, ik mag gaan laten zien dat ik met succes een triatlon-
wedstrijd kan afronden. Met als beloning; een medaille, een omhelzing, felicitaties en een hapje 
en een drankje!
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DAnkwooRD
Onder een parasol van palmbladeren, met mijn voeten in het zachte witte zand en 
uitzicht op een azuurblauwe zee mag ik terugkijken op de afgelopen 6 jaar. Jaren waarin 
ik veel heb geleerd en veel te danken heb aan verschillende personen aan wie ik nu, in 
dit meest gelezen hoofdstuk, het woord mag richten.
Allereerst, dit proefschrift was niet mogelijk geweest zonder de belangeloze medewer-
king van ouders en hun kinderen. Ouders en kinderen in het Sophia Kinderziekenhuis en 
Kinderhaven, maar ook kinderen van de Jacob Maris basisschool. Jullie zijn het wetsuit, 
de fiets en de hardloopschoenen geweest waar een triatleet niet zonder kan. Zonder 
jullie belangeloze bijdrage is klinisch onderzoek niet mogelijk, bedankt!
Mijn supervisor, dr. M.W. Pijnenburg. Beste Mariëlle, mijn allround trainster, samen heb-
ben we dit traject, wat begon met bezoekjes aan de kelders van de TU Delft, tot een 
goed einde gebracht. De combinatie van een klinische opleiding en wetenschappelijk 
onderzoek was niet altijd even makkelijk en jij leerde me het belang van prioriteiten 
stellen. De afgelopen jaren stond jouw deur altijd open voor een lach of een traan, al 
vond ik het niet altijd gemakkelijk om daar gebruik van te maken. Veel bewondering ook 
voor jouw klinisch werk en de intense betrokkenheid bij jouw patiënten. Kinderhaven 
en nu ook het Kinderthoraxcentrum zijn daar het resultaat van.
Mijn promotoren prof. dr. J.C. de Jongste en prof. dr. I.K.M. Reis.
Beste Johan, bedankt voor het vertrouwen in mij als student, ANIOS, PhD en AIOS. Jij 
hebt geholpen mijn parcours uit te zetten en te bewaken, met altijd een supersnelle 
kritische en opbouwende blik. Mede dankzij jou kan ik nu ontzettend trots zijn op dit 
eindresultaat, bedankt!
Beste Irwin, “alles komt gut” en zie hier het resultaat. Bedankt voor je eeuwige optimisme, 
de vele ideeën en de mogelijkheid om mijn parcours een beetje te verleggen naar de 
neonatologie afdeling, met de hulp van ‘jouw’ patiënten.
Prof. dr. V.W.V. Jaddoe, prof. dr. G.G.O. Brusselle en prof. dr. M. Post, de jury. Bedankt voor 
uw bereidheid plaats te nemen in de kleine commissie en voor de primaire beoordeling 
van mijn proefschrift. Martin, bedankt voor de mogelijkheid om onze samples met be-
hulp van jullie platform te analyseren, het transport naar Toronto is uiteindelijk gelukkig 
ook allemaal goed gegaan. Prof. dr. L.J.I. Zimmerman, dr. R.J. Rottier, en dr. A.M.C. van 
Rossum, hartelijk dank voor uw deelname aan de grote commissie en uw aanwezigheid 
bij de verdediging.
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Nandini en Adonis, de materiaalverzorgers voor het eerste deel van mijn traject. Een 
klinische dokter op een technische universiteit. Dank voor jullie geduld, de vele lessen 
in optica en het vele werk van analyseren van al die ballonnen met uitademingslucht 
die steeds weer in boodschappentassen vol jullie kant op kwamen. Het analyseren van 
al die piekjes, het heeft uiteindelijk allemaal geleid tot een technisch en een klinisch 
proefschrift.
Alle medewerkers van KinderHaven. Het is alweer een behoorlijke tijd geleden dat een 
groot apparaat behoorlijk wat ruimte in de longfunctiekamer in beslag nam en een 
volgend onderzoek waar ik graag uitademingslucht in rare ballonnen wilde verzamelen. 
Ik heb me altijd meer dan welkom gevoeld, dank voor al jullie hulp!
De afdeling neonatologie van het Sophia kinderziekenhuis, alle stafleden en verpleeg-
kundigen, in het bijzonder: André Kroon, Bas Bol en alle verpleegkundigen die geholpen 
hebben samples voor de SPIN studie te verzamelen en te verwerken. Dankzij jullie is het 
mogelijk geweest in relatief korte tijd zoveel patiënten te includeren!
Een klinische dokter in het laboratorium, een Master traject naast een PhD traject en de 
opleiding tot kinderarts. Beste dr. J.N. Samsom, prof. dr. R.W. Hendriks, en dr. R.J. Rottier, 
beste Janneke, Rudi en Robbert, jullie hebben dit mede mogelijk gemaakt. Bedankt voor 
het vertrouwen, het meedenken, de opbouwende kritiek, en de bereidheid tot het ge-
bruik maken van jullie laboratoria, de materialen en de vele helpende handjes. Ik hoop 
ook in de toekomst bij translationeel onderzoek betrokken te kunnen blijven en op die 
manier een steentje bij te dragen aan de vooruitgang binnen de kindergeneeskunde!
Ismé, de perfecte wisseltrainster, zonder jouw hulp en kennis was het laboratoriumwerk 
nooit tot dit niveau gekomen. Daarnaast heb je een grote rol gespeeld in het succesvol 
afronden van mijn Master Infection and Immunity. Het bleek alles behalve makkelijk 
klinisch onderzoek te combineren met laboratoriumonderzoek, maar jij hebt me laten 
zien dat het mogelijk is. Het vervelende toeval van beiden een enkelbreuk in 3 maanden 
tijd heeft ons dichter bij elkaar gebracht. Altijd optimistisch en vol met nieuwe ideeën! 
Nu is het dan echt tijd voor die goede fles wijn met zijn vieren.
Het voordeel van een lang traject waarin klinisch werk en onderzoek elkaar afwisselen is 
dat ik veel leuke mede-triatleten, collega’s heb leren kennen.
Alle (ex)Z-flat onderzoekers, dank voor het delen van lief en leed in onderzoekerswe-
reld, maar met name dank voor jullie gezelligheid de afgelopen jaren, de vele lunches 
(met mooi weer altijd buiten), de etentjes en de uitjes. In het bijzonder: Sandra, jij ging 
me voor als eerste promovenda van Mariëlle, wat een eer dat ik naast je mocht staan 
tijdens jouw promotie! Succes met je prachtige carrière in de jeugdgezondheidszorg, en 
je mooie gezin op jullie prachtige plekje op het eiland. Suzanne, jammer dat ik steeds 
weer de kliniek in ging en we maar relatief kort een kamer hebben gedeeld; altijd een 
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lach, tijd voor een goed gesprek, en vele sportieve fietskilometers. Prachtig hoe jullie 
momenteel als gezin zeilend over de wereld een langgekoesterde droom waarmaken, 
wie weet tot ziens bij de San Blas-eilanden. Veel succes daarna met de start als AIOS in 
Utrecht! Salomé, bedankt voor jouw hulp met het opzetten van de SPIN studie, je kwam 
precies op het juiste moment! Veel succes met jouw carrière in de jeugdgezondheids-
zorg en de forensische geneeskunde. Altijd pret in de Z-flat, dank ook aan: Karlijn, Yuen, 
Gerthe, Marjolein, Charlotte, Yvonne, Laura, Daan, Sjoerd, Nienke, Nynke, Alexandra, 
Marianne, Lennart, Gertrude, Noortje, Marijke, Dwight, Maarten, Esther, Rosalie, Niina, 
Eva, Martina, Badies en Annelies.
De pulmo-collega’s, mede-onderzoekers en stafleden, wil ik graag ook bedanken voor 
een mooie tijd: poli-patiënten, röntgenbesprekingen, researchmeetings, de congressen 
en vele andere momenten daarbuiten. In het bijzonder: Marjolein, wat fijn dat al het 
harde werken dan uiteindelijk is beloond met een AIOS plek kindergeneeskunde, in Rot-
terdam! Jeroen, zonder jouw muisonderzoek had het tweede deel van mijn proefschrift 
niet bestaan, dank daarvoor! Pier, dank voor jouw hulp en expertise in het ontwikkelen 
van de PRAGMA-BPD score en het scoren van de vele CT scans van kinderen met BPD. 
Irma, bedankt voor al je hulp de afgelopen jaren, o.a. de vele datumprikkers, niet altijd 
even gemakkelijk. Aan jou kon ik het printen en versturen van mijn manuscript met een 
gerust hart overlaten, dank!
Alle collega’s op de laboratoria van Kindergeneeskunde, Pulmonologie en Kinderchi-
rurgie, dank voor jullie vele praktische hulp bij de experimenten en natuurlijk ook de 
gezelligheid, ik heb me altijd welkom gevoeld!
Alle (oud)SOV leden, bedankt voor een geweldige tijd, met bijeenkomsten, borrels, 
BBQ’s en natuurlijk de SOV-weekenden en de ski-reis.
Lieve AGIKO’s: Evelien, Hanneke en Nienke, bedankt voor jullie vriendschap in deze af-
gelopen jaren van ons lange traject met kliniek en onderzoek. Bedankt voor alle etentjes 
waarin we AGIKO-leed konden delen maar met name ook gezellig konden bijkletsen: 3 
boekjes af en 1 in de maak, maar bijna klaar, we did it!
Collega A(N)IOS van het Sophia, ik heb vele collega’s zien komen en gaan de afgelopen 
jaren, waarin ik zelf afwisselend een klinische en dan weer een onderzoekersrol had. 
Bedankt, ik heb me altijd welkom gevoeld in het Sophia.
(Ex)collega-assistenten in het Maasstadziekenhuis, bedankt voor de gezelligheid de af-
gelopen 2 jaar! Alle kinderartsen in het Maasstadziekenhuis, dank voor de altijd prettige 
samenwerking! Ik heb super veel kunnen zien en kunnen leren van al jullie expertise. 
Dank ook voor jullie geduld met die assistent die toch ook wel erg veel met onderzoek 
bezig was.
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Lieve vrienden en familie, de EHBO-post en de wateruitdelers, jullie staan er altijd op het 
moment dat ik jullie nodig heb. In het bijzonder:
Lieve paranimfen, allebei al een PhD op zak, wat fantastisch dat jullie vandaag achter 
mij staan! Lieve Lein, we hebben samen al veel meegemaakt de afgelopen jaren! Je 
staat altijd voor me klaar en ik hoop dat we nog vele jaren samen alle mooie en min-
der mooie momenten met elkaar blijven delen. Lieve Leonie, (ex)Sophia-ANIOS en 
pulmo-collegaatje, samen hebben we de eerste stappen gezet binnen onze carrière in 
de kindergeneeskunde. De afstand tussen Groningen, waar jij nu je opleiding volgt, en 
Rotterdam is groot, ik hoop dat deze dag ons weer een stapje dichter bij elkaar brengt.
Triatlonvriendjes en vriendinnetjes, ik heb jullie gemist de afgelopen periode met bles-
sureleed en de vele overwerkuren. Hillie en Niek, leuk om jullie ook buiten het sporten 
te hebben leren kennen, Lapaz is altijd welkom! Hedwig, superleuk dat we nu ook AIOS-
collega’s zijn. Ik hoop de komende tijd, na een kleine wereldreis, weer sportief te kunnen 
gaan pieken.
Ariadne, Mariëlle en Mariska, jaargenootjes. Al zien we elkaar soms te weinig, druk…
druk…druk…, we kunnen altijd bij elkaar terecht. Ariadne, samen op reis in Zuid Afrika 
was een groot avontuur. Hoop dat we nog lang avonturen met elkaar zullen delen.
Marieke, Marijana, Marjolein (Mar) en Marjolein (Lein), sta er nu bij stil dat ik de enige 
niet-M ben in ons groepje. Bedankt voor jullie eeuwige interesse in mijn lange traject. 
Mar, Cuba was geweldig, en jouw cadeau het zwemmen met dolfijnen een lang gekoes-
terde meisjesdroom die uitkwam.
Berry en Annette, Dennis en Saartje en de kids (Guusje en Floor), lieve schoonfamilie, ik 
heb me vanaf het begin welkom gevoeld bij jullie in het Brabantse, bedankt daarvoor!
Ernst-Jan en Riette. Broertje, fijn dat wij er altijd voor elkaar zijn als we elkaar nodig 
hebben. De etentjes met zijn vieren zijn een mooie traditie die we in ere moeten laten. 
De komende jaren ga jij weer een nieuwe uitdaging aan met een universitaire master 
opleiding, succes! Riette, ik had me geen leuker schoonzusje kunnen wensen.
Lieve pap en mam, mijn trouwste supporters langs de lijn en nu ook bij de finish van 
deze wedstrijd. Ja, mijn boekje is eindelijk af! Woorden schieten tekort om jullie te be-
danken voor alles wat jullie voor mij betekenen. Ik kan altijd bij jullie terecht, mijn dank 
is oneindig groot. En pap, achter de kassa zit er nu echt niet meer in.
Lieve Rob, vele functies heb jij verricht de afgelopen 5 jaar. De omroeper die me steeds 
weer moed insprak, de EHBO-post, helaas soms letterlijk nodig, en bovenal mijn favo-
riete supporter met sterke armen bij de finish. “Pura Vida” is jouw lijfspreuk, waar ik de 
afgelopen jaren ook van heb mogen genieten! Ik kijk uit naar onze 4 maanden samen 
op het Zuid-Amerikaanse continent en naar alle andere avonturen die we samen nog 
mogen gaan beleven!
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